0001437749-21-012046.txt : 20210513 0001437749-21-012046.hdr.sgml : 20210513 20210513160626 ACCESSION NUMBER: 0001437749-21-012046 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 51 CONFORMED PERIOD OF REPORT: 20210331 FILED AS OF DATE: 20210513 DATE AS OF CHANGE: 20210513 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DYADIC INTERNATIONAL INC CENTRAL INDEX KEY: 0001213809 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 450486747 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-32513 FILM NUMBER: 21919593 BUSINESS ADDRESS: STREET 1: 140 INTRACOASTAL POINTE DRIVE STREET 2: SUITE 404 CITY: JUPITER STATE: FL ZIP: 33477 BUSINESS PHONE: 561-743-8333 MAIL ADDRESS: STREET 1: 140 INTRACOASTAL POINTE DRIVE STREET 2: SUITE 404 CITY: JUPITER STATE: FL ZIP: 33477 FORMER COMPANY: FORMER CONFORMED NAME: CCP WORLDWIDE INC DATE OF NAME CHANGE: 20030110 10-Q 1 dyai20210331_10q.htm FORM 10-Q dyai20210331_10q.htm
0001213809 DYADIC INTERNATIONAL INC false --12-31 Q1 2021 0.0001 0.0001 5,000,000 5,000,000 0 0 0 0 0.001 0.001 100,000,000 100,000,000 39,807,659 39,747,659 27,554,157 27,494,157 12,253,502 12,253,502 3 1 8 5 7 9 3 1 1 0 0 0 0 100 2 936,000 2 1 8.0 1.5 2 1.1 1.0 284,709 10 1 3 5 3 1 4 1 4 1 1 1 1 12,253,502 18.9 Represents the following stock options granted: Annual share-based compensation awards on January 4, 2021, including: (a) 417,500 stock options with an exercise price of $5.16 per share granted to executives and key personnel, upon one year anniversary, or vesting annually in equal installments over four years, (b) 227,500 stock options with an exercise price of $5.16 per share granted to members of the Board of Directors, vesting upon one year anniversary, (c) 23,325 stock options with an exercise price of $5.16 per share granted to employees, vesting annually in equal installments over four years and (d) 5,000 stock options with an exercise price of $5.16 per share granted to a consultant, vesting upon one year anniversary. One-time award on January 8, 2021, 35,000 stock options with an exercise price of $5.50 per share granted to a new member of the Board of Directors, vesting in one year from the grant date. One-time award on January 21, 2021, 7,500 stock options with an exercise price of $5.65 per share granted to a consultant, vesting in one year from the grant date. One-time award on March 22, 2021, 30,000 stock options with an exercise price of $6.87 per share granted to a consultant, vesting in one year from the grant date. Represents the following stock options exercised: A total of 60,000 stock options exercised with a weighted average exercise price of $1.93. The premium paid to purchase held-to-maturity investment securities was $283,940 and $196,385 for the three months ended March 31, 2021 and 2020, respectively. The premium paid to purchase held-to-maturity investment securities was $282,946 for the year ended December 31, 2020. Short-term investment securities will mature within 12 months or less, from the applicable reporting date. 00012138092021-01-012021-03-31 xbrli:shares 00012138092021-05-12 thunderdome:item iso4217:USD 00012138092021-03-31 00012138092020-12-31 iso4217:USDxbrli:shares 00012138092020-01-012020-03-31 0001213809us-gaap:CommonStockMember2020-12-31 0001213809us-gaap:TreasuryStockMember2020-12-31 0001213809us-gaap:AdditionalPaidInCapitalMember2020-12-31 0001213809us-gaap:RetainedEarningsMember2020-12-31 0001213809us-gaap:CommonStockMember2021-01-012021-03-31 0001213809us-gaap:TreasuryStockMember2021-01-012021-03-31 0001213809us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-31 0001213809us-gaap:RetainedEarningsMember2021-01-012021-03-31 0001213809us-gaap:CommonStockMember2021-03-31 0001213809us-gaap:TreasuryStockMember2021-03-31 0001213809us-gaap:AdditionalPaidInCapitalMember2021-03-31 0001213809us-gaap:RetainedEarningsMember2021-03-31 00012138092019-12-31 00012138092020-03-31 xbrli:pure 0001213809us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-03-31 0001213809us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-03-31 0001213809us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-03-31 0001213809us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-12-31 0001213809us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:NonUsMember2021-01-012021-03-31 0001213809us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:NonUsMember2020-01-012020-03-31 0001213809us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:NonUsMember2021-01-012021-03-31 0001213809us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:NonUsMember2021-03-31 0001213809us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:NonUsMember2020-01-012020-12-31 0001213809us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:NonUsMember2020-12-31 0001213809dyai:ContractResearchOrganizationsMemberus-gaap:SupplierConcentrationRiskMember2021-01-012021-03-31 0001213809dyai:ContractResearchOrganizationsMemberus-gaap:SupplierConcentrationRiskMemberdyai:ThreeCROsMember2021-01-012021-03-31 0001213809us-gaap:AccountsPayableMemberus-gaap:SupplierConcentrationRiskMemberdyai:ThreeCROsMember2021-03-31 0001213809us-gaap:AccountsPayableMemberus-gaap:SupplierConcentrationRiskMemberdyai:ThreeCROsMember2021-01-012021-03-31 0001213809dyai:ContractResearchOrganizationsMemberus-gaap:SupplierConcentrationRiskMember2020-01-012020-03-31 0001213809dyai:ContractResearchOrganizationsMemberus-gaap:SupplierConcentrationRiskMemberdyai:OneCROMember2020-01-012020-03-31 0001213809us-gaap:AccountsPayableMemberus-gaap:SupplierConcentrationRiskMember2020-01-012020-12-31 0001213809us-gaap:AccountsPayableMemberus-gaap:SupplierConcentrationRiskMemberdyai:OneCROMember2020-12-31 0001213809us-gaap:AccountsPayableMemberus-gaap:SupplierConcentrationRiskMemberdyai:OneCROMember2020-01-012020-12-31 0001213809us-gaap:BilledRevenuesMember2021-03-31 0001213809us-gaap:BilledRevenuesMember2020-12-31 0001213809us-gaap:UnbilledRevenuesMember2021-03-31 0001213809us-gaap:UnbilledRevenuesMember2020-12-31 00012138092020-01-012020-12-31 0001213809us-gaap:CashMember2021-03-31 0001213809us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2021-03-31 0001213809dyai:ShortTermCorporateBondsMemberus-gaap:FairValueInputsLevel2Member2021-03-31 0001213809us-gaap:FairValueInputsLevel2Memberdyai:ShortTermCorporateBondsMember2021-03-31 0001213809us-gaap:CorporateBondSecuritiesMember2021-03-31 0001213809us-gaap:CashMember2020-12-31 0001213809us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Member2020-12-31 0001213809dyai:ShortTermCorporateBondsMemberus-gaap:FairValueInputsLevel2Member2020-12-31 0001213809us-gaap:FairValueInputsLevel2Memberdyai:ShortTermCorporateBondsMember2020-12-31 0001213809us-gaap:CorporateBondSecuritiesMember2020-12-31 0001213809us-gaap:CorporateDebtSecuritiesMember2021-01-012021-03-31 0001213809us-gaap:CorporateDebtSecuritiesMember2020-01-012020-03-31 0001213809us-gaap:CorporateDebtSecuritiesMember2020-01-012020-12-31 utr:Y 00012138092017-06-302017-06-30 0001213809dyai:ResearchServicesAgreementMemberdyai:BDIHoldingsMember2017-06-302017-06-30 0001213809dyai:ResearchServicesAgreementMemberdyai:VLPbioMember2017-06-302017-06-30 0001213809dyai:ResearchServicesAgreementMemberdyai:BDIHoldingsMember2017-06-30 0001213809dyai:ResearchServicesAgreementMemberdyai:BDIHoldingsMembersrt:MinimumMember2017-06-302017-06-30 0001213809dyai:ResearchServicesAgreementMemberdyai:BDIHoldingsMembersrt:MaximumMember2017-06-302017-06-30 iso4217:EUR 0001213809dyai:ResearchServicesAgreementMemberdyai:BDIHoldingsMembersrt:MinimumMember2017-06-30 0001213809dyai:ResearchServicesAgreementMember2017-06-30 0001213809dyai:ServiceFrameworkAgreementMember2017-06-30 0001213809dyai:ServiceFrameworkAgreementMember2017-06-302017-06-30 0001213809dyai:ResearchServicesAgreementMember2017-06-302017-06-30 0001213809dyai:BDIMemberdyai:ServiceAgreementToPerformResearchProjectMember2021-01-012021-03-31 0001213809dyai:NovovetMember2019-04-26 0001213809dyai:AlphazymeMember2020-06-242020-06-24 0001213809dyai:AlphazymeMember2020-12-01 0001213809dyai:AlphazymeMember2020-12-31 0001213809dyai:IDBiologicsIncMember2020-07-08 0001213809dyai:IDBiologicsIncMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2020-07-08 0001213809dyai:IDBiologicsIncMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2020-07-08 0001213809dyai:IDBiologicsIncMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2020-07-08 0001213809dyai:The2011PlanMember2011-04-28 0001213809dyai:The2011PlanMember2019-01-012019-01-01 0001213809dyai:The2011PlanMemberus-gaap:SubsequentEventMember2021-04-162021-04-16 0001213809dyai:The2011PlanMember2021-03-31 0001213809dyai:The2011PlanMember2020-12-31 0001213809us-gaap:EmployeeStockOptionMemberdyai:The2011PlanMember2021-01-012021-03-31 0001213809us-gaap:EmployeeStockOptionMemberdyai:The2011PlanMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2021-01-012021-03-31 0001213809us-gaap:EmployeeStockOptionMemberdyai:The2011PlanMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2021-01-012021-03-31 0001213809us-gaap:EmployeeStockOptionMemberdyai:The2011PlanMembersrt:ChiefExecutiveOfficerMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2021-01-012021-03-31 0001213809us-gaap:EmployeeStockOptionMemberdyai:The2011PlanMembersrt:ChiefExecutiveOfficerMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2021-01-012021-03-31 0001213809us-gaap:EmployeeStockOptionMemberdyai:ContractorMemberdyai:The2011PlanMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2021-01-012021-03-31 0001213809us-gaap:EmployeeStockOptionMemberdyai:ContractorMemberdyai:The2011PlanMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2021-01-012021-03-31 0001213809srt:MinimumMember2021-01-012021-03-31 0001213809srt:MaximumMember2021-01-012021-03-31 0001213809dyai:ExecutivesAndKeyPersonnelMember2021-01-042021-01-04 0001213809us-gaap:EmployeeStockOptionMemberdyai:ExecutivesAndKeyPersonnelMemberdyai:SharebasedCompensationAwardTrancheTwoThroughFiveMember2021-01-042021-01-04 0001213809srt:DirectorMember2021-01-042021-01-04 0001213809us-gaap:EmployeeStockOptionMembersrt:DirectorMember2021-01-042021-01-04 0001213809dyai:EmployeesMember2021-01-042021-01-04 0001213809us-gaap:EmployeeStockOptionMembersrt:MinimumMemberdyai:EmployeesMember2021-01-042021-01-04 0001213809dyai:ConsultantMember2021-01-042021-01-04 0001213809us-gaap:EmployeeStockOptionMemberdyai:ConsultantMember2021-01-042021-01-04 0001213809srt:DirectorMember2021-01-082021-01-08 0001213809us-gaap:EmployeeStockOptionMembersrt:DirectorMember2021-01-082021-01-08 0001213809dyai:ConsultantMember2021-01-212021-01-21 0001213809us-gaap:EmployeeStockOptionMemberdyai:ConsultantMember2021-01-212021-01-21 0001213809dyai:ConsultantMember2021-03-222021-03-22 0001213809us-gaap:EmployeeStockOptionMemberdyai:ConsultantMember2021-03-222021-03-22 0001213809us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-03-31 0001213809us-gaap:GeneralAndAdministrativeExpenseMember2020-01-012020-03-31 0001213809us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-03-31 0001213809us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-03-31 0001213809us-gaap:CommonStockMember2020-01-012020-03-31 0001213809us-gaap:CommonStockMember2019-12-31 0001213809us-gaap:TreasuryStockMember2019-12-31 0001213809us-gaap:AdditionalPaidInCapitalMember2019-12-31 0001213809us-gaap:RetainedEarningsMember2019-12-31 0001213809us-gaap:TreasuryStockMember2020-01-012020-03-31 0001213809us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-31 0001213809us-gaap:RetainedEarningsMember2020-01-012020-03-31 0001213809us-gaap:CommonStockMember2020-03-31 0001213809us-gaap:TreasuryStockMember2020-03-31 0001213809us-gaap:AdditionalPaidInCapitalMember2020-03-31 0001213809us-gaap:RetainedEarningsMember2020-03-31 00012138092020-08-13 0001213809dyai:OpenMarketSaleAgreementMember2020-08-13 0001213809dyai:OpenMarketSaleAgreementMember2020-08-132020-08-13
 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

(Mark One)

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2021
  
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to ______

 

Commission File Number: 000-55264

 

dyai-20200930_g1copy.jpgDYADIC INTERNATIONAL, INC.

(Exact Name of Registrant as Specified in its Charter)

 

Delaware 45-0486747
State or Other Jurisdiction of Incorporation or Organization I.R.S. Employer Identification No.

 

140 Intracoastal Pointe Drive, Suite 404  
Jupiter, Florida 33477
Address of Principal Executive Offices Zip Code

 

(561) 743-8333

 Registrant’s Telephone Number, Including Area Code 
  N/A  
 Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.             Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).        Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐

 

Accelerated filer ☐

   

Non-accelerated filer

 

Smaller reporting company

   
  

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes  No ☒

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per share

DYAI

The NASDAQ Stock Market LLC

 

The number of shares outstanding of each of the registrant’s Common Stock as of May 12, 2021 was 27,554,157.

 

 

 

 
 
 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

Information (other than historical facts) set forth in this Quarterly Report contains forward-looking statements within the meaning of the Federal securities laws, which involve many risks and uncertainties that could cause our actual results to differ materially from those reflected in the forward-looking statements. Forward-looking statements generally can be identified by use of the words “expect,” “should,” “intend,” “anticipate,” “will,” “project,” “may,” “might,” “potential,” or “continue” and other similar terms or variations of them or similar terminology. Such forward-looking statements are included under Item 2 “Management’s Discussion and Analysis”. Dyadic International, Inc., and its subsidiaries cautions readers that any forward-looking information is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking information. Such statements reflect the current views of our management with respect to our operations, results of operations and future financial performance. Forward-looking statements involve many risks, uncertainties or other factors within and/or beyond Dyadic’s control. These factors include, but are not limited to, (1) general economic, political and market conditions; (2) our ability to generate the required productivity, stability, purity, performance, cost, safety and other data necessary to carry out and implement our biopharmaceutical research and business plans and strategic initiatives; (3) our ability to retain and attract employees, consultants, directors and advisors; (4) our ability to implement and successfully carry out Dyadic’s and third parties’ research and development efforts; (5) our ability to obtain new license and research agreements; (6) our ability to maintain our existing access to, and/or expand access to third party contract research organizations in order to carry out our research projects for ourselves and third parties; (7) competitive pressures and reliance on our key customers and collaborators; (8) our ability, and the ability of the contract research organizations with whom we are currently working with, to advance vaccine candidates into, and successfully complete, preclinical studies and clinical trials; (9) the commercialization of our vaccine candidates, if approved; (10) the pharmaceutical and biotech industry, governmental regulatory and other agencies’ willingness to adopt, utilize and approve the use of the C1 gene expression platform; (11) the risk of theft, misappropriation or expiration of owned or licensed proprietary and intellectual property, genetic and biological materials owned by us and/or Danisco US, Inc. and VTT Technical Research Centre of Finland Ltd; (12) speculative nature and illiquidity of equity securities received as consideration from sub-licenses; (13) our expectations concerning the impact of the novel coronavirus identified as “COVID-19” on our business and operating results; and (14) other factors discussed in Dyadic’s publicly available filings, including information set forth under the caption “Risk Factors” in this Form 10-Q and our Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 30, 2021. We caution you that the foregoing list of important factors is not exclusive. The forward-looking statements are based on our beliefs, assumptions and expectations of future performance, considering the information currently available to us. These statements are only predictions based upon our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Moreover, we operate in a highly regulated, competitive and rapidly changing environment. Our competitors have far greater resources, infrastructure and market presence than we do which makes it difficult for us to enter certain markets, and/or to gain or maintain customers. New risks emerge from time to time and it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Before investing in our common stock, investors should carefully read the information set forth under the caption “Risk Factors” in this Form 10-Q and elsewhere in our Form 10-K filed with the SEC on March 30, 2021 which could have a material adverse effect on our business, results of operations and financial condition.

 

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. Except as required by law, we undertake no obligation to publicly update any forward-looking statements for any reason after the date of this Quarterly Report to conform these statements to actual results or to changes in our expectations.

 

We qualify all our forward-looking statements by these cautionary statements. In addition, with respect to all our forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

 

2

 

 

PART I

 

Item 1.

Financial Statements

 

DYADIC INTERNATIONAL, INC. AND SUBSIDIARIES

 

CONSOLIDATED BALANCE SHEETS

 

  

March 31, 2021

  

December 31, 2020

 
  

(Unaudited)

  

(Audited)

 

Assets

        

Current assets:

        

Cash and cash equivalents

 $13,055,558  $20,637,045 

Short-term investment securities

  14,177,441   8,457,452 

Interest receivable

  157,201   112,247 

Accounts receivable

  384,963   294,199 

Prepaid expenses and other current assets

  216,189   280,555 

Total current assets

  27,991,352   29,781,498 
         

Non-current assets:

        

Investment in Alphazyme

  284,709   284,709 

Other assets

  6,151   6,225 

Total assets

 $28,282,212  $30,072,432 
         

Liabilities and stockholders’ equity

        

Current liabilities:

        

Accounts payable

 $1,473,813  $1,013,099 

Accrued expenses

  277,668   489,756 

Deferred research and development obligations

  842,248   123,016 

Total current liabilities

  2,593,729   1,625,871 
         

Commitments and contingencies (Note 4)

          
         

Stockholders’ equity:

        

Preferred stock, $.0001 par value:

        

Authorized shares - 5,000,000; none issued and outstanding

      

Common stock, $.001 par value:

        

Authorized shares - 100,000,000; issued shares - 39,807,659 and 39,747,659, outstanding shares - 27,554,157 and 27,494,157 as of March 31, 2021 and December 31, 2020, respectively

  39,808   39,748 

Additional paid-in capital

  98,549,890   98,013,079 

Treasury stock, shares held at cost - 12,253,502

  (18,929,915)  (18,929,915)

Accumulated deficit

  (53,971,300)  (50,676,351)

Total stockholders’ equity

  25,688,483   28,446,561 

Total liabilities and stockholders’ equity

 $28,282,212  $30,072,432 

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

3

 

 

DYADIC INTERNATIONAL, INC. AND SUBSIDIARIES

 

CONSOLIDATED STATEMENTS OF OPERATIONS

 

(Unaudited)

 

   

Three Months Ended March 31,

 
   

2021

   

2020

 

Revenues:

               

Research and development revenue

  $ 460,520     $ 315,372  
                 

Costs and expenses:

               

Costs of research and development revenue

    390,762       278,182  

Research and development

    1,808,098       755,453  

General and administrative

    1,554,007       1,653,392  

Foreign currency exchange loss (gain), net

    28,272       10,867  

Total costs and expenses

    3,781,139       2,697,894  
                 

Loss from operations

    (3,320,619 )     (2,382,522 )
                 

Interest income

    25,670       168,383  
                 

Net loss

  $ (3,294,949 )   $ (2,214,139 )
                 

Basic and diluted net loss per common share

  $ (0.12 )   $ (0.08 )
                 

Basic and diluted weighted-average common shares outstanding

    27,533,268       27,452,490  

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

4

 

 

DYADIC INTERNATIONAL, INC. AND SUBSIDIARIES

 

CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY

 

(Unaudited)

 

   

Common Stock

   

Treasury Stock

   

Additional

   

Accumulated

         
   

Shares

   

Amount

   

Shares

   

Amount

   

Paid-in Capital

   

Deficit

   

Total

 
                                                         

Balance at December 31, 2020

    39,747,659     $ 39,748       (12,253,502 )   $ (18,929,915 )   $ 98,013,079     $ (50,676,351 )   $ 28,446,561  
                                                         

Stock-based compensation

                            421,071             421,071  
                                                         

Exercise of stock options

    60,000       60                   115,740             115,800  
                                                         

Net loss

                                  (3,294,949 )     (3,294,949 )
                                                         

Balance at March 31, 2021

    39,807,659     $ 39,808       (12,253,502 )   $ (18,929,915 )   $ 98,549,890     $ (53,971,300 )   $ 25,688,483  

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

5

 

 

DYADIC INTERNATIONAL, INC. AND SUBSIDIARIES

 

CONSOLIDATED STATEMENTS OF CASH FLOWS

 

(Unaudited)

 

   

Three Months Ended March 31,

 
   

2021

   

2020

 

Cash flows from operating activities

               

Net loss

  $ (3,294,949 )   $ (2,214,139 )

Adjustments to reconcile net loss to net cash used in operating activities:

               

Stock-based compensation expense

    421,071       426,939  

Amortization of held-to-maturity securities, net

    63,951       107,256  

Foreign currency exchange loss (gain), net

    28,272       10,867  

Changes in operating assets and liabilities:

               

Interest receivable

    (44,954 )     102,565  

Accounts receivable

    (131,800 )     35,258  

Prepaid expenses and other current assets

    64,297       (10,529 )

Accounts payable

    480,455       (292,361 )

Accrued expenses

    (212,088 )     (326,000 )

Deferred research and development obligation

    719,232       163,799  

Net cash used in operating activities

    (1,906,513 )     (1,996,345 )
                 

Cash flows from investing activities

               

Purchases of held-to-maturity investment securities

    (11,283,940 )     (11,652,385 )

Proceeds from maturities of investment securities

    5,500,000       13,350,000  

Net cash (used in) provided by investing activities

    (5,783,940 )     1,697,615  
                 

Cash flows from financing activities

               

Proceeds from exercise of options

    115,800       175,000  

Net cash provided by financing activities

    115,800       175,000  

Effect of exchange rate changes on cash

    (6,834 )     (2,983 )

Net decrease in cash and cash equivalents

    (7,581,487 )     (126,713 )

Cash and cash equivalents at beginning of period

    20,637,045       4,823,544  

Cash and cash equivalents at end of period

  $ 13,055,558     $ 4,696,831  
                 
                 
                 

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

6

 

Notes to Consolidated Financial Statements

 

 

Note 1:    Organization and Summary of Significant Accounting Policies

 

Description of Business

 

Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) is a global biotechnology platform company based in Jupiter, Florida with operations in the United States, a satellite office in the Netherlands and predominantly three research organizations performing services in the Netherlands, Finland and Israel. Over the past two plus decades, the Company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has previously licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica (formerly known as Myceliophthora thermophila) fungus, which the Company named C1. The C1 technology is a robust and versatile fungal expression system for the development and production of enzymes and other proteins.

 

On December 31, 2015, the Company sold its industrial technology business to Danisco USA (“Danisco”), the industrial biosciences business of DuPont (NYSE: DD) (the “DuPont Transaction”). As part of the DuPont Transaction, Dyadic retained co-exclusive rights to the C1 technology for use in all human and animal pharmaceutical applications, and currently has the exclusive ability to enter into sub-license agreements (subject to the terms of the license and to certain exceptions). Danisco retained certain rights to utilize the C1 technology in pharmaceutical applications, including the development and production of pharmaceutical products, for which it will be required to make royalty payments to Dyadic upon commercialization. In certain circumstances, Dyadic may owe a royalty to either Danisco or certain licensors of Danisco, depending upon whether Dyadic elects to utilize certain patents either owned by Danisco or licensed in by Danisco.

 

After the DuPont Transaction, the Company has been focused on the biopharmaceutical industry, specifically in further improving and applying the proprietary C1 technology into a safe and efficient gene expression platform to help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs and other biological products at flexible commercial scales. Currently, the Company is involved in multiple funded research collaborations with animal and human pharmaceutical companies to leverage its C1 technology to help develop products such as innovative vaccines and drugs, biosimilars and/or biobetters. The Company is also working on several COVID-19 related vaccine and antibody opportunities, including its proprietary COVID-19 vaccine candidate, DYAI-100, towards a first-in-human Phase 1 clinical trial. 

 

Effective April 17, 2019, our common stock began trading on the NASDAQ Stock Market LLC’s NASDAQ Capital Market, under the symbol “DYAI”.

 

Impact of COVID-19

 

The outbreak of COVID-19 has led to adverse impacts on the U.S. and global economies and created uncertainty regarding the potential impact to the Company’s employees, operations, and research projects.

 

To date, some of our employees are still working remotely. The extent to which the COVID-19 pandemic will directly or indirectly impact our business will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants and the actions taken and the level of success to contain or treat the SARS-CoV-2 virus and its variants, the economic impact on local, regional, national and international business partners and markets, delays or disruptions in our on-going research projects, and unavailability of the employees of the Company or third-party contract research organizations with whom we conduct business, due to illness or quarantines, all of which are highly uncertain and cannot be predicted at this time. Management is actively monitoring this situation and the possible effects on its financial condition, liquidity, operations, vendors, industry, and workforce. Even after the COVID-19 pandemic has subsided, the Company may continue to experience adverse impacts to its business because of economic recession or depression that has occurred or may occur in the future. Given the daily evolution of the COVID-19 outbreak and the ongoing response to curb its spread (including government travel and meeting restrictions) currently we are not able to accurately estimate the effects of the COVID-19 outbreak to our results of operations, financial condition, or liquidity.

 

7

 

We rely on our existing cash and cash equivalents, investments in debt securities, and operating cash flow to provide the working capital needs for our operations. We believe that our existing cash position and investment in investment grade securities will be adequate to meet our operational, business, and other liquidity requirements for at least the next twelve (12) months. However, in the event our financing needs for the foreseeable future are not able to be met by our existing cash, cash equivalents and investments, we would seek to raise funds through public or private equity offerings, and through other means to meet our financing requirements. Additionally, the Company may decide to fund all of a Phase I clinical trial to demonstrate the safety in humans of a protein produced from the C1 expression platform in humans. There is no assurance that external funding will be available at acceptable terms, if at all, and the Company may, therefore, self-fund these vital projects.

 

Summary of Significant Accounting Policies

 

Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements, including the accounts of the Company and its wholly owned subsidiaries, have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and footnote disclosures normally included in consolidated financial statements have been condensed or omitted pursuant to such rules and regulations. All significant intra-entity transactions and balances have been eliminated in consolidation. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and footnotes as of and for the year ended December 31, 2020, included in our Form 10-K which was filed with the SEC on March 30, 2021.

 

In the opinion of management, the accompanying unaudited interim consolidated financial statements reflect all adjustments, which are of a normal recurring nature, considered necessary for a fair presentation of all periods presented. The results of the Company’s operations for any interim periods are not necessarily indicative of the results of operations for any other interim period or for a full fiscal year.

 

Since concluding the DuPont Transaction, the Company has conducted business in one operating segment, which is identified by the Company based on how resources are allocated, and operating decisions are made. Management evaluates performance and allocates resources based on the Company as a whole.

 

Use of Estimates

 

The preparation of these consolidated financial statements in accordance with GAAP requires management to make estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the applicable period. Actual results may differ from these estimates under different assumptions or conditions. Such differences could be material to the consolidated financial statements.

 

Concentrations and Credit Risk

 

The Company’s financial instruments that are potentially subject to concentrations of credit risk consist primarily of cash and cash equivalents, investment securities, and accounts receivable. At times, the Company has cash, cash equivalents, and investment securities at financial institutions exceeding the Federal Depository Insurance Company (“FDIC”) and the Securities Investor Protection Corporation (“SIPC”) insured limit on domestic currency and the Netherlands’ FDIC counterpart for foreign currency. The Company only deals with reputable financial institutions and has not experienced any losses in such accounts.

 

For the three months ended  March 31, 2021 and 2020, the Company’s revenue was generated from eight and five customers, respectively. As of  March 31, 2021 and  December 31, 2020, the Company’s accounts receivable was from seven and nine customers, respectively. The loss of business from one or a combination of the Company’s customers could adversely affect its operations.

 

The Company conducts operations in the Netherlands through its foreign subsidiary and generates a portion of its revenues from customers that are located outside of the United States. For the three months ended  March 31, 2021, the Company had six customers outside of the United States (i.e. European and Asian customers) that accounted for approximately 76.7% or $353,000 of the revenue. For the three months ended  March 31, 2020, the Company had three customers outside of the United States that accounted for approximately 58.0% or $183,000 of the revenue. As of the three months ended  March 31, 2021, the Company had four customers outside of the United States (i.e. European and Asian customers) that accounted for approximately 46.0% or $174,000 of accounts receivable. As of  December 31, 2020, the Company had seven customers outside of the United States that accounted for approximately 41.6% or $123,000 of accounts receivable.

 

8

 

The Company uses several contract research organizations (“CROs”) to conduct its research projects. As of and for the three months ended  March 31, 2021, three CROs accounted for approximately $2,017,000 or 98.1% of total research services we purchased and $1,324,000 or 89.8% of the accounts payable. For the three months ended March 31, 2020, one CRO accounted for approximately $855,000, or 100% of total research services we purchased. As of  December 31, 2020, one CRO accounted for approximately $690,000 or 68.1% of the accounts payable. The loss of this CRO or a combination of the Company’s CROs could adversely affect its operations.

Cash and Cash Equivalents

We treat highly liquid investments with original maturities of three months or less when purchased as cash equivalents, including money market funds, which are unrestricted for withdrawal or use.

 

Investment Securities

 

The Company invests excess cash balances in short-term and long-term investment grade securities. Short-term investment securities mature within twelve (12) months or less, and long-term investment securities mature over twelve (12) months from the applicable reporting date. Management determines the appropriate classification of its investments at the time of purchase and reevaluates the classifications at each balance sheet date. The Company’s investments in debt securities have been classified and accounted for as held-to-maturity. Held-to-maturity securities are those securities that the Company has the ability and intent to hold until maturity. Held-to-maturity securities are recorded at amortized cost, adjusted for the amortization or accretion of premiums or discounts. Premiums and discounts are amortized over the life of the related held-to-maturity security. When a debt security is purchased at a premium, both the face value of the debt and premium amount are reflected as investing outflow. Other-than-temporary impairment charges, if incurred, will be included in other income (expense).

 

The Company’s investments in money market funds have been classified and accounted for as available-for-sale securities and presented as cash equivalents on the consolidated balance sheets. As of  March 31, 2021 and  December 31, 2020, all of our money market funds were invested in U.S. Government money market funds. The Company did not have any investment securities classified as trading as of  March 31, 2021 or  December 31, 2020.

 

Accounts Receivable

 

Accounts receivable consist of billed receivables currently due from customers and unbilled receivables. Unbilled receivables represent the excess of contract revenue (or amounts reimbursable under contracts) over billings to date. Such amounts become billable in accordance with the contract terms, which usually consider the passage of time, achievement of certain milestones or completion of the project.

 

Outstanding account balances are reviewed individually for collectability. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing accounts receivable. Substantially all of our accounts receivable were current and include unbilled amounts that will be billed and collected over the next twelve (12) months. There was no allowance for doubtful accounts as of  March 31, 2021 and  December 31, 2020.

 

Accounts receivable consist of the following:

 

  

March 31, 2021

  

December 31, 2020

 
  

(Unaudited)

  

(Audited)

 

Billed receivable

 $293,323  $130,532 

Unbilled receivable

  91,640   163,667 
  $384,963  $294,199 

 

9

 

Prepaid Expenses and Other Current Assets

 

Prepaid expenses and other current assets consist of the following:

 

  

March 31, 2021

  

December 31, 2020

 
  

(Unaudited)

  

(Audited)

 

Prepaid insurance

 $94,841  $204,988 

Prepaid expenses - various

  120,534   72,403 

Prepaid taxes

  814   3,164 
  $216,189  $280,555 

 

Accounts Payable

 

Accounts payable consist of the following:

 

  

March 31, 2021

  

December 31, 2020

 
  

(Unaudited)

  

(Audited)

 

Research and development expenses

 $1,337,755  $904,572 

Legal expenses

  93,071   24,496 

Other

  42,987   84,031 
  $1,473,813  $1,013,099 

 

Accrued Expenses

 

Accrued expenses consist of the following:

 

  

March 31, 2021

  

December 31, 2020

 
  

(Unaudited)

  

(Audited)

 

Employee wages and benefits

 $175,210  $447,881 

Research and development expenses

  42,006   28,508 

Other

  60,452   13,367 
  $277,668  $489,756 

 

Revenue Recognition

 

The Company has no pharmaceutical products approved for sale at this point, and all of our revenue to date has been research revenue from third-party collaborations and government grants. The Company is expected to generate future revenue from license agreements and collaborative arrangements, which may include upfront payments for licenses or options to obtain a license, payment for research and development services and milestone payments, in the form of cash or non-cash considerations (e.g., minority equity interest).

 

Revenue related to research collaborations and agreements: The Company typically performs research and development services as specified in each respective agreement on a best efforts basis, and recognizes revenue from research funding under collaboration agreements in accordance with the 5-step process outlined in ASC Topic 606 (“Topic 606”): (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We recognize revenue when we satisfy a performance obligation by transferring control of the service to a customer in an amount that reflects the consideration that we expect to receive. Since the performance obligation under our collaboration agreements is generally satisfied over time, we elected to use the input method under Topic 606 to measure the progress toward complete satisfaction of a performance obligation.

 

Under the input methods, revenue will be recognized on the basis of the entity’s efforts or inputs to the satisfaction of a performance obligation (e.g., resources consumed, labor hours expended, costs incurred, or time elapsed) relative to the total expected inputs to the satisfaction of that performance obligation. The Company believes that the cost-based input method is the best measure of progress to reflect how the Company transfers its performance obligation to a customer. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to budgeted costs to fulfill the performance obligation. These costs consist primarily of full-time equivalent effort and third-party contract costs. Revenue will be recognized based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligations.

 

10

 

A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company’s performance obligations. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete the Company’s performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.

 

Revenue related to grants: The Company may receive grants from governments, agencies, and other private and not-for-profit organizations. These grants are intended to be used to partially or fully fund the Company’s research collaborations, including opportunities arising in connection with COVID-19 that the Company is pursuing with certain collaborators. However, most, if not all, of such potential grant revenues, if received, is expected to be earmarked for third parties to advance the research required, including preclinical and clinical trials for SARS-CoV-2 vaccines and/or antibodies candidates.

 

Revenue related to sublicensing agreements: If the sublicense to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue allocated to the license when technology is transferred to the customer and the customer is able to use and benefit from the license.

 

Milestone payments: At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Company evaluates whether the achievement of the milestones is considered probable and estimates the amount to be included in the transaction price. If the milestone payment is in exchange for a sublicense and is based on the sublicensee’s subsequent sale of product, the Company recognizes milestone payment by applying the accounting guidance for royalties. To date, the Company has not recognized any milestone payment revenue resulting from any of its sublicensing arrangements.

 

Royalties: With respect to licenses deemed to be the predominant item to which the sales-based royalties relate, including milestone payments based on the level of sales, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its sublicensing arrangements.

 

We invoice customers based on our contractual arrangements with each customer, which may not be consistent with the period that revenues are recognized. When there is a timing difference between when we invoice customers and when revenues are recognized, we record either a contract asset (unbilled accounts receivable) or a contract liability (deferred research and development obligations), as appropriate. If upfront fees or considerations related to sublicensing agreement are received prior to the technology transfer, the Company will record the amount received as deferred revenue from licensing agreement.

 

We are not required to disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.

 

The Company adopted a practical expedient to expense sales commissions when incurred because the amortization period would be one year or less.

 

Research and Development Costs

 

Research and development (“R&D”) costs are expensed as incurred. R&D costs are for the Company’s internally funded pharmaceutical programs and other governmental and commercial projects.

 

11

 

Research and development costs consist of personnel-related costs, facilities, research-related overhead, services from independent contract research organizations, and other external costs. Research and development costs, including related party, during the three months ended March 31, 2021 and 2020 were as follows:

 

  

Three Months Ended March 31,

 
  

2021

  

2020

 
  

(Unaudited)

  

(Unaudited)

 

Outside contracted services

 $1,659,194  $613,790 

Personnel related costs

  148,162   123,638 

Facilities, overhead and other

  742   18,025 
  $1,808,098  $755,453 

 

Foreign Currency Transaction Gain or Loss

 

The Company and its foreign subsidiary use the U.S. dollar as its functional currency, and initially measure the foreign currency denominated assets and liabilities at the transaction date. Monetary assets and liabilities are then re-measured at exchange rates in effect at the end of each period, and property and non-monetary assets and liabilities are converted at historical rates.

 

Fair Value Measurements

 

The Company applies fair value accounting for certain financial instruments that are recognized or disclosed at fair value in the financial statements. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:

 

 Level 1 – Quoted prices in active markets for identical assets or liabilities.
 Level 2 – Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
 Level 3 – Inputs that are generally unobservable and typically reflect management’s estimate of assumptions that market participants would use in pricing the asset or liability.

 

The Company’s financial instruments included cash and cash equivalents, investment in debt securities, accounts receivable, accounts payable and accrued expenses, accrued payroll and related liabilities, deferred research and development obligations and deposits. The carrying amount of these financial instruments, except for investment in debt securities, approximates fair value due to the short-term maturities of these instruments. The Company’s short-term and long-term investments in debt securities are recorded at amortized cost, and their estimated fair value amounts are provided by the third-party broker service for disclosure purposes.

 

Non-Marketable Investments

 

The Company also holds investments in non-marketable equity securities of privately-held companies, which usually do not have a readily determinable fair value. Our policy is to measure these investments at cost less impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer such observable price changes may include instances where the investee issues equity securities to new investors, thus creating a new indicator of fair value, as an example. On a quarterly basis, we perform a qualitative assessment considering impairment indicators to evaluate whether these investments are impaired and also monitor for any observable price changes. If indicators of impairment exist, we will prepare a quantitative assessment of the fair value of our equity investments, which may include using both the market and income approaches which require judgment and the use of estimates, including discount rates, investee revenues and costs, and available comparable market data of private and public companies, among others. Valuations of such privately-held companies are inherently complex and uncertain due to the lack of liquid market for the company’s securities. In addition, such investments are inherently risky in that such companies are typically at an early stage of development, may have no or limited revenues, may not be or may never become profitable, may not be able to secure additional funding or their technologies, services or products may not be successfully developed or introduced into the market.

 

12

 

Income Taxes

 

The Tax Cuts and Jobs Act (“TCJA”) was enacted on December 22, 2017 and became effective January 1, 2018. The TCJA contains several key provisions, including a reduction in the U.S. federal corporate income tax rate from 35% to 21% and repeal of the corporate alternative minimum tax (“AMT”). The TCJA’s reduction in the U.S. statutory tax rate had no additional impact on the consolidated financial statement for the year ended  December 31, 2020.

 

For the three months ended March 31, 2021, there were no provision for income taxes and unrecognized tax benefits recorded. As of  March 31, 2021 and  December 31, 2020, deferred tax assets were approximately $10.2 million and $9.4 million, respectively. Due to the Company’s history of operating losses and the uncertainty regarding our ability to generate taxable income in the future, the Company has established a 100% valuation allowance against deferred tax assets as of  March 31, 2021 and  December 31, 2020.

 

Comprehensive Income (Loss)

 

Comprehensive income (loss) includes net income (loss) and other revenue, expenses, gains and losses that are recorded as an element of shareholders’ equity but are excluded from net income (loss) under GAAP. The Company does not have any significant transactions that are required to be reported in other comprehensive income (loss), and therefore, does not separately present a statement of comprehensive income (loss) in its consolidated financial statements.

 

Stock-Based Compensation

 

We recognize all share-based payments to employees, consultants, and our board of directors (“Board of Directors”), as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statement of operations based on the grant date fair values of such payments. Stock-based compensation expense recognized each period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur.

 

Net Loss Per Share

 

Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common stock shares outstanding during the reporting period. Diluted net loss per share adjusts the weighted average number of common stock shares outstanding for the potential dilution that could occur if common stock equivalents, such as stock options were exercised and converted into common stock, calculated by applying the treasury stock method.

 

For the three months ended March 31, 2021 and 2020, the effect of the potential exercise of options to purchase 5,324,215 and 4,663,390 shares of common stock, respectively, were excluded from the computation of diluted net loss per share as their effect would have been anti-dilutive.

 

Recently Adopted Accounting Pronouncements 

 

In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which modifies the measurement of expected credit losses of certain financial instruments. ASU 2016-13 will be effective for the Company beginning in the first quarter of 2023. The Company does not expect ASU 2016-13 to have a material impact on our consolidated financial positions, results of operations, and cash flows.

 

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The amendments of this update simplify the accounting for income taxes by removing certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The Company adopted ASU 2019-12 on  January 1, 2021, and adoption of ASU 2019-12 did not have any material impact on our consolidated financial positions, results of operations, cash flows and related disclosures.

 

Other pronouncements issued by the FASB or other authoritative accounting standards group with future effective dates are either not applicable or not significant to our consolidated financial statements.

 

13

 
 

Note 2:    Cash, Cash Equivalent, and Investments

 

The Company’s investments in debt securities are classified as held-to-maturity and are recorded at amortized cost, and its investments in money market funds are classified as cash equivalents. The following table shows the Company’s cash, available-for-sale securities, and investment securities by major security type as of  March 31, 2021, and  December 31, 2020:

 

  

March 31, 2021 (Unaudited)

 
         

Gross

  

Gross

     
  

Level

      

Unrealized

  

Unrealized

     
  

(1)

  

Fair Value

  

Holding Gains

  

Holding Losses

  

Adjusted Cost

 

Cash and Cash Equivalents

                   

Cash

    $1,217,419  $  $  $1,217,419 

Money Market Funds

 1   11,838,139         11,838,139 

Subtotal

     13,055,558         13,055,558 

Short-Term Investment Securities (2)

                   

Corporate Bonds (3)

 2   14,161,252   1,658   (17,847)  14,177,441 

Total

    $27,216,810  $1,658  $(17,847) $27,232,999 

 

 

  

December 31, 2020 (Audited)

 
         

Gross

  

Gross

     
  

Level

      

Unrealized

  

Unrealized

     
  

(1)

  

Fair Value

  

Holding Gains

  

Holding Losses

  

Adjusted Cost

 

Cash and Cash Equivalents

                   

Cash

    $149,015  $  $  $149,015 

Money Market Funds

 1   20,488,030         20,488,030 

Subtotal

     20,637,045         20,637,045 

Short-Term Investment Securities (2)

                   

Corporate Bonds (3)

 2   8,473,461   22,473   (6,463)  8,457,451 

Total

    $29,110,506  $22,473  $(6,463) $29,094,496 

_________________

Notes:

(1) Definition of the three-level fair value hierarchy:

 

Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities

 

Level 2 - Other inputs that are directly or indirectly observable in the markets

 

Level 3 - Inputs that are generally unobservable

(2) Short-term investment securities will mature within 12 months or less, from the applicable reporting date.

(3) The premium paid to purchase held-to-maturity investment securities was $283,940 and $196,385 for the three months ended March 31, 2021 and 2020, respectively. The premium paid to purchase held-to-maturity investment securities was $282,946 for the year ended  December 31, 2020.

 

The Company considers the declines in market value of its investment portfolio to be temporary in nature. The Company’s investment policy requires investment securities to be investment grade and held to maturity with the primary objective to maintain a high degree of liquidity while maximizing yield. When evaluating an investment for other-than-temporary impairment, the Company reviews factors such as the length of time and extent to which fair value has been below its cost basis, the financial condition of the issuer and any changes thereto, changes in market interest rates, and whether it is more likely than not the Company will be required to sell the investment before recovery of the investment’s cost basis. As of  March 31, 2021, the Company does not consider any of its investments to be other-than-temporarily impaired.

 

14

 
 

Note 3:    Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately-Held Companies

 

BDI 

 

On June 30, 2017, the Company entered into a strategic Research Services Agreement (the “RSA”) with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U. (“BDI Pharma”), and a Service Framework Agreement (the “SFA”, and together with the RSA, the “R&D Agreements”), with VLP The Vaccines Company, S.L.U. (“VLPbio”), both of which are subsidiaries of Biotechnology Developments for Industry, S.L., a Spanish biotechnology company (“BDI Holdings” and together with BDI Pharma and VLPbio, “BDI”). 

 

The R&D Agreements provide a framework under which the parties will engage in a research and development collaboration encompassing several different projects over approximately a two-year period, with a focus on advancing Dyadic’s proprietary C1 technology in the development of next generation biological vaccines and drugs. Dyadic expects to leverage the BDI team’s previous C1 gene expression and industrial fermentation scale-up and commercialization experience with yeast and filamentous fungi processes to further advance Dyadic’s proprietary C1 technology with the potential to commercialize certain biopharmaceutical product(s). All of the data and any products developed from the funded research projects will be owned by Dyadic.

 

Upon closing of the BDI transaction, the Company paid EUR €1.0 million (the “RSA Initial Payment”) in cash to engage BDI to develop designated C1 based product candidates and further improve the C1 manufacturing process, in consideration of which Dyadic also received a 16.1% equity interest in BDI Holdings and a 3.3% equity interest in VLPbio. BDI is obligated to spend a minimum amount of EUR €936,000 over two years in the conduct of the research and development project under the RSA. If the research and development activities produce a product that is selected for additional development and commercialization, then Dyadic expects to share with BDI a range of between 50% and 75% of the net income from such selected product, depending upon the amount of BDI’s aggregate spend in the development of the selected product, with a minimum aggregate spend by BDI of EUR €1 million for a 50% share and EUR 8.0 million for a 75% share. If BDI does not enter into an agreement with Dyadic for such additional development and commercialization of the selected product, then Dyadic will pay to BDI EUR €1.5 million of the net income from Dyadic’s commercialization, if any, of the selected product. In addition, under the SFA, Dyadic agreed to purchase from BDI at least USD $1.0 million (the “SFA Commitment”) in contract research services specified by Dyadic over two years since the closing of the BDI transaction.

 

The Company has concluded that BDI is not a Variable Interest Entity (“VIE”), because BDI has sufficient equity to finance its activities without additional subordinated financial support and its at-risk equity holders have the characteristics of a controlling financial interest. Additionally, Dyadic is not the primary beneficiary of BDI as Dyadic does not have the power to control or direct the activities of BDI or its operations. As a result, the Company does not consolidate its investments in BDI, and the financial results of BDI are not included in the Company’s consolidated financial results.

 

The Company performed a valuation analysis of the components of the transaction and allocated the consideration based on the relative fair value of each component. As the fair value of BDI equity interest was considered immaterial, the RSA Initial Payment of approximately USD $1.1 million (EUR €1.0 million) was accounted for as a prepaid research and development collaboration payment on our consolidated balance sheet, and both the collaboration payment under the RSA and the SFA Commitment of USD $1.0 million paid by Dyadic were expensed as the related research services were performed by BDI. In June 2019, BDI has completed its services under the RSA and the entire amount of the RSA Initial Payment was expensed. Dyadic had fulfilled its SFA commitment and completed all research projects under the SFA in 2019.

 

On February 18, 2021, the Company entered into a separate service agreement with BDI to perform a research project unrelated to the R&D Agreements. For the three months ended March 31, 2021, approximately $15,000 recorded in the cost of research and development revenue was associated with this new service agreement.

 

Novovet and Luina Bio 

 

On April 26, 2019, the Company entered into a sub-license agreement (the “Luina Bio Sub-License Agreement”) with Luina Bio Pty Ltd. (“Luina Bio”) and Novovet Pty Ltd (“Novovet”). Under the terms of the Luina Bio Sub-License Agreement, the Company has granted to Novovet, subject to the terms of the license agreement entered into between the Company and Danisco US, Inc. on December 31, 2015, a worldwide sub-license to certain patent rights and know-how related to Dyadic’s proprietary C1 gene expression platform for the exclusive and sole purpose of commercializing certain targeted antigen and biological products for the prevention and treatment of various ailments for companion animals.

 

In consideration of the license granted pursuant to the Luina Bio Sub-License Agreement, Dyadic received a 20% equity interest in Novovet (“Novovet Up-Front Consideration”) in accordance with the terms of Novovet’s Shareholder Agreement, and will receive a percentage of royalties on future net sales and non-sales revenue, if any, which incorporates Dyadic’s proprietary C1 gene expression platform.

 

15

 

The Company evaluated the nature of its equity interest investment in Novovet and determined that Novovet is a VIE, because Novovet does not have sufficient equity to finance its activities without additional financial support from third party investors or lenders. However, the Company is not the primary beneficiary of Novovet as Dyadic does not have the power to control or direct the activities of Novovet that most significantly impact the VIE. As a result, the Company will not consolidate its investment in Novovet, but account for under the equity method investment, given that it has the ability to exercise significant influence, but not control, over Novovet.

 

To date Novovet has not raised the capital required to move this opportunity forward, and therefore, the Company has not transferred its C1 technology to Novovet. Therefore, the Novovet Up-Front Consideration received under the Luina Bio Sub-License Agreement, in the form of a 20% equity interest in Novovet, does not yet meet the revenue recognition criteria under ASC 606. The Company will account for its investment in Novovet and the related income under the equity method of accounting, once the transfer of its C1 technology is completed and Novovet receives adequate financing required to commence its research and development activities. The Company intends to terminate the Luina Bio Sub-License Agreement in 2021 should Novovet be unable to raise the required funding.

 

Alphazyme 

 

On May 5, 2019, the Company entered into a sub-license agreement (the “Alphazyme Sub-License Agreement”) with Alphazyme, LLC (“Alphazyme”). Under the terms of the Alphazyme Sub-License Agreement, the Company has granted to Alphazyme, subject to the terms of the license agreement entered into between the Company and Danisco US, Inc. on December 31, 2015, a sub-license to certain patent rights and know-how related to Dyadic’s proprietary C1 gene expression platform for the purpose of commercializing certain pharmaceutical products that are used as reagents to catalyze a chemical reaction to detect, measure, or be used as a process intermediate to produce a nucleic acid as a therapeutic or diagnostic agent.

 

On June 24, 2020, the Company entered into an Amended and Restated Non-Exclusive Sub-License Agreement (the “Amended Sub-License Agreement”) with Alphazyme. Pursuant to the Amended Sub-License Agreement and in consideration of Dyadic’s transfer of its C1 technology, Alphazyme issued 2.50% of the Class A shares of Alphazyme to Dyadic, and Dyadic became a party to the Alphazyme Limited Liability Company Agreement pursuant to which the Company has agreed to certain customary rights, covenants and obligations. In addition, and subject to achieving certain milestones, Alphazyme is obligated to pay a potential milestone payment and royalties, based on net sales, if any, which incorporate Dyadic’s proprietary C1 gene expression platform. 

 

On December 1, 2020, the Company entered into an Amended and Restated Limited Liability Company Agreement with Alphazyme (the “Amended Alphazyme LLC Agreement”) was entered into. Under the Amended Alphazyme LLC Agreement, Alphazyme obtained an additional capital contribution and Dyadic’s ownership was diluted to 1.99%.

 

The Company evaluated the nature of its equity interest investment in Alphazyme and determined that Alphazyme is a VIE due to the capital structure of the entity. However, the Company is not the primary beneficiary of Alphazyme as Dyadic does not have the power to control or direct the activities of Alphazyme that most significantly impact the VIE. As a result, the Company does not consolidate its investment in Alphazyme. The Company reports its investment in Alphazyme under the cost method of accounting, given that it does not have the ability to exercise significant influence or control,

 

For the year ended December 31, 2020, the Company recorded a gain of $284,709 from its investment in Alphazyme as a result of a third-party additional capital contribution obtained by Alphazyme. As of March31, 2021, the Company does not consider its investment in Alphazyme to be impaired.

 

IDBiologics, Inc. 

 

On July 8, 2020, the Company entered into a Common Stock Purchase Agreement (the “IDBiologics Agreement”) with IDBiologics, Inc (“IDBiologics”). IDBiologics is a private biotechnology company focused on the development of human monoclonal antibodies for the treatment and prevention of serious infectious diseases. The Company was founded in 2017 and seeded by Vanderbilt University Medical Center in response to the repeated threats of epidemics around the world, including Ebola in West Africa and Zika in the Americas. IDBiologics is developing a portfolio of monoclonal antibodies against SARS-CoV-2, influenza and Zika viruses.

 

Under the term of the IDBiologics Agreement, Dyadic agreed to receive 129,611 shares of IDBiologics’ common stock, which represent 0.37% of IDBiologics’ outstanding equity, in exchange for the services to be provided by Dyadic. Such services include the use of Dyadic’s C1 technology to express a SARS-CoV-2 monoclonal antibody which IDBiologics licensed from the Vanderbilt Vaccine Center. The shares of common stock of IDBiologics vested 50% upon the signing of the IDBiologics Agreement, 25% will vest upon the completion of Step 3 of a feasibility study required by the IDBiologics Agreement, and 25% will vest at the end of the project.

 

The Company evaluated the nature of its equity interest in IDBiologics and determined that IDBiologics is a VIE due to the capital structure of the entity. However, the Company is not the primary beneficiary of IDBiologics as Dyadic does not have the power to control or direct the activities of IDBiologics that most significantly impact the VIE. As a result, the Company does not consolidate its investment in IDBiologics. Upon receipt its shares, Dyadic will account for the equity interest in IDBiologics under the cost method. No revenue from the IDBiologics Agreement was recorded during the three months ended March 31, 2021, because the amount of consideration received was immaterial.

 

 

 

16

 

Note 4:    Commitments and Contingencies

 

Legal Proceedings

 

We are not currently involved in any litigation that we believe could have a materially adverse effect in our financial condition or results of operations. From time to time, the Company is subject to legal proceedings, asserted claims and investigations in the ordinary course of business, including commercial claims, employment and other matters, which management considers immaterial, individually and in the aggregate. The Company makes a provision for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The requirement for these provisions is reviewed at least quarterly and adjusted to reflect the impact of negotiations, settlements, rulings, advice of legal counsel and other information and events pertaining to a particular case. Litigation is inherently unpredictable and costly. Protracted litigation and/or an unfavorable resolution of one or more of proceedings, claims or investigations against the Company could have a material adverse effect on the Company’s consolidated financial position, cash flows or results of operations.

 

 

Note 5:    Share-Based Compensation

 

Description of Equity Plans

 

The 2011 Equity Incentive Plan (the “2011 Plan”) was adopted by the Company’s Board of Directors on April 28, 2011 and approved by the Company’s stockholders on June 15, 2011. The 2011 Plan serves as the successor to the Company’s 2006 Stock Option Plan (the “2006 Plan”). Since the effective date of the 2011 Plan, all equity awards were made from the 2011 Plan, and no additional awards will be granted under the 2006 plan. Under the 2011 Plan, 3,000,000 shares of the Company’s common stock were initially reserved for issuance pursuant to a variety of share-based compensation awards, plus any shares available for issuance under the 2006 Plan or are subject to awards under the 2006 Plan which are forfeited or lapse unexercised and which following the effective date are not issued under the 2006 Plan. In accordance with the provisions of the 2011 Plan, the Board of Directors approved an increase of 1,500,000 shares to the plan on January 1, 2019 and 2020.

 

At our 2021 Virtual Annual Meeting of Shareholders (“Annual Meeting”) to be held on June 11, 2021, shareholders will be asked to approve the Company’s 2021 Equity Incentive Award Plan (the “2021 Plan”), which was adopted, subject to shareholder approval, by the Board of Directors on April 9, 2021. We are seeking stockholder approval of the 2021 Plan to increase the number of shares available for the grant of stock options, restricted stock awards and other awards by 3,000,000 in addition to the number of shares remaining available for the grant of new awards under the 2011 Plan as of April 16, 2021. If this proposal is approved by our shareholders, the 2021 Plan will become effective as of the date of the Annual Meeting and as of such date, no additional awards will be granted under the 2011 Plan. If our shareholders do not approve this proposal, the 2021 Plan will not become effective and the 2011 Plan will continue to be effective in accordance with its terms, until its expiration date.

 

As of  March 31, 2021, the Company had 5,324,215 stock options outstanding and an additional 1,388,386 shares of common stock available for grant under the 2011 Plan. As of  December 31, 2020, there were 4,638,390 stock options outstanding and 2,134,211 shares of common stock available for grant under the 2011 Plan.

 

Stock Options

 

Options are granted to purchase common stock at prices that are equal to the fair value of the common stock on the date the option is granted. Vesting is determined by the Board of Directors at the time of grant. The term of any stock option awards under the Company’s 2011 Plan is ten years except for certain options granted to the contractors which are one or three years.

 

The grant-date fair value of each option grant is estimated using the Black-Scholes option pricing model and amortized on a straight-line basis over the requisite service period, which is generally the vesting period, for each separately vesting portion of the award as if the award was, in substance, multiple awards. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs, including the following:

 

Risk-free interest rate. The risk-free interest rate is based on U.S. Treasury rates with securities approximating the expected lives of options at the date of grant.

 

Expected dividend yield. The expected dividend yield is zero, as the Company has never paid dividends to common shareholders and does not currently anticipate paying any in the foreseeable future.

 

17

 

Expected stock price volatility. The expected stock price volatility was calculated based on the Company’s own volatility after the DuPont Transaction. The Company reviews its volatility assumption on an annual basis and has used the Company’s historical volatility since 2016, as the DuPont Transaction resulted in significant changes in the Company’s business and capital structure.

 

Expected life of option. The expected life of option was based on the contractual term of the option and expected employee exercise and post-vesting employment termination behavior. The Company uses the weighted average vesting period and contractual term of the option as the best estimate of the expected life of a new option, except for the options granted to the CEO (i.e., 5 or 10 years) and certain contractors (i.e., 2 or 3years).

 

The assumptions used in the Black-Scholes option pricing model for stock options granted during the three months ended March 31, 2021 are as follows:

 

Risk-Free interest rate

  0.13%-0.55% 

Expected dividend yield

  —% 

Expected stock price volatility

  54.52%-56.07% 

Expected life of options (in years)

  2.00-6.25 

 

The following table summarizes the stock option activities during the three months ended March 31, 2021:

 

          

Weighted-Average

     
      

Weighted-Average

  

Remaining Contractual

  

Aggregate Intrinsic

 
  

Shares

  

Exercise Price

  

Term (Years)

  

Value

 

Outstanding at December 31, 2020

  4,638,390  $2.44   5.64  $13,701,610 

Granted (1)

  745,825   5.25         

Exercised (2)

  (60,000)  1.93         

Expired

              

Canceled

              

Outstanding at March 31, 2021

  5,324,215  $2.84   6.03  $14,209,431 
                 

Exercisable at March 31, 2021

  4,016,141  $2.28   5.09  $12,927,908 

_________________

Notes:

(1) Represents the following stock options granted:

 

Annual share-based compensation awards on January 4, 2021, including: (a) 417,500 stock options with an exercise price of $5.16 per share granted to executives and key personnel, upon one year anniversary, or vesting annually in equal installments over four years, (b) 227,500 stock options with an exercise price of $5.16 per share granted to members of the Board of Directors, vesting upon one year anniversary, (c) 23,325 stock options with an exercise price of $5.16 per share granted to employees, vesting annually in equal installments over four years and (d) 5,000 stock options with an exercise price of $5.16 per share granted to a consultant, vesting upon one year anniversary.

 

One-time award on January 8, 2021, 35,000 stock options with an exercise price of $5.50 per share granted to a new member of the Board of Directors, vesting in one year from the grant date.

 

One-time award on January 21, 2021, 7,500 stock options with an exercise price of $5.65 per share granted to a consultant, vesting in one year from the grant date.

 

One-time award on March 22, 2021, 30,000 stock options with an exercise price of $6.87 per share granted to a consultant, vesting in one year from the grant date.

 

(2) Represents the following stock options exercised:

 

A total of 60,000 stock options exercised with a weighted average exercise price of $1.93.

 

Compensation Expenses

 

We recognize all share-based payments to employees and our Board of Directors, as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statement of operations, and these charges had no impact on the Company’s reported cash flows. Stock-based compensation expense is calculated on the grant date fair values of such awards, and recognized each period based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur.

 

18

 

Total non-cash stock option compensation expense was allocated among the following expense categories:    

 

  

Three Months Ended March 31,

 
  

2021

  

2020

 

General and administrative

 $377,052  $380,251 

Research and development

  44,019   46,688 

Total

 $421,071  $426,939 

 

 

 
Note 6:     Shareholders Equity

 

Issuances of Common Stock

 

For the three months ended March 31, 2021, there were 60,000 shares of the Company’s common stock issued as a result of the exercise of stock options with a weighted average issue price of $1.93 per share. For the three months ended March 31, 2020, there were 100,000 shares of the Company’s common stock issued as a result of the exercise of stock options with a weighted average issue price of $1.78 per share.

 

Changes in Stockholders Equity

 

      

Three Months Ended March 31, 2021 (Unaudited)

     
  

Common Stock

  

Treasury Stock

  

Additional Paid-In Capital

  

Accumulated Deficit

  

Total

 

January 1, 2021

 $39,748  $(18,929,915) $98,013,079  $(50,676,351) $28,446,561 

Stock-based compensation

        421,071      421,071 

Stock issued

  60      115,740      115,800 

Net loss

           (3,294,949)  (3,294,949)

March 31, 2021

 $39,808  $(18,929,915) $98,549,890  $(53,971,300) $25,688,483 

 

      

Three Months Ended March 31, 2020 (Unaudited)

     
  

Common Stock

  

Treasury Stock

  

Additional Paid-In Capital

  

Accumulated Deficit

  

Total

 

January 1, 2020

 $39,613  $(18,929,915) $96,105,851  $(41,351,078) $35,864,471 

Stock-based compensation

        426,939      426,939 
Stock issued  100      174,900      175,000 

Net loss

           (2,214,139)  (2,214,139)

March 31, 2020

 $39,713  $(18,929,915) $96,707,690  $(43,565,217) $34,252,271 

 

19

 

Treasury Stock

 

As of  March 31, 2021, and  December 31, 2020, there were 12,253,502 shares of common stock held in treasury, at a cost of approximately $18.9 million, representing the purchase price on the date the shares were surrendered to the Company.

 

Open Market Sale Agreement

 

On August 13, 2020, we entered into an Open Market Sale Agreement℠ with Jefferies LLC, or Jefferies, with respect to an at the market offering program under which we may offer and sell, from time to time at our sole discretion, shares of our common stock, par value $0.001 per share, having an aggregate offering price of up to $50.0 million through Jefferies as our sales agent or principal.

 

We have not and are not obligated to sell any shares under the sale agreement. Subject to the terms and conditions of the sale agreement, Jefferies will use commercially reasonable efforts, consistent with its normal trading and sales practices and applicable laws and regulations, to sell shares of our common stock from time to time based upon our instructions, including any price, time or size limits or other customary parameters or conditions we specify, subject to certain limitations. Under the sale agreement, Jefferies may sell shares of our common stock by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended.

 

We will pay Jefferies a commission equal to 3.0% of the gross proceeds from each sale of shares of our common stock sold through Jefferies under the sale agreement and will provide Jefferies with customary indemnification and contribution rights. In addition, we agreed to reimburse certain legal expenses and fees by Jefferies in connection with the offering up to a maximum of $50,000, in addition to certain ongoing disbursements of Jefferies’ counsel, if required. The sale agreement will terminate upon the sale of all $50.0 million of shares under the sale agreement, unless earlier terminated by either party as permitted therein.

 

The issuance and sale, if any, of shares of our common stock by us under the sale agreement will be made pursuant to a registration statement on Form S-3 filed with the SEC on August 13, 2020 and declared effective by the SEC on August 25, 2020 and the accompanying Prospectus, as supplemented by a Prospectus Supplement. As of the date of this filing, there have been no sales made under the Open Market Sale Agreement℠.

 

 

Note 7:    Subsequent Events

 

Management continues to actively monitor the COVID-19 pandemic and its development, and the possible effects on the Company’s financial condition, liquidity, operations, vendors, industry, and workforce.

 

For purpose of disclosure in the consolidated financial statements, the Company has evaluated subsequent events through May 13, 2021, the date the consolidated financial statements were available to be issued. Management is not aware of any material events that have occurred subsequent to the balance sheet date that would require adjustment to, or disclosure in the accompanying financial statements.

 

 

Item 2.

Managements Discussion and Analysis of Financial Condition and Results of Operations

 

The following discussion and analysis of financial condition and results of operations should be read in conjunction with the financial statements and the notes to those statements appearing in this Quarterly Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks, assumptions and uncertainties. Important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis include, but not limited to those set forth in Item 1A. Risk Factors in this Quarterly Report. All forward-looking statements included in this Quarterly Report are based on information available to us as of the time we file this Quarterly Report and, except as required by law, we undertake no obligation to update publicly or revise any forward-looking statements.

 

20

 

Overview

 

Description of Business

 

Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) is a global biotechnology platform company based in Jupiter, Florida with operations in the United States, a satellite office in the Netherlands and predominantly three research organizations performing services under contract to Dyadic in the Netherlands, Finland and Israel. Over the past two plus decades, the Company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has previously licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica (formerly known as Myceliophthora thermophila) fungus, which the Company named C1. The C1 technology is a robust and versatile fungal expression system for the development and production of enzymes and other proteins.

 

On December 31, 2015, the Company sold its industrial technology business to Danisco USA (“Danisco”), the industrial biosciences business of DuPont (NYSE: DD) (the “DuPont Transaction”). As part of the DuPont Transaction, Dyadic retained co-exclusive rights to the C1 technology for use in all human and animal pharmaceutical applications, and currently has the exclusive ability to enter into sub-license agreements (subject to the terms of the license and to certain exceptions). Danisco retained certain rights to utilize the C1 technology in pharmaceutical applications, including the development and production of pharmaceutical products, for which it will be required to make royalty payments to Dyadic upon commercialization. In certain circumstances, Dyadic may owe a royalty to either Danisco or certain licensors of Danisco, depending upon whether Dyadic elects to utilize certain patents either owned by Danisco or licensed in by Danisco.

 

After the DuPont Transaction, the Company has been focused on the biopharmaceutical industry, specifically in further improving and applying the proprietary C1 technology into a safe and efficient gene expression platform to help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs and other biological products at flexible commercial scales. 

 

The Company and its C1 technology played an important role in the €20 million Zoonosis Anticipation Preparedness Initiative (“ZAPI”) program, which was a five-year research and development program sponsored by the European Union. ZAPI brought together experts in human and animal health to create new platforms and technologies that will facilitate a fast, coordinated, and practical response to new pandemic threats as soon as they emerge. The Company’s C1 gene expression and recombinant protein production platform was selected by ZAPI as a production host of antigens for the Schmallenberg virus (“SBV”) and Rift Valley Fever virus (“RVFV”). The C1 expressed SBV antigen was produced at approximately 300 times greater yield than the SBV antigen expressed from insect (baculovirus) cells and was more stable. Additionally, the C1 SBV antigen was shown to be safe and effective to provide full protection to cattle, sheep, and mice. Based on these results, ZAPI has provided the Company with additional funding, in 2021, to produce both the SBV and RVFV antigens in order to perform expanded animal trials with the C1 expressed antigens which is expected to generate additional safety and efficacy data. In the first quarter of 2021, ZAPI expanded its program with Dyadic by providing additional funding to C1 research and development efforts as well as to conduct additional animal studies using the SBV and RVFV antigens produced from C1. Several positive outcomes have already originated from the ZAPI results, including several fully funded animal health projects and a number of COVID-19 vaccine collaborations, including Dyadic’s proprietary receptor-binding domain (“RBD”) antigen of the SARS-CoV-2 spike protein, used in the production of the Company’s proprietary COVID-19 DYAI-100 vaccine candidate. The C1 expressed SARS-CoV-2 RBD antigen has been developed and tested in various collaborations, including with three of the top infectious disease and coronavirus scientists who worked with Dyadic and C1 in the ZAPI consortium, the Israel Institute for Biological Research (“IIBR”), Medytox, Inc., and others. These activities have positioned the Company to determine its current path forward for an anticipated first-in-human Phase 1 clinical program of DYAI-100 which is anticipated to start in the second half of 2021. The main goal of the DYAI-100 Phase 1 clinical trial is to demonstrate that a protein produced from the Company’s proprietary and patented C1-cells can be safely used in humans which we anticipate will help to accelerate the C1 technology platform’s adoption, use and commercialization and also to serve as a proof of concept for the development of next generation multivariant COVID-19 vaccine candidates.

 

Based on a growing amount of safety, efficacy and productivity data from research and development programs within ZAPI, the IIBR and several internal and externally funded programs, we and a growing number of scientists globally believe that the C1 cell protein production platform can be used to speed the development, lower production costs, and improve the performance of biologic vaccines, drugs and other biological products which can be efficiently manufactured at flexible commercial scales more affordably. Based on these internally and externally funded C1-cell engineering programs, the number and types of potential vaccines, drugs and biologic products which may be developed and commercialized, continues to grow. Some examples of human and animal vaccines and drugs which have the potential to be produced from C1-cells are protein antigens, virus-like particles (“VLPs”), monoclonal antibodies (“mAbs”), Bi/Tri-specific antibodies, Fab antibody fragments, Fc-Fusion proteins, as well as other therapeutic enzymes and proteins. The Company is involved in multiple funded research collaborations with animal and human pharmaceutical companies which are designed to leverage its C1 technology to develop innovative vaccines and drugs, biosimilars and/or biobetters. 

 

21

 

Recent Developments

 

In 2021, the Company continues to advance its internal research projects and expand its relationships with business and research partners in the biotech and pharmaceutical industry, academic and other institutions, as well as certain government agencies, as follows: 

 

COVID-19 Initiatives:

 

Advancing the Company’s proprietary COVID-19 vaccine candidate (C1 produced SARS-CoV-2-S-RBD antigen), DYAI-100, towards a first-in-human Phase 1 clinical trial:

 

o

DYAI-100 is supported by a strategic collaboration with, among other parties, the IIBR and leading infectious disease scientists from Erasmus Medical Centre, University Utrecht, TiHo Hannover (scientists who were involved in the ZAPI program) to develop a temperature stable, safe and effective COVID-19 vaccine candidate that can be rapidly manufactured, in large quantities, at low cost, using standard microbial fermenters that are readily available globally.
 

o

In March 2021, the Company engaged CR2O, a contract research organization, to manage and support further preclinical and clinical development of DYAI-100. The animal GLP toxicology study began at the end of April 2021, the cGMP production of the C1 expressed SARS-CoV-2 RBD drug product has begun, and a first-in-human Phase 1 clinical trial is expected to begin by year-end.

 

o

There are a number of benefits the Company expects to come from the DYAI-100 Phase 1 clinical trial, including demonstrating that certain C1 produced proteins can be produced under cGMP conditions and are safe and tolerated in humans, which will be required by regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Additionally, this will also serve as a proof of concept study for potential C1 manufactured next-generation monovalent and multivalent COVID-19 variant vaccine candidates that can be developed and manufactured rapidly, in large quantities, and more affordably.

 

In parallel with advancing the DYAI-100 vaccine candidate towards a Phase 1 clinical trial, the Company has already started to engineer several C1 cell lines to produce several SARS-CoV-2 variant antigens, and has successfully expressed the South African, Brazilian, and UK variant antigens at high productivity and stability. The Company and its collaborators are  working to produce RBD antigen and full spike proteins for additional COVID-19 variants.

 

In March 2021, the Company expanded a vaccine development partnership with South Korea’s Medytox Inc. to co-develop C1 enabled COVID-19 variant vaccines and/or boosters (e.g., tetravalent or quadrivalent COVID-19 vaccine candidates) to immunize people against two or more of the current and future COVID-19 variants in Korea and Southeast Asia.

 

In April 2021, the Company signed a separate fully funded research collaboration with CR2O to develop a COVID-19 antibody.

 

 

Human Health (Non-COVID) Collaborations:

 

 

In February 2021, the Company initiated a fully funded collaboration with TurtleTree Scientific to develop several recombinant protein growth factors, which have the potential to play a critical role in tissue development and healing, including regenerative therapies.

 

In March 2021, the Company signed a research collaboration with a new research partner to develop an antigen.

 

In April 2021, the Company expanded its collaboration with IDBiologics and started a new fully funded collaboration to develop a second antibody.

 

Collaborating with Jiangsu Hengrui Medicine and two top pharmaceutical companies for proof of concept studies designed to improve the production of biologic drugs, including bispecific antibodies, of therapeutic interest. Interim results have demonstrated these biologic drugs were expressed from C1 and there are ongoing discussions for advancing some of these projects towards potential clinical development.

 

Continued progress in several ongoing collaborations to develop potential therapeutic candidates of commercial potential, including expressing two new bispecific antibodies and advancing two other antibodies which are entering the second stages for applications in oncology and autoimmune disease.

 

Conducting a feasibility study with the University of Oslo for a potential influenza vaccine. Interim results demonstrated that C1 can express hemagglutinin at a high level, and most importantly, that C1 hemagglutinin induced a high level response of neutralizing antibodies in a mice study.

 

Animal Health Collaborations:

 

 

In collaboration with a top global animal health company, initial studies have demonstrated production of two different antigens for a potential vaccine for an acute respiratory disease of birds. Interim results demonstrated that the antigens were effective at generating high antibody titers. An animal challenge study designed to evaluate protection against the acute respiratory disease is expected to start in June 2021.

 

ZAPI held its Final Stakeholders Virtual Web Meeting on February 4-5, 2021, where positive results were reported from animal studies in mice, sheep, and cattle which evaluated the safety, efficacy, and protection of the C1 produced SBV antigen. The C1 platform was selected by ZAPI to produce recombinant antigens after demonstrating far greater antigen productivity from C1-cells than insect (baculovirus) cells, the next leading expression platform, for both SBV and RVFV. As previously disclosed, in the first quarter of 2021, ZAPI has provided the Company with additional funding to produce larger quantities of both the SBV and RVFV antigens to demonstrate commercial-scale viability of C1 produced SBV and RVFV antigens, and to further optimize the use of C1 to produce recombinant protein subunit nanoparticle vaccines. Preliminary results have been very encouraging and continues to further support C1’s potential for use in developing nanoparticle vaccines in larger quantities at lower cost. Several positive outcomes have already originated from the ZAPI results, including several fully funded animal health projects and several SARS-CoV-2 vaccine collaborations, including Dyadic’s RBD antigen of the SARS-CoV-2 spike protein. 

 

Corporate Highlights:

 

 

The Company extended two non-exclusive research license agreements, including WuXi Biologics and an affiliate of a top pharma company, to continue their C1 research projects in a CDMO and manufacturing environment at their own facilities.

 

Hosted KOL Fireside Chat: “The Potential of the Transformative Dyadic C1 Protein Technology in Helping Meet Global Health Challenges”, which is available on the Investors section of the Company’s website, which is available on the Investors section of the Company’s website.

 

To date, the Company participated in several scientific conferences, including the recently held World Vaccine Conference, Protein Engineering and Cell Therapy Conference (PEGS) and the ZAPI Final Stakeholders Virtual Conference. ZAPI Stakeholders Final Conference speaker slides and webinar replay are now available on the IABS website via the following link: https://zapi-stakeholders-final-conference.iabs.org/conference-information.php?parag=slides

 

22

 

Impact of COVID-19

 

The outbreak of COVID-19 has led to adverse impacts on the U.S. and global economies and created uncertainty regarding the potential impact to the Company’s employees, operations, and research projects.

 

To date, some of our employees are still working remotely. The extent to which the COVID-19 pandemic will directly or indirectly impact our business will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and SARS-CoV-2 variants and the actions taken and the level of success to contain or treat the SARS-CoV-2 virus and its variants, the economic impact on local, regional, national and international business partners and markets, delays or disruptions in our on-going research projects, and unavailability of the employees of the Company or third-party contract research organizations with whom we conduct business, due to illness or quarantines, all of which are highly uncertain and cannot be predicted at this time. Management is actively monitoring this situation and the possible effects on its financial condition, liquidity, operations, vendors, industry, and workforce. Even after the COVID-19 pandemic has subsided, the Company may continue to experience adverse impacts to its business because of economic recession or depression that has occurred or may occur in the future. Given the daily evolution of the COVID-19 outbreak and the ongoing response to curb its spread (including government travel and meeting restrictions) currently we are not able to accurately estimate the effects of the COVID-19 outbreak to our results of operations, financial condition, or liquidity.

 

Open Market Sale Agreement

 

On August 13, 2020, we entered into an Open Market Sale Agreement℠ with Jefferies LLC, or Jefferies, with respect to an at the market offering program under which we may offer and sell, from time to time at our sole discretion, shares of our common stock, par value $0.001 per share, having an aggregate offering price of up to $50.0 million through Jefferies as our sales agent or principal.

 

We have not and are not obligated to sell any shares under the sale agreement. Subject to the terms and conditions of the sale agreement, Jefferies will use commercially reasonable efforts, consistent with its normal trading and sales practices and applicable laws and regulations, to sell shares of our common stock from time to time based upon our instructions, including any price, time or size limits or other customary parameters or conditions we specify, subject to certain limitations. Under the sale agreement, Jefferies may sell shares of our common stock by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended.

 

We will pay Jefferies a commission equal to 3.0% of the gross proceeds from each sale of shares of our common stock sold through Jefferies under the sale agreement and will provide Jefferies with customary indemnification and contribution rights. In addition, we agreed to reimburse certain legal expenses and fees by Jefferies in connection with the offering up to a maximum of $50,000, in addition to certain ongoing disbursements of Jefferies’ counsel, if required. The sale agreement will terminate upon the sale of all $50.0 million of shares under the sale agreement, unless earlier terminated by either party as permitted therein.

 

The issuance and sale, if any, of shares of our common stock by us under the sale agreement will be made pursuant to a registration statement on Form S-3 filed with the SEC on August 13, 2020 and declared effective by the SEC on August 25, 2020 and the accompanying Prospectus, as supplemented by a Prospectus Supplement. As of the date of this filing, there have been no sales made under the Open Market Sale Agreement℠.

 

Critical Accounting Policies, Estimates, and Judgments

 

The preparation of these consolidated financial statements in accordance with GAAP requires management to make estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the applicable period. Actual results may differ from these estimates under different assumptions or conditions. Such differences could be material to the consolidated financial statements.

 

We define critical accounting policies as those that are reflective of significant judgments and uncertainties and which may potentially result in materially different results under different assumptions and conditions. In applying these critical accounting policies, our management uses its judgment to determine the appropriate assumptions to be used in making certain estimates. These estimates are subject to an inherent degree of uncertainty. Our critical accounting policies include the following:

 

Revenue Recognition

 

The Company has no pharmaceutical products approved for sale at this point, and all of our revenue to date has been research revenue from third party collaborations and government grants. The Company is expected to generate future revenue from license agreements and collaborative arrangements, which may include upfront payments for licenses or options to obtain a license, payment for research and development services and milestone payments, in the form of cash or non-cash considerations (e.g., minority equity interest).

 

23

 

Revenue related to research collaborations and agreements: The Company typically performs research and development services as specified in each respective agreement on a best efforts basis, and recognizes revenue from research funding under collaboration agreements in accordance with the 5-step process outlined in Topic 606: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We recognize revenue when we satisfy a performance obligation by transferring control of the service to a customer in an amount that reflects the consideration that we expect to receive. Since the performance obligation under our collaboration agreements is generally satisfied over time, we elected to use the input method under Topic 606 to measure the progress toward complete satisfaction of a performance obligation.

 

Under the input methods, revenue will be recognized on the basis of the entity’s efforts or inputs to the satisfaction of a performance obligation (e.g., resources consumed, labor hours expended, costs incurred, or time elapsed) relative to the total expected inputs to the satisfaction of that performance obligation. The Company believes that the cost-based input method is the best measure of progress to reflect how the Company transfers its performance obligation to a customer. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to budgeted costs to fulfill the performance obligation. These costs consist primarily of full-time equivalent effort and third-party contract costs. Revenue will be recognized based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligations.

 

A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company’s performance obligations. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete the Company’s performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.

 

Revenue related to grants: The Company may receive grants from governments, agencies, and other private and not-for-profit organizations. These grants are intended to be used to partially or fully fund the Company’s research collaborations, including opportunities arising in connection with COVID-19 that the Company is pursuing with certain collaborators. However, most, if not all, of such potential grant revenues, if received, is expected to be earmarked for third parties to advance the research required, including preclinical and clinical trials for SARS-CoV-2 vaccines and/or antibodies candidates.

 

Revenue related to sublicensing agreements: If the sublicense to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue allocated to the license when technology is transferred to the customer and the customer is able to use and benefit from the license.

 

Milestone payments: At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Company evaluates whether the achievement of the milestones is considered probable and estimates the amount to be included in the transaction price. If the milestone payment is in exchange for a sublicense and is based on the sublicensee’s subsequent sale of product, the Company recognizes milestone payment by applying the accounting guidance for royalties. To date, the Company has not recognized any milestone payment revenue resulting from any of its sublicensing arrangements.

 

Royalties: With respect to licenses deemed to be the predominant item to which sales-based royalties relate, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its sublicensing arrangements.

 

We invoice customers based on our contractual arrangements with each customer, which may not be consistent with the period that revenues are recognized. When there is a timing difference between when we invoice customers and when revenues are recognized, we record either a contract asset (unbilled accounts receivable) or a contract liability (deferred research and development obligations), as appropriate.

 

We are not required to disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.

 

The Company adopted a practical expedient to expense sales commissions when incurred because the amortization period would be one year or less.

 

24

 

Accrued Research and Development Expenses

 

In order to properly record services that have been rendered but not yet billed to the Company, we review open contracts and purchase orders, communicate with our personnel and we estimate the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. The majority of our service providers invoice us monthly or quarterly in arrears for services performed or when contractual milestones are met. We make estimates of our accrued expenses as of each balance sheet date in our consolidated financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of our estimates with the service providers and make adjustments if necessary. Examples of accrued research and development expenses include amounts owed to contract research organizations, to service providers in connection with commercialization and development activities.

 

Stock-Based Compensation

 

We have granted stock options and restricted stock to employees, directors and consultants. The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes model considers volatility in the price of our stock, the risk-free interest rate, the estimated life of the option, the closing market price of our stock and the exercise price. For purposes of the calculation, we assumed that no dividends would be paid during the life of the options and restricted stock and applied a discount to reflect the lack of marketability due to the holding period restriction of its shares under Rule 144 prior to the Company April 2019 uplisting to NASDAQ. We also used the weighted-average vesting period and contractual term of the option as the best estimate of the expected life of a new option except in the case of our CEO, 5 or 10 years, and in the case of contractors, 2 or 3 years). The Company performs a review of assumptions used in the Black-Scholes option-pricing model on an annual basis. During the Company’s annual review of its volatility assumption in 2018, the Company determined that it would be appropriate to use the Company’s historical volatility since 2016, as the DuPont Transaction resulted in significant changes in the Company’s business and capital structure. The change in assumption was effective January 1, 2018 and only impacts new options granted in 2018 and thereafter.

 

The estimates utilized in the Black-Scholes calculation involve inherent uncertainties and the application of management judgment. These estimates are neither predictive nor indicative of the future performance of our stock. As a result, if other assumptions had been used, our recorded share-based compensation expense could have been materially different from that reported. In addition, because some of the options and restricted stock issued to employees, consultants and other third-parties vest upon the achievement of certain milestones, the total ultimate expense of share-based compensation is uncertain.

 

In connection with board member and employee terminations, the Company may modify certain terms to outstanding share-based awards. We have recorded charges related to these modifications based on the estimated fair value of the share-based options immediately prior to and immediately after the modification occurs, with any incremental value being charged to expense. We have used the Black-Scholes pricing model in this valuation process, and this requires management to use various assumptions and estimates. Future modifications to share-based compensation transactions may result in significant expenses being recorded in our consolidated financial statements.

 

Accounting for Income Taxes

 

The Company accounts for income taxes under the asset and liability method in accordance with ASC Topic 740 (“Topic 740”), “Income Taxes”. Under this method, income tax expense/(benefit) is recognized for: (i) taxes payable or refundable for the current year and (ii) deferred tax consequences of temporary differences resulting from matters that have been recognized in an entity’s financial statements or tax returns. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the results of operations in the period that includes the enactment date. A valuation allowance is provided to reduce the deferred tax assets reported if based on the weight of the available positive and negative evidence, it is more likely than not some portion or all the deferred tax assets will not be realized.

 

25

 

In determining taxable income for the Company’s consolidated financial statements, we are required to estimate our income taxes in each of the jurisdictions in which we operate. This process requires the Company to make certain estimates of our actual current tax exposure and assessment of temporary differences between the tax and financial statement recognition of revenue and expense. In evaluating the Company’s ability to recover its deferred tax assets, the Company must consider all available positive and negative evidence including its past operating results, the existence of cumulative losses in the most recent years and its forecast of future taxable income. Significant management judgment is required in determining our provision for income taxes, deferred tax assets and liabilities and any valuation allowance recorded against our net deferred tax assets.

 

The Company is required to evaluate the provisions of Topic 740 related to the accounting for uncertainty in income taxes recognized in a company’s financial statements. Topic 740 prescribes a comprehensive model for how a company should recognize, present, and disclose uncertain positions that the company has taken or expects to take in its tax return. For those benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. Differences between tax positions taken or expected to be taken in a tax return and the net benefit recognized and measured pursuant to the interpretation are referred to as “unrecognized benefits.” A liability should be recognized (or amount of net operating loss carry forward or amount of tax refundable is reduced) for unrecognized tax benefit because it represents a company’s potential future obligation to the taxing authority for a tax position that was not recognized because of applying the provision of Topic 740.

 

Non-Marketable Investments

 

The Company also holds investments in non-marketable equity securities of privately-held companies, which usually do not have a readily determinable fair value. Our policy is to measure these investments at cost less impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Such observable price changes may include instances where the investee issues equity securities to new investors, thus creating a new indicator of fair value, as an example. On a quarterly basis, we perform a qualitative assessment considering impairment indicators to evaluate whether these investments are impaired and also monitor for any observable price changes. If indicators of impairment exist, we will prepare a quantitative assessment of the fair value of our equity investments, which may include using both the market and income approaches which require judgment and the use of estimates, including discount rates, investee revenues and costs, and available comparable market data of private and public companies, among others. Valuations of such privately-held companies are inherently complex and uncertain due to the lack of liquid market for the company’s securities. In addition, such investments are inherently risky in that such companies are typically at an early stage of development, may have no or limited revenues, may not be or may never become profitable, may not be able to secure additional funding or their technologies, services or products may not be successfully developed or introduced into the market.

 

The Company bases its fair value estimates on assumptions it believes to be reasonable, but which are unpredictable and inherently uncertain. Actual future results may differ from those estimates.

 

Off-Balance Sheet Arrangements

 

We do not have any off-balance sheet arrangements.

 

Recent Accounting Pronouncements

 

See Note 1 to the Consolidated Financial Statements for information about recent accounting pronouncements.

 

26

 

Results of Operations

 

Three Months Ended March 31, 2021 Compared to the Same Periods in 2020

 

Revenue and Cost of Research and Development Revenue

 

The following table summarizes the Company’s revenue and cost of research and development revenue for the three months ended March 31, 2021 and 2020:

 

   

Three Months Ended March 31,

 
   

2021

   

2020

 

Revenue

  $ 460,520     $ 315,372  

Cost of research and development revenue

    390,762       278,182  

 

The increase in revenue and cost of research and development revenue for the three months ended March 31, 2021, reflected the increased number of on-going research collaborations to eight compared to five collaborations for the same period a year ago. 

 

Research and Development Expenses

 

Research and development costs are expensed as incurred and primarily include salary and benefits of research personnel, third-party contract research organization services and supply costs.

 

Research and development expenses for the three months ended March 31, 2021 increased to approximately $1,808,000 compared to $755,000 for the same period a year ago. The increase primarily reflected Phase 1 clinical trial cost of DYAI-100, our COVID-19 vaccine in the amount of $882,000 and an additional cost of $159,000 related to our other internal research projects.

 

General and Administrative Expenses

 

General and administrative expenses for the three months ended March 31, 2021, decreased 6.0% to approximately $1,554,000 compared to $1,653,000 for the same period a year ago. The decrease principally reflected reductions in travel and rent expenses of $65,000, insurance and other outside services of $47,000, other decrease of $30,000, offset by increase in legal expenses of $43,000.

 

 

27

 

Interest Income

 

Interest income for the three months ended March 31, 2021 was approximately $26,000 compared to $168,000 for the same period a year ago. The decrease was primarily due to the lower balance of hold-to-maturity securities and less reinvestment as a result of the decrease in interest rate.

 

Net Loss

 

Net loss for the three months ended March 31, 2021 was approximately $3,295,000 compared to $2,214,000 for the same period a year ago.

 

Liquidity and Capital Resources

 

Our primary source of cash has been the cash received from the DuPont Transaction in December 2015, interest income received from investment grade securities, and funding from our research collaboration agreements. The Company’s liquidity was further improved with the receipt of an approximately $0.5 million tax refund in June 2019 and an approximately $0.5 million additional tax refund in July 2020 resulting from the elimination of corporate Alternative Minimum Tax (AMT) under the TCJA.

 

Our ability to achieve profitability depends on a number of factors, including our scientific results and our ability to continue to obtain funded research and development collaborations from industry and government programs, as well as sub-license agreements. We may continue to incur substantial operating losses even if we begin to generate revenues from research and development and licensing. Our primary future cash needs are expected to be for general operating activities, including our business development and research expenses, as well as additional costs as an SEC reporting and NASDAQ listed company. 

 

We rely on our existing cash and cash equivalents, investments in debt securities, and operating cash flow to provide the working capital needs for our operations. We believe that our existing cash position and investment in investment grade securities will be adequate to meet our operational, business, and other liquidity requirements for at least the next twelve (12) months. However, in the event our financing needs for the foreseeable future are not able to be met by our existing cash, cash equivalents and investments, we would seek to raise funds through public or private equity offerings, and through other means to meet our financing requirements. Additionally, the Company may decide to fund all or part of a Phase I clinical trial to demonstrate the safety in humans of a protein produced from the C1 expression platform in humans. There is no assurance that external funding will be available at acceptable terms, if at all, and the Company may, therefore, self-fund these vital projects.

 

On August 13, 2020, we entered into an Open Market Sale Agreement℠ with Jefferies LLC, or Jefferies, with respect to an at the market offering program under which we may offer and sell, from time to time at our sole discretion, shares of our common stock at an aggregate offering price of up to $50.0 million through Jefferies as our sales agent or principal. This program adds to our financial flexibility to pursue additional opportunities that leverage the broad application potential of C1. However, as of the date of this filing, there have been no sales made under the Open Market Sale Agreement℠.

 

As of March 31, 2021, cash and cash equivalents were approximately $13.1 million compared to $20.6 million as of December 31, 2020. The carrying value of investment grade securities, including accrued interest as of March 31, 2021 was approximately $14.3 million compared to $8.6 million as of December 31, 2020.

 

Net cash used in operating activities for the three months ended March 31, 2021 of approximately $1.9 million was principally attributable to a net loss of approximately $3.3 million, partially offset by changes in operating assets and liabilities of approximately $0.9 million, share-based compensation expenses of approximately $0.4 million, and amortization of held-to-maturity securities of approximately $0.1 million.

 

Net cash used in operating activities for the three months ended March 31, 2020 of approximately $2.0 million was principally attributable to a net loss of approximately $2.2 million and changes in other operating assets and liabilities of approximately $0.3 million, offset by share-based compensation expense of approximately $0.4 million, and amortization of held-to-maturity securities of approximately $0.1 million.

 

28

 

Net cash used in investing activities for the three months ended March 31, 2021 was approximately $5.8 million compared to a net cash provided by investing activity of $1.7 million for the three months ended March 31, 2020. Cash flows from investing activities during the three months ended March 31, 2021 and 2020 were primarily related to proceeds from maturities and purchases of investment grade debt securities.

 

Net cash provided by financing activities for the three months ended March 31, 2020 was approximately $116,000 compared to $175,000 for the three months ended March 31, 2020. Cash flows from financing activities during the three months ended March 31, 2021 and 2020 were primarily related to proceeds from exercise of options.

 

Item 3.

Quantitative and Qualitative Disclosures about Market Risk

 

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

 

Item 4.

Controls and procedures

 

Evaluation of Disclosure Controls and Procedures

 

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms. Based on the evaluation of our disclosure controls and procedures as of the end of the period covered by this report, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective.

 

Changes in Internal Controls Over Financial Reporting

 

There were no changes in our internal control over financial reporting that occurred during the three months ended March 31, 2021, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. We have not experienced any material impact to our internal controls over financial reporting despite the fact that most of our employees are working remotely due to the COVID-19 pandemic. We are continually monitoring and assessing the COVID-19 situation on our internal controls to minimize the impact on their design and operating effectiveness.

 

Inherent Limitation on Effectiveness of Controls

 

A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

 

PART II

 

 

Item 1.

Legal Proceedings

 

We are not currently involved in any litigation that we believe could have a materially adverse effect in our financial condition or results of operations. From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business.

 

Item 1A.

Risk Factors

 

There have been no changes to our risk factors from those disclosed in our Form 10-K for the 2020 fiscal year filed on March 30, 2021.

 

29

 

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

 

None.

 

Item 3.

Defaults Upon Senior Securities

 

Not applicable.

 

Item 4.

Mine Safety Disclosures

 

Not applicable.

 

Item 5.

Other Information

 

None.

 

Item 6.

Exhibits

 

Following Exhibits are filed as part of this report pursuant to Item 601 of Regulation S-K:

 

          Incorporated by Reference    
Exhibit No.   Description of Exhibit Form   Original No.   Date Filed   Filed Herewith
1.1   Open Market Sale Agreement by and between the Company and Jeffries LLC, dated August 13, 2020 S-3   1.2   August 13, 2020    
10.1   Dyadic International, Inc. 2021 Equity Inventive Award Plan DEF14A   10.1   April 27, 2021    
31.1   Certification of Principal Executive Officer of Dyadic Pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002             x
31.2   Certification of Principal Financial Officer of Dyadic Pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002             x
32.1   Certification of Principal Executive Officer of Dyadic Pursuant to 18 U.S.C Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002             x
32.2   Certification of Principal Financial Officer of Dyadic Pursuant to18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002             x

 

Exhibit No. Description
101.INS Inline XBRL Instance Document
101.SCH Inline XBRL Taxonomy Extension Schema Document
101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB Inline XBRL Taxonomy Extension Labels Linkbase Document
101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document
104 Cover Page Interactive Data File (embedded within the Inline XBRL and contained in Exhibit 101)

 

 

30

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 
 

DYADIC INTERNATIONAL, INC.

     

May 13, 2021

By:

/s/ Mark A. Emalfarb

   

Mark A. Emalfarb

   

President and Chief Executive Officer

   

(Principal Executive Officer)

     
     
May 13, 2021

By:

/s/ Ping W. Rawson

   

Ping W. Rawson

   

Chief Financial Officer

   

(Principal Financial Officer and Principal Accounting Officer)

 

31
EX-31.1 2 ex_237822.htm EXHIBIT 31.1 ex_237822.htm

Exhibit 31.1

 

Certification of Principal Executive Officer

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

and Securities and Exchange Commission Release 34-46427

 

 

I, Mark A. Emalfarb, certify that:

 

  1. I have reviewed this quarterly report on Form 10-Q of Dyadic International Inc.;
     
  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     
  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
     
  4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:
     
  5. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:
  a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  c. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  d. disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

  6. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
  a. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: May 13, 2021
By: /s/   Mark A. Emalfarb
   
Name: Mark A. Emalfarb
Title: Chief Executive Officer

 

 
EX-31.2 3 ex_237823.htm EXHIBIT 31.2 ex_237823.htm

Exhibit 31.2

 

Certification of Principal Executive Officer

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

and Securities and Exchange Commission Release 34-46427

 

 

I, Ping W. Rawson, certify that:

 

  1. I have reviewed this quarterly report on Form 10-Q of Dyadic International Inc.;
     
  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
     
  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
     
  4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and we have:

 

  a. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  b. designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  c. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  d. disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

  5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

  a. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
     
  b. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: May 13, 2021
By: /s/   Ping W. Rawson
   
Name: Ping W. Rawson
Title: Chief Financial Officer

 

 
EX-32.1 4 ex_237824.htm EXHIBIT 32.1 ex_237824.htm

Exhibit 32.1

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Dyadic International Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Mark A. Emalfarb, certify, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

 

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: May 13, 2021
By: /s/   Mark A. Emalfarb
   
Name:  Mark A. Emalfarb
Title: Chief Executive Officer

 

 
EX-32.2 5 ex_237825.htm EXHIBIT 32.2 ex_237825.htm

Exhibit 32.2

 

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Dyadic International Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Ping W. Rawson, certify, pursuant to 18 U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

 

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: May 13, 2021
By: /s/   Ping W. Rawson
   
Name: Ping W. Rawson
Title: Chief Financial Officer

 

 
EX-101.SCH 6 dyai-20210331.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Consolidated Balance Sheets (Current Period Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Consolidated Statements of Operations (Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited) link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 006 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 2 - Cash, Cash Equivalent, and Investments link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 3 - Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately-held Companies link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 4 - Commitments and Contingencies link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 5 - Share-based Compensation link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 6 - Shareholders' Equity link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 7 - Subsequent Events link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies (Tables) link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 2 - Cash, Cash Equivalent, and Investments (Tables) link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 5 - Share-based Compensation (Tables) link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 6 - Shareholders' Equity (Tables) link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies - Accounts Receivable (Details) link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies - Prepaid Expenses and Other Current Assets (Details) link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies - Accounts Payable (Details) link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies - Accrued Expenses (Details) link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies - Research and Development Costs (Details) link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Note 2 - Cash, Cash Equivalent, and Investments (Details Textual) link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note 2 - Cash, Cash Equivalent, and Investments - Major Security Type (Details) link:calculationLink link:definitionLink link:presentationLink 026 - Disclosure - Note 3 - Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately-held Companies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 027 - Disclosure - Note 5 - Share-based Compensation (Details Textual) link:calculationLink link:definitionLink link:presentationLink 028 - Disclosure - Note 5 - Share-based Compensation - Black-Scholes Options Pricing Model (Details) link:calculationLink link:definitionLink link:presentationLink 029 - Disclosure - Note 5 - Share-based Compensation - Stock Option Activity (Details) link:calculationLink link:definitionLink link:presentationLink 030 - Disclosure - Note 5 - Share-based Compensation - Noncash Stock Option Compensation (Details) link:calculationLink link:definitionLink link:presentationLink 031 - Disclosure - Note 6 - Shareholders' Equity (Details Textual) link:calculationLink link:definitionLink link:presentationLink 032 - Disclosure - Note 6 - Shareholders' Equity - Schedule of Stockholders Equity (Details) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 7 dyai-20210331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 dyai-20210331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 dyai-20210331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Fair Value Measurement, Policy [Policy Text Block] Note To Financial Statement Details Textual Significant Accounting Policies Note 1 - Organization and Summary of Significant Accounting Policies Note 2 - Cash, Cash Equivalent, and Investments Note 5 - Share-based Compensation Risk-Free interest rate, maximum Note 6 - Shareholders' Equity Note 1 - Organization and Summary of Significant Accounting Policies - Accounts Receivable (Details) Note 1 - Organization and Summary of Significant Accounting Policies - Prepaid Expenses and Other Current Assets (Details) Note 1 - Organization and Summary of Significant Accounting Policies - Accounts Payable (Details) Note 1 - Organization and Summary of Significant Accounting Policies - Accrued Expenses (Details) Risk-Free interest rate, minimum Note 1 - Organization and Summary of Significant Accounting Policies - Research and Development Costs (Details) Note 2 - Cash, Cash Equivalent, and Investments - Major Security Type (Details) Foreign Currency Transactions and Translations Policy [Policy Text Block] Note 5 - Share-based Compensation - Black-Scholes Options Pricing Model (Details) Expected stock price volatility, minimum us-gaap_ShareBasedCompensation Stock-based compensation expense Other assets Note 5 - Share-based Compensation - Stock Option Activity (Details) Expected stock price volatility, maximum Note 5 - Share-based Compensation - Noncash Stock Option Compensation (Details) us-gaap_LiabilitiesCurrent Total current liabilities Note 6 - Shareholders' Equity - Schedule of Stockholders Equity (Details) Notes To Financial Statements Notes To Financial Statements [Abstract] Expected life of options (Year) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year) Earnings Per Share, Policy [Policy Text Block] dyai_CollaborativeArrangementDurationOfAgreement Collaborative Arrangement, Duration Of Agreement (Year) Represents duration of agreement for collaborative agreement. Interest receivable Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Comprehensive Income, Policy [Policy Text Block] dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment Collaborative Arrangement, Minimum Obligation For Research and Development Represents minimum obligation for research and development for collaborative agreement. dyai_CollaborativeArrangementPaymentForResearchAndDevelopmentAgreement Collaborative Arrangement, Payment for Research and Development Agreement Represents payment for research and development agreement for collaborate arrangement. Income Tax, Policy [Policy Text Block] Research Services Agreement [Member] Represents information related to research services agreement. dyai_CollaborativeArrangementEquityInterestAcquired Collaborative Arrangement, Equity Interest Acquired Represents equity interest acquired for collaborative agreement. Share-based Payment Arrangement, Option, Activity [Table Text Block] BDI Holdings [Member] Represents information related to BDI Holdings. Share-based Payment Arrangement, Activity [Table Text Block] Proceeds from maturities of investment securities dyai_CollaborativeArrangementRevenueSharingPercentage Collaborative Arrangement, Revenue Sharing, Percentage Represents percentage of revenue sharing for collaborate arrangement. dyai_CollaborativeArrangementMaximumObligationForResearchAndDevelopment Collaborative Arrangement, Maximum Obligation For Research and Development Represents maximum obligation for research and development for collaborative agreement. Research and Development Expense, Policy [Policy Text Block] dyai_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners Represents ownership percentage by noncontrolling owners for noncontrolling interest. dyai_CollaborativeArrangementVestingPercentages Collaborative Arrangement, Vesting Percentages Represents vesting percentage for collaborative arrangement. ID Biologics Inc [Member] Represents ID Biologics Inc. Corporate Debt Securities [Member] dyai_CollaborativeArrangementNumberOfSharesToBeReceived Collaborative Arrangement, Number of Shares To Be Received (in shares) Represents number of shares to be received for collaborative arrangement. dyai_CollaborativeArrangementPaymentForAdditionalDevelopmentAndCommercialization Collaborative Arrangement, Payment for Additional Development and Commercialization Represents payments for additional development and commercialization for collaborative arrangement. us-gaap_AssetsCurrent Total current assets Exercisable, weighted average exercise price (in dollars per share) Service Framework Agreement [Member] Represents information related to service framework agreement. Non-current assets: Weighted-average remaining contractual term, exercisable (Year) Cash and cash equivalent, fair value Novovet [Member] Represents information related to Novovet. Aggregate intrinsic value, exercisable Share-based Payment Arrangement [Policy Text Block] dyai_CollaborativeArrangementOutstandingCommitment Collaborative Arrangement, Outstanding Commitment Represents outstanding commitment for collaborative. Stockholders' Equity Note Disclosure [Text Block] Exercisable, shares (in shares) Weighted-average remaining contractual term, outstanding (Year) Aggregate intrinsic value, outstanding Treasury stock (in shares) Treasury Stock, Common, Shares (in shares) Interest income us-gaap_PaymentsToAcquireHeldToMaturitySecurities Purchases of held-to-maturity investment securities Common stock, $.001 par value: Authorized shares - 100,000,000; issued shares - 39,807,659 and 39,747,659, outstanding shares - 27,554,157 and 27,494,157 as of March 31, 2021 and December 31, 2020, respectively Financial Instruments [Domain] Adjustments to reconcile net loss to net cash used in operating activities: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Outstanding, weighted average exercise price (in dollars per share) Outstanding, weighted average exercise price (in dollars per share) Common stock, shares authorized (in shares) Canceled, weighted average exercise price (in dollars per share) Common stock, shares issued (in shares) Deferred research and development obligations Expired, weighted average exercise price (in dollars per share) Financial Instrument [Axis] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share (in dollars per share) Granted, weighted average exercise price (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) Revenue from Contract with Customer [Policy Text Block] Exercised, weighted average exercise price (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price (in dollars per share) Accrued expenses Accrued Liabilities, Current, Total Employee wages and benefits us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Common Stock, Capital Shares Reserved for Future Issuance (in shares) Statistical Measurement [Domain] Maximum [Member] Minimum [Member] The 2011 Plan [Member] Represents information regarding the 2011 plan. Contractor [Member] Represents information related to contractor. Accounts payable Accounts Payable, Current, Total Ownership [Domain] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares) Outstanding, shares (in shares) Outstanding, shares (in shares) Statistical Measurement [Axis] Investment, Name [Domain] Expired, shares (in shares) Share-based Compensation Award Tranche Two through Five [Member] Represents shares-based compensation award tranche two through five. Ownership [Axis] Employees [Member] Represents information related to employees. Preferred stock, $.0001 par value: Authorized shares - 5,000,000; none issued and outstanding us-gaap_DeferredTaxAssetsLiabilitiesNet Deferred Tax Assets, Net, Total Other us-gaap_OtherAccruedLiabilitiesCurrent Preferred stock, shares issued (in shares) Cash, Cash Equivalents and Investments [Table Text Block] Prepaid taxes Prepaid expenses - various us-gaap_PolicyTextBlockAbstract Accounting Policies Investment, Name [Axis] Executives and Key Personnel [Member] Represents executives and key personnel. Geographical [Axis] Geographical [Domain] Preferred stock, shares authorized (in shares) Consultant [Member] Represents information related to consultant. us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares) Legal expenses Preferred stock, par value (in dollars per share) Prepaid insurance us-gaap_ForeignCurrencyTransactionGainLossBeforeTax Foreign currency exchange loss (gain), net us-gaap_AccountsPayableOtherCurrent Other us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares) dyai_SaleOfStockTerminationAmountUnderAgreement Sale of Stock, Termination Amount Under Agreement Represents termination amount under agreement for sale of stock. Fair Value Hierarchy and NAV [Domain] us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) Fair Value, Inputs, Level 1 [Member] Open Market Sale Agreement [Member] Represents information related to open market for sale agreement. Fair Value, Inputs, Level 2 [Member] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) dyai_SaleOfStockAuthorizedOfferingAmount Sale of Stock, Authorized Offering Amount Represents authorized offering amount of sale of stock. us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period (Year) dyai_SaleOfStockPercentageOfCommissionsPaidOfGrossProceedsFromSaleOfEachShare Sale of Stock, Percentage of Commissions Paid of Gross Proceeds From Sale Of Each Share Represents percentage of commission paid on gross proceeds from sale of each share dyai_SaleOfStockReimbursableLegalExpenses Sale of Stock, Reimbursable Legal Expenses Represents reimbursable legal expense for sale of stock. Fair Value Hierarchy and NAV [Axis] VL Pbio Member Represents information related to VL Pbio. Share-based Payment Arrangement, Tranche Three [Member] Current liabilities: dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty Research And Development Expense, Including Related Party Represents research and development expense including related party. Vesting [Axis] Vesting [Domain] Share-based Payment Arrangement, Tranche One [Member] Share-based Payment Arrangement, Tranche Two [Member] us-gaap_Assets Total assets Plan Name [Axis] Plan Name [Domain] Cash flows from operating activities Cash, Cash Equivalents, and Marketable Securities [Text Block] Statement [Line Items] us-gaap_NumberOfOperatingSegments Number of Operating Segments Accounts receivable dyai_OwnershipPercentage Ownership Percentage Percentage of ownership. Additional paid-in capital Revenues: Short-term investment securities Share-based Payment Arrangement [Text Block] Stockholders’ equity: Award Type [Domain] Business Description and Accounting Policies [Text Block] Chief Executive Officer [Member] Current assets: us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction Sale of Stock, Percentage of Ownership after Transaction Award Type [Axis] Net loss Net loss Amortization of held-to-maturity securities, net us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Effect of exchange rate changes on cash us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Net decrease in cash and cash equivalents us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash provided by financing activities Commitments and contingencies (Note 4) Director [Member] Sale of Stock [Axis] Sale of Stock [Domain] Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block] us-gaap_OperatingIncomeLoss Loss from operations Share-based Payment Arrangement, Option [Member] us-gaap_NetCashProvidedByUsedInOperatingActivities Net cash used in operating activities us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash (used in) provided by investing activities Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Costs of research and development revenue Cost of Goods and Services Sold, Total Counterparty Name [Axis] Counterparty Name [Domain] Commitments and Contingencies Disclosure [Text Block] Equity Securities without Readily Determinable Fair Value [Policy Text Block] Investment, Policy [Policy Text Block] us-gaap_AccountsPayableCurrentAndNoncurrent Accounts Payable, Total Concentration Risk, Credit Risk, Policy [Policy Text Block] us-gaap_EquityMethodInvestmentOwnershipPercentage Equity Method Investment, Ownership Percentage us-gaap_CostsAndExpenses Total costs and expenses Costs and expenses: Cash flows from investing activities us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount Equity Securities without Readily Determinable Fair Value, Amount Retained Earnings [Member] Research and development revenue Revenue from Contract with Customer, Excluding Assessed Tax, Total Proceeds from exercise of options Title of Individual [Domain] Title of Individual [Axis] Treasury Stock [Member] Additional Paid-in Capital [Member] Common Stock [Member] us-gaap_IncreaseDecreaseInAccruedLiabilities Accrued expenses Equity Components [Axis] Equity Component [Domain] us-gaap_IncreaseDecreaseInAccountsPayable Accounts payable General and administrative Cash, adjusted cost Cash and cash equivalents Cash and cash equivalents, adjusted cost us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss Gross Unrealized Holding Losses Gross Unrealized Holding Gains Stock-based compensation us-gaap_AllocatedShareBasedCompensationExpense dyai_DeferredTaxAssetsValuationAllowanceCoveragePercent Deferred Tax Assets, Valuation Allowance Coverage, Percent Percent after allocation of valuation allowance coverage of deferred tax asset attributable to deductible temporary differences and carryforwards. Money Market Funds, adjusted cost Accounts Receivable [Policy Text Block] Cash and Cash Equivalents, Policy [Policy Text Block] Document Quarterly Report Amendment Flag Entity Incorporation, State or Country Code us-gaap_UnrecognizedTaxBenefits Unrecognized Tax Benefits, Ending Balance General and Administrative Expense [Member] Accounting Policies [Abstract] Document Transition Report City Area Code Basis of Accounting, Policy [Policy Text Block] Use of Estimates, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] Entity Interactive Data Current us-gaap_IncreaseDecreaseInContractWithCustomerLiability Deferred research and development obligation us-gaap_SharesOutstanding Balance (in shares) Balance (in shares) Security Exchange Name Common stock, shares outstanding (in shares) Preferred stock, shares outstanding (in shares) Title of 12(b) Security Current Fiscal Year End Date dyai_ResearchServicesPurchased Research Services Purchased Represents the amount of research services purchased during the period. us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Prepaid expenses and other current assets Billing Status, Type [Axis] Research and Development Expense [Member] Receivables Billing Status [Domain] Document Fiscal Period Focus Unbilled Revenues [Member] Document Fiscal Year Focus Billed Revenues [Member] Document Period End Date Income Statement Location [Axis] Income Statement Location [Domain] Entity File Number Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Entity Emerging Growth Company Document Type Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Entity Small Business Entity Shell Company Collaborative Arrangement Disclosure [Text Block] Document Information [Line Items] Document Information [Table] Contract Research Organizations [Member] Represents information related to contract research organizations, or to research services purchased from such organizations. Entity Filer Category Entity Current Reporting Status Impact of COVID-19, Policy [Policy Text Block] Disclosure of accounting policy for impact of COVID-19. BDI [Member] Represents information regarding Biotechnology Developments for Industry, S.L., a Spanish biotechnology company. us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet Interest receivable dyai_ConcentrationRiskNumberOfCustomers Concentration Risk, Number of Customers Represents the number of major customers accounting for 10% or more of the specified concentration risk benchmark, which includes, but not limited to, sales revenue, accounts receivable, etc. us-gaap_InvestmentsAndCash Total, adjusted Basic and diluted weighted-average common shares outstanding (in shares) us-gaap_AccountsReceivableNet Accounts Receivable, after Allowance for Credit Loss, Total Alphazyme [Member] Represents information related to Alphazyme. Service Agreement to Perform Research Project [Member] Represents information regarding a service agreement to perform a research project. Prepaid Expenses and Other Current Assets, Policy [Policy Text Block] Disclosure of accounting policy for prepaid expenses and other current assets. us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) us-gaap_ConcentrationRiskPercentage1 Concentration Risk, Percentage us-gaap_IncreaseDecreaseInAccountsReceivable Accounts receivable Stock-based compensation Entity Tax Identification Number Non-US [Member] Basic and diluted net loss per common share (in dollars per share) Entity Central Index Key Three CROs [Member] Represents information regarding three contract research organizations. Capitalized Contract Cost [Axis] Entity Registrant Name Capitalized Contract Cost [Domain] One CRO [Member] Represents information regarding one contract research organization. Entity [Domain] Customer Concentration Risk [Member] Asset Class [Axis] Legal Entity [Axis] Accounts Payable, Policy [Policy Text Block] Disclosure of accounting policy for accounts payable. Asset Class [Domain] Statement [Table] Entity Address, Address Line One Statement of Financial Position [Abstract] Accrued Expenses, Policy [Policy Text Block] Disclosure of accounting policy for accrued expenses. Supplier Concentration Risk [Member] Investment in Alphazyme Represents the current amount of prepaid research and development in process as of the balance sheet date. Entity Address, City or Town Entity Address, Postal Zip Code dyai_ConcentrationRiskNumberOfSuppliers Concentration Risk, Number of Suppliers Represents the number of suppliers accounting for 10% or more of the specified concentration risk benchmark. Accounts Payable [Member] Entity Address, State or Province Concentration Risk Type [Axis] Concentration Risk Type [Domain] us-gaap_AllowanceForDoubtfulAccountsReceivable Accounts Receivable, Allowance for Credit Loss, Ending Balance us-gaap_TreasuryStockValue Treasury Stock, Value, Ending Balance Treasury stock, shares held at cost - 12,253,502 dyai_ResearchAndDevelopmentInProcessCurrent Research and development expenses Represents current research and development in process. Statement of Cash Flows [Abstract] Research and development expenses dyai_AccruedResearchAndDevelopmentInProcessCurrent Represents current accrued research and development in process. Entity Common Stock, Shares Outstanding Project [Axis] Statement of Stockholders' Equity [Abstract] Project [Domain] Income Statement [Abstract] Revenue Benchmark [Member] Accounts Receivable [Member] Schedule of Accrued Liabilities [Table Text Block] Facilities, overhead and other Represents facilities, overhead and other for research and development expense. Personnel related costs Represents personnel related costs for research and development expenses. Outside contracted services Represents outside contracted services for research and development expense. Investments [Domain] Trading Symbol Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Concentration Risk Benchmark [Axis] dyai_DebtSecuritiesHeldtomaturityPremiumPaidOnPurchase Debt Securities, Held-to-maturity, Premium Paid on Purchase Represents premium paid on purchase for debt securities held-to-maturity. Concentration Risk Benchmark [Domain] Investment Type [Axis] Local Phone Number Exercise of stock options (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares) Exercised, shares (in shares) us-gaap_TableTextBlock Notes Tables Exercise of stock options Schedule of Research and Development Costs [Table Text Block] Tabular disclosure of research and development costs. Short-term Corporate Bonds [Member] Represents short-term corporate bonds. Granted, shares (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) Cash flows from financing activities Canceled, shares (in shares) Collaborative Arrangement and Arrangement Other than Collaborative [Domain] dyai_CashCashEquivalentsAndInvestmentsFairValue Total, fair value Represents fair value of cash, cash equivalents and investments. Stock issued Corporate Bonds, fair value us-gaap_LiabilitiesAndStockholdersEquity Total liabilities and stockholders’ equity Corporate Bond Securities [Member] Research and development Accumulated deficit Money Market Funds [Member] Cash [Member] Changes in operating assets and liabilities: us-gaap_StockholdersEquity Total stockholders’ equity Balance Balance us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements Subsequent Event [Member] us-gaap_ForeignCurrencyTransactionGainLossRealized Foreign currency exchange loss (gain), net Supplier [Axis] Class of Stock [Axis] Supplier [Domain] Schedule of Stockholders Equity [Table Text Block] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent Events [Text Block] dyai_NumberOfResearchOrganizations Number of Research Organizations Represents the number of research organizations through which the entity operates. EX-101.PRE 10 dyai-20210331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 11 dyai-20200930_g1copy.jpg begin 644 dyai-20200930_g1copy.jpg M_]C_X 02D9)1@ ! @$ > !X #_[0C 4&AO=&]S:&]P(#,N, X0DE- ^T M ! > $ 0!X 0 !.$))300- $ >#A"24T#\P M " .$))300* ! X0DE-)Q H 0 M ".$))30/U !( "]F9@ ! &QF9@ & ! "]F9@ ! *&9F@ & M ! #( ! %H & ! #4 ! "T & !.$)) M30/X !P #_____________________________ ^@ ________ M_____________________P/H /____________________________\# MZ #_____________________________ ^@ #A"24T$" $ M $ ) "0 X0DE-!!0 0 !.$))300,

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end XML 12 dyai20210331_10q_htm.xml IDEA: XBRL DOCUMENT 0001213809 2021-01-01 2021-03-31 0001213809 2021-05-12 0001213809 2021-03-31 0001213809 2020-12-31 0001213809 2020-01-01 2020-03-31 0001213809 us-gaap:CommonStockMember 2020-12-31 0001213809 us-gaap:TreasuryStockMember 2020-12-31 0001213809 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001213809 us-gaap:RetainedEarningsMember 2020-12-31 0001213809 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001213809 us-gaap:TreasuryStockMember 2021-01-01 2021-03-31 0001213809 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001213809 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001213809 us-gaap:CommonStockMember 2021-03-31 0001213809 us-gaap:TreasuryStockMember 2021-03-31 0001213809 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001213809 us-gaap:RetainedEarningsMember 2021-03-31 0001213809 2019-12-31 0001213809 2020-03-31 0001213809 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-03-31 0001213809 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-03-31 0001213809 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-03-31 0001213809 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001213809 us-gaap:NonUsMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-03-31 0001213809 us-gaap:NonUsMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-03-31 0001213809 us-gaap:NonUsMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-03-31 0001213809 us-gaap:NonUsMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-03-31 0001213809 us-gaap:NonUsMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001213809 us-gaap:NonUsMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-12-31 0001213809 dyai:ContractResearchOrganizationsMember us-gaap:SupplierConcentrationRiskMember 2021-01-01 2021-03-31 0001213809 dyai:ContractResearchOrganizationsMember us-gaap:SupplierConcentrationRiskMember dyai:ThreeCROsMember 2021-01-01 2021-03-31 0001213809 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember dyai:ThreeCROsMember 2021-03-31 0001213809 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember dyai:ThreeCROsMember 2021-01-01 2021-03-31 0001213809 dyai:ContractResearchOrganizationsMember us-gaap:SupplierConcentrationRiskMember 2020-01-01 2020-03-31 0001213809 dyai:ContractResearchOrganizationsMember us-gaap:SupplierConcentrationRiskMember dyai:OneCROMember 2020-01-01 2020-03-31 0001213809 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2020-01-01 2020-12-31 0001213809 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember dyai:OneCROMember 2020-12-31 0001213809 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember dyai:OneCROMember 2020-01-01 2020-12-31 0001213809 us-gaap:BilledRevenuesMember 2021-03-31 0001213809 us-gaap:BilledRevenuesMember 2020-12-31 0001213809 us-gaap:UnbilledRevenuesMember 2021-03-31 0001213809 us-gaap:UnbilledRevenuesMember 2020-12-31 0001213809 2020-01-01 2020-12-31 0001213809 us-gaap:CashMember 2021-03-31 0001213809 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2021-03-31 0001213809 dyai:ShortTermCorporateBondsMember us-gaap:FairValueInputsLevel2Member 2021-03-31 0001213809 us-gaap:FairValueInputsLevel2Member dyai:ShortTermCorporateBondsMember 2021-03-31 0001213809 us-gaap:CorporateBondSecuritiesMember 2021-03-31 0001213809 us-gaap:CashMember 2020-12-31 0001213809 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001213809 dyai:ShortTermCorporateBondsMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001213809 us-gaap:FairValueInputsLevel2Member dyai:ShortTermCorporateBondsMember 2020-12-31 0001213809 us-gaap:CorporateBondSecuritiesMember 2020-12-31 0001213809 us-gaap:CorporateDebtSecuritiesMember 2021-01-01 2021-03-31 0001213809 us-gaap:CorporateDebtSecuritiesMember 2020-01-01 2020-03-31 0001213809 us-gaap:CorporateDebtSecuritiesMember 2020-01-01 2020-12-31 0001213809 2017-06-30 2017-06-30 0001213809 dyai:BDIHoldingsMember dyai:ResearchServicesAgreementMember 2017-06-30 2017-06-30 0001213809 dyai:VLPbioMember dyai:ResearchServicesAgreementMember 2017-06-30 2017-06-30 0001213809 dyai:BDIHoldingsMember dyai:ResearchServicesAgreementMember 2017-06-30 0001213809 dyai:BDIHoldingsMember srt:MinimumMember dyai:ResearchServicesAgreementMember 2017-06-30 2017-06-30 0001213809 dyai:BDIHoldingsMember srt:MaximumMember dyai:ResearchServicesAgreementMember 2017-06-30 2017-06-30 0001213809 dyai:BDIHoldingsMember srt:MinimumMember dyai:ResearchServicesAgreementMember 2017-06-30 0001213809 dyai:ResearchServicesAgreementMember 2017-06-30 0001213809 dyai:ServiceFrameworkAgreementMember 2017-06-30 0001213809 dyai:ServiceFrameworkAgreementMember 2017-06-30 2017-06-30 0001213809 dyai:ResearchServicesAgreementMember 2017-06-30 2017-06-30 0001213809 dyai:BDIMember dyai:ServiceAgreementToPerformResearchProjectMember 2021-01-01 2021-03-31 0001213809 dyai:NovovetMember 2019-04-26 0001213809 dyai:AlphazymeMember 2020-06-24 2020-06-24 0001213809 dyai:AlphazymeMember 2020-12-01 0001213809 dyai:AlphazymeMember 2020-12-31 0001213809 dyai:IDBiologicsIncMember 2020-07-08 0001213809 dyai:IDBiologicsIncMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2020-07-08 0001213809 dyai:IDBiologicsIncMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2020-07-08 0001213809 dyai:IDBiologicsIncMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2020-07-08 0001213809 dyai:The2011PlanMember 2011-04-28 0001213809 dyai:The2011PlanMember 2019-01-01 2019-01-01 0001213809 dyai:The2011PlanMember us-gaap:SubsequentEventMember 2021-04-16 2021-04-16 0001213809 dyai:The2011PlanMember 2021-03-31 0001213809 dyai:The2011PlanMember 2020-12-31 0001213809 us-gaap:EmployeeStockOptionMember dyai:The2011PlanMember 2021-01-01 2021-03-31 0001213809 us-gaap:EmployeeStockOptionMember dyai:The2011PlanMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2021-01-01 2021-03-31 0001213809 us-gaap:EmployeeStockOptionMember dyai:The2011PlanMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2021-01-01 2021-03-31 0001213809 srt:ChiefExecutiveOfficerMember us-gaap:EmployeeStockOptionMember dyai:The2011PlanMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2021-01-01 2021-03-31 0001213809 srt:ChiefExecutiveOfficerMember us-gaap:EmployeeStockOptionMember dyai:The2011PlanMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2021-01-01 2021-03-31 0001213809 dyai:ContractorMember us-gaap:EmployeeStockOptionMember dyai:The2011PlanMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2021-01-01 2021-03-31 0001213809 dyai:ContractorMember us-gaap:EmployeeStockOptionMember dyai:The2011PlanMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2021-01-01 2021-03-31 0001213809 srt:MinimumMember 2021-01-01 2021-03-31 0001213809 srt:MaximumMember 2021-01-01 2021-03-31 0001213809 dyai:ExecutivesAndKeyPersonnelMember 2021-01-04 2021-01-04 0001213809 dyai:ExecutivesAndKeyPersonnelMember us-gaap:EmployeeStockOptionMember dyai:SharebasedCompensationAwardTrancheTwoThroughFiveMember 2021-01-04 2021-01-04 0001213809 srt:DirectorMember 2021-01-04 2021-01-04 0001213809 srt:DirectorMember us-gaap:EmployeeStockOptionMember 2021-01-04 2021-01-04 0001213809 dyai:EmployeesMember 2021-01-04 2021-01-04 0001213809 srt:MinimumMember dyai:EmployeesMember us-gaap:EmployeeStockOptionMember 2021-01-04 2021-01-04 0001213809 dyai:ConsultantMember 2021-01-04 2021-01-04 0001213809 dyai:ConsultantMember us-gaap:EmployeeStockOptionMember 2021-01-04 2021-01-04 0001213809 srt:DirectorMember 2021-01-08 2021-01-08 0001213809 srt:DirectorMember us-gaap:EmployeeStockOptionMember 2021-01-08 2021-01-08 0001213809 dyai:ConsultantMember 2021-01-21 2021-01-21 0001213809 dyai:ConsultantMember us-gaap:EmployeeStockOptionMember 2021-01-21 2021-01-21 0001213809 dyai:ConsultantMember 2021-03-22 2021-03-22 0001213809 dyai:ConsultantMember us-gaap:EmployeeStockOptionMember 2021-03-22 2021-03-22 0001213809 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-03-31 0001213809 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-03-31 0001213809 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-03-31 0001213809 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-03-31 0001213809 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001213809 us-gaap:CommonStockMember 2019-12-31 0001213809 us-gaap:TreasuryStockMember 2019-12-31 0001213809 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001213809 us-gaap:RetainedEarningsMember 2019-12-31 0001213809 us-gaap:TreasuryStockMember 2020-01-01 2020-03-31 0001213809 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001213809 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001213809 us-gaap:CommonStockMember 2020-03-31 0001213809 us-gaap:TreasuryStockMember 2020-03-31 0001213809 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001213809 us-gaap:RetainedEarningsMember 2020-03-31 0001213809 2020-08-13 0001213809 dyai:OpenMarketSaleAgreementMember 2020-08-13 0001213809 dyai:OpenMarketSaleAgreementMember 2020-08-13 2020-08-13 shares thunderdome:item iso4217:USD iso4217:USD shares pure utr:Y iso4217:EUR 0001213809 DYADIC INTERNATIONAL INC false --12-31 Q1 2021 0.0001 0.0001 5000000 5000000 0 0 0 0 0.001 0.001 100000000 100000000 39807659 39747659 27554157 27494157 12253502 12253502 3 1 8 5 7 9 3 1 1 0 0 0 0 1 P2Y 936000 P2Y 1000000 8000000.0 1500000 P2Y 1100000 1000000.0 284709 P10Y P1Y P3Y P5Y P3Y P1Y P4Y P1Y P4Y P1Y P1Y P1Y P1Y 12253502 18900000 10-Q true 2021-03-31 false 000-55264 DE 45-0486747 140 Intracoastal Pointe Drive, Suite 404 Jupiter FL 33477 561 743-8333 Yes Yes Non-accelerated Filer true false false Common Stock, par value $0.001 per share DYAI NASDAQ 27554157 13055558 20637045 14177441 8457452 157201 112247 384963 294199 216189 280555 27991352 29781498 284709 284709 6151 6225 28282212 30072432 1473813 1013099 277668 489756 842248 123016 2593729 1625871 0 0 39808 39748 98549890 98013079 18929915 18929915 -53971300 -50676351 25688483 28446561 28282212 30072432 460520 315372 390762 278182 1808098 755453 1554007 1653392 -28272 -10867 3781139 2697894 -3320619 -2382522 25670 168383 -3294949 -2214139 -0.12 -0.08 27533268 27452490 39747659 39748 -12253502 -18929915 98013079 -50676351 28446561 0 0 421071 0 421071 60000 60 0 0 115740 0 115800 0 0 0 -3294949 -3294949 39807659 39808 -12253502 -18929915 98549890 -53971300 25688483 -3294949 -2214139 421071 426939 63951 107256 -28272 -10867 44954 -102565 131800 -35258 -64297 10529 480455 -292361 -212088 -326000 719232 163799 -1906513 -1996345 11283940 11652385 5500000 13350000 -5783940 1697615 115800 175000 115800 175000 -6834 -2983 -7581487 -126713 20637045 4823544 13055558 4696831 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">1:</em></b>    <b>Organization and Summary of Significant Accounting Policies</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Description of Business</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) is a global biotechnology platform company based in Jupiter, Florida with operations in the United States, a satellite office in the Netherlands and predominantly <span style="-sec-ix-hidden:c73543703">three</span> research organizations performing services in the Netherlands, Finland and Israel. Over the past <em style="font: inherit;">two</em> plus decades, the Company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has previously licensed this technology to <em style="font: inherit;">third</em> parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the <i>Thermothelomyces heterothallica </i>(formerly known as <i>Myceliophthora thermophila</i>) fungus, which the Company named <em style="font: inherit;">C1.</em> The <em style="font: inherit;">C1</em> technology is a robust and versatile fungal expression system for the development and production of enzymes and other proteins.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">On <em style="font: inherit;"> December 31, 2015, </em>the Company sold its industrial technology business to Danisco USA (“Danisco”), the industrial biosciences business of DuPont (NYSE: DD) (the “DuPont Transaction”). As part of the DuPont Transaction, Dyadic retained co-exclusive rights to the <em style="font: inherit;">C1</em> technology for use in all human and animal pharmaceutical applications, and currently has the exclusive ability to enter into sub-license agreements (subject to the terms of the license and to certain exceptions). Danisco retained certain rights to utilize the <em style="font: inherit;">C1</em> technology in pharmaceutical applications, including the development and production of pharmaceutical products, for which it will be required to make royalty payments to Dyadic upon commercialization. In certain circumstances, Dyadic <em style="font: inherit;"> may </em>owe a royalty to either Danisco or certain licensors of Danisco, depending upon whether Dyadic elects to utilize certain patents either owned by Danisco or licensed in by Danisco.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">After the DuPont Transaction, the Company has been focused on the biopharmaceutical industry, specifically in further improving and applying the proprietary <em style="font: inherit;">C1</em> technology into a safe and efficient gene expression platform to help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs and other biological products at flexible commercial scales. Currently, the Company is involved in multiple funded research collaborations with animal and human pharmaceutical companies to leverage its <em style="font: inherit;">C1</em> technology to help develop products such as innovative vaccines and drugs, biosimilars and/or biobetters. The Company is also working on several COVID-<em style="font: inherit;">19</em> related vaccine and antibody opportunities, including its proprietary COVID-<em style="font: inherit;">19</em> vaccine candidate, DYAI-<em style="font: inherit;">100,</em> towards a <em style="font: inherit;">first</em>-in-human Phase <em style="font: inherit;">1</em> clinical trial. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Effective <em style="font: inherit;"> April 17, 2019, </em>our common stock began trading on the NASDAQ Stock Market LLC’s NASDAQ Capital Market, under the symbol “DYAI”.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i/></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Impact of COVID-<em style="font: inherit;">19</em></i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The outbreak of COVID-<em style="font: inherit;">19</em> has led to adverse impacts on the U.S. and global economies and created uncertainty regarding the potential impact to the Company’s employees, operations, and research projects.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">To date, some of our employees are still working remotely. The extent to which the COVID-<em style="font: inherit;">19</em> pandemic will directly or indirectly impact our business will depend on future developments that are highly uncertain, including as a result of new information that <em style="font: inherit;"> may </em>emerge concerning the severe acute respiratory syndrome coronavirus <em style="font: inherit;">2</em> (SARS-CoV-<em style="font: inherit;">2</em>) and its variants and the actions taken and the level of success to contain or treat the SARS-CoV-<em style="font: inherit;">2</em> virus and its variants, the economic impact on local, regional, national and international business partners and markets, delays or disruptions in our on-going research projects, and unavailability of the employees of the Company or <em style="font: inherit;">third</em>-party contract research organizations with whom we conduct business, due to illness or quarantines, all of which are highly uncertain and cannot be predicted at this time. Management is actively monitoring this situation and the possible effects on its financial condition, liquidity, operations, vendors, industry, and workforce. Even after the COVID-<em style="font: inherit;">19</em> pandemic has subsided, the Company <em style="font: inherit;"> may </em>continue to experience adverse impacts to its business because of economic recession or depression that has occurred or <em style="font: inherit;"> may </em>occur in the future. Given the daily evolution of the COVID-<em style="font: inherit;">19</em> outbreak and the ongoing response to curb its spread (including government travel and meeting restrictions) currently we are <em style="font: inherit;">not</em> able to accurately estimate the effects of the COVID-<em style="font: inherit;">19</em> outbreak to our results of operations, financial condition, or liquidity.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">We rely on our existing cash and cash equivalents, investments in debt securities, and operating cash flow to provide the working capital needs for our operations. We believe that our existing cash position and investment in investment grade securities will be adequate to meet our operational, business, and other liquidity requirements for at least the next <em style="font: inherit;">twelve</em> (<em style="font: inherit;">12</em>) months. However, in the event our financing needs for the foreseeable future are <em style="font: inherit;">not</em> able to be met by our existing cash, cash equivalents and investments, we would seek to raise funds through public or private equity offerings, and through other means to meet our financing requirements. Additionally, the Company <em style="font: inherit;"> may </em>decide to fund all of a Phase I clinical trial to demonstrate the safety in humans of a protein produced from the <em style="font: inherit;">C1</em> expression platform in humans. There is <em style="font: inherit;">no</em> assurance that external funding will be available at acceptable terms, if at all, and the Company <em style="font: inherit;"> may, </em>therefore, self-fund these vital projects.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Summary of Significant Accounting Policies</b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b/></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b>Basis of Presentation </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The accompanying unaudited condensed consolidated financial statements, including the accounts of the Company and its wholly owned subsidiaries, have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and footnote disclosures normally included in consolidated financial statements have been condensed or omitted pursuant to such rules and regulations. All significant intra-entity transactions and balances have been eliminated in consolidation. The information included in this Quarterly Report on Form <em style="font: inherit;">10</em>-Q should be read in conjunction with the audited consolidated financial statements and footnotes as of and for the year ended <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2020,</em> included in our Form <em style="font: inherit;">10</em>-K which was filed with the SEC on <em style="font: inherit;"> March </em><em style="font: inherit;">30,</em> <em style="font: inherit;">2021.</em><b><i> </i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In the opinion of management, the accompanying unaudited interim consolidated financial statements reflect all adjustments, which are of a normal recurring nature, considered necessary for a fair presentation of all periods presented. The results of the Company’s operations for any interim periods are <em style="font: inherit;">not</em> necessarily indicative of the results of operations for any other interim period or for a full fiscal year.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Since concluding the DuPont Transaction, the Company has conducted business in <span style="-sec-ix-hidden:c73543760">one</span> operating segment, which is identified by the Company based on how resources are allocated, and operating decisions are made. Management evaluates performance and allocates resources based on the Company as a whole.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i/></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Use of Estimates</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The preparation of these consolidated financial statements in accordance with GAAP requires management to make estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the applicable period. Actual results <em style="font: inherit;"> may </em>differ from these estimates under different assumptions or conditions. Such differences could be material to the consolidated financial statements.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i/></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Concentrations and Credit Risk</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company’s financial instruments that are potentially subject to concentrations of credit risk consist primarily of cash and cash equivalents, investment securities, and accounts receivable. At times, the Company has cash, cash equivalents, and investment securities at financial institutions exceeding the Federal Depository Insurance Company (“FDIC”) and the Securities Investor Protection Corporation (“SIPC”) insured limit on domestic currency and the Netherlands’ FDIC counterpart for foreign currency. The Company only deals with reputable financial institutions and has <em style="font: inherit;">not</em> experienced any losses in such accounts.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">For the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2021 </em>and <em style="font: inherit;">2020</em>, the Company’s revenue was generated from <span style="-sec-ix-hidden:c73543764">eight</span> and <span style="-sec-ix-hidden:c73543765">five</span> customers, respectively. As of <em style="font: inherit;"> March 31, 2021</em> and <em style="font: inherit;"> December 31, 2020</em>, the Company’s accounts receivable was from <span style="-sec-ix-hidden:c73543766">seven</span> and <span style="-sec-ix-hidden:c73543767">nine</span> customers, respectively. The loss of business from <em style="font: inherit;">one</em> or a combination of the Company’s customers could adversely affect its operations.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company conducts operations in the Netherlands through its foreign subsidiary and generates a portion of its revenues from customers that are located outside of the United States. For the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2021</em>, the Company had six customers outside of the United States (i.e. European and Asian customers) that accounted for approximately 76.7% or $353,000 of the revenue. For the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2020</em>, the Company had three customers outside of the United States that accounted for approximately 58.0% or $183,000 of the revenue. As of the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2021</em>, the Company had four customers outside of the United States (i.e. European and Asian customers) that accounted for approximately 46.0% or $174,000 of accounts receivable. As of <em style="font: inherit;"> December 31, 2020</em>, the Company had seven customers outside of the United States that accounted for approximately 41.6% or $123,000 of accounts receivable.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company uses several contract research organizations (“CROs”) to conduct its research projects. As of and for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2021</em>, <span style="-sec-ix-hidden:c73543786">three</span> CROs accounted for approximately $2,017,000 or 98.1% of total research services we purchased and $1,324,000 or 89.8% of the accounts payable. For the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2020, </em><span style="-sec-ix-hidden:c73543792">one</span> CRO accounted for approximately $855,000, or 100% of total research services we purchased. As of <em style="font: inherit;"> December 31, 2020</em>, <span style="-sec-ix-hidden:c73543795">one</span> CRO accounted for approximately $690,000 or 68.1% of the accounts payable. The loss of this CRO or a combination of the Company’s CROs could adversely affect its operations.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"/> <p style="margin-left: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><b><i/></b></p> <p style="margin-left: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><b><i>Cash and Cash Equivalents</i></b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">We treat highly liquid investments with original maturities of <em style="font: inherit;">three</em> months or less when purchased as cash equivalents, including money market funds, which are unrestricted for withdrawal or use.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i/></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Investment Securities</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company invests excess cash balances in short-term and long-term investment grade securities. Short-term investment securities mature within <em style="font: inherit;">twelve</em> (<em style="font: inherit;">12</em>) months or less, and long-term investment securities mature over <em style="font: inherit;">twelve</em> (<em style="font: inherit;">12</em>) months from the applicable reporting date. Management determines the appropriate classification of its investments at the time of purchase and reevaluates the classifications at each balance sheet date. The Company’s investments in debt securities have been classified and accounted for as held-to-maturity. Held-to-maturity securities are those securities that the Company has the ability and intent to hold until maturity. Held-to-maturity securities are recorded at amortized cost, adjusted for the amortization or accretion of premiums or discounts. Premiums and discounts are amortized over the life of the related held-to-maturity security. When a debt security is purchased at a premium, both the face value of the debt and premium amount are reflected as investing outflow. Other-than-temporary impairment charges, if incurred, will be included in other income (expense).</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company’s investments in money market funds have been classified and accounted for as available-for-sale securities and presented as cash equivalents on the consolidated balance sheets. As of <em style="font: inherit;"> March 31, 2021</em> and <em style="font: inherit;"> December 31, 2020</em>, all of our money market funds were invested in U.S. Government money market funds. The Company did <em style="font: inherit;">not</em> have any investment securities classified as trading as of <em style="font: inherit;"> March 31, 2021</em> or <em style="font: inherit;"> December 31, 2020</em>.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i/></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Accounts Receivable</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Accounts receivable consist of billed receivables currently due from customers and unbilled receivables. Unbilled receivables represent the excess of contract revenue (or amounts reimbursable under contracts) over billings to date. Such amounts become billable in accordance with the contract terms, which usually consider the passage of time, achievement of certain milestones or completion of the project.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Outstanding account balances are reviewed individually for collectability. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing accounts receivable. Substantially all of our accounts receivable were current and include unbilled amounts that will be billed and collected over the next <em style="font: inherit;">twelve</em> (<em style="font: inherit;">12</em>) months. There was <span style="-sec-ix-hidden:c73543806"><span style="-sec-ix-hidden:c73543807">no</span></span> allowance for doubtful accounts as of <em style="font: inherit;"> March 31, 2021</em> and <em style="font: inherit;"> December 31, 2020</em>.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Accounts receivable consist of the following:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">March 31, 2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31, 2020</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Unaudited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Audited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Billed receivable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">293,323</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">130,532</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Unbilled receivable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">91,640</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">163,667</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">384,963</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">294,199</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i/></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Prepaid Expenses and Other Current Assets</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Prepaid expenses and other current assets consist of the following:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">March 31, 2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31, 2020</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Unaudited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Audited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Prepaid insurance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">94,841</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">204,988</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Prepaid expenses - various</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">120,534</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">72,403</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Prepaid taxes</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">814</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,164</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">216,189</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">280,555</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i/></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i/></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Accounts Payable</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Accounts payable consist of the following:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">March 31, 2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31, 2020</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Unaudited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Audited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Research and development expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,337,755</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">904,572</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Legal expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">93,071</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">24,496</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">42,987</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">84,031</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,473,813</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,013,099</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i/></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i/></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Accrued Expenses</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Accrued expenses consist of the following:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">March 31, 2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31, 2020</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Unaudited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Audited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Employee wages and benefits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">175,210</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">447,881</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Research and development expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">42,006</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">28,508</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">60,452</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">13,367</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">277,668</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">489,756</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b><i/></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b><i>Revenue Recognition </i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company has <em style="font: inherit;">no</em> pharmaceutical products approved for sale at this point, and all of our revenue to date has been research revenue from <em style="font: inherit;">third</em>-party collaborations and government grants. The Company is expected to generate future revenue from license agreements and collaborative arrangements, which <em style="font: inherit;"> may </em>include upfront payments for licenses or options to obtain a license, payment for research and development services and milestone payments, in the form of cash or non-cash considerations (e.g., minority equity interest).</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Revenue related to research collaborations and agreements: </i>The Company typically performs research and development services as specified in each respective agreement on a best efforts basis, and recognizes revenue from research funding under collaboration agreements in accordance with the <em style="font: inherit;">5</em>-step process outlined in ASC Topic <em style="font: inherit;">606</em> (“Topic <em style="font: inherit;">606”</em>): (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We recognize revenue when we satisfy a performance obligation by transferring control of the service to a customer in an amount that reflects the consideration that we expect to receive. Since the performance obligation under our collaboration agreements is generally satisfied over time, we elected to use the input method under Topic <em style="font: inherit;">606</em> to measure the progress toward complete satisfaction of a performance obligation.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Under the input methods, revenue will be recognized on the basis of the entity’s efforts or inputs to the satisfaction of a performance obligation (e.g., resources consumed, labor hours expended, costs incurred, or time elapsed) relative to the total expected inputs to the satisfaction of that performance obligation. The Company believes that the cost-based input method is the best measure of progress to reflect how the Company transfers its performance obligation to a customer. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to budgeted costs to fulfill the performance obligation. These costs consist primarily of full-time equivalent effort and <em style="font: inherit;">third</em>-party contract costs. Revenue will be recognized based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligations.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company’s performance obligations. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete the Company’s performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"><i>Revenue related to grants: </i>The Company <em style="font: inherit;"> may </em>receive grants from governments, agencies, and other private and <em style="font: inherit;">not</em>-for-profit organizations. These grants are intended to be used to partially or fully fund the Company’s research collaborations, including opportunities arising in connection with COVID-<em style="font: inherit;">19</em> that the Company is pursuing with certain collaborators. However, most, if <em style="font: inherit;">not</em> all, of such potential grant revenues, if received, is expected to be earmarked for <em style="font: inherit;">third</em> parties to advance the research required, including preclinical and clinical trials for SARS-CoV-<em style="font: inherit;">2</em> vaccines and/or antibodies candidates.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Revenue related to sublicensing agreements: </i>If the sublicense to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue allocated to the license when technology is transferred to the customer and the customer is able to use and benefit from the license.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Milestone payments: </i>At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Company evaluates whether the achievement of the milestones is considered probable and estimates the amount to be included in the transaction price. If the milestone payment is in exchange for a sublicense and is based on the sublicensee’s subsequent sale of product, the Company recognizes milestone payment by applying the accounting guidance for royalties. To date, the Company has <em style="font: inherit;">not</em> recognized any milestone payment revenue resulting from any of its sublicensing arrangements.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Royalties: </i>With respect to licenses deemed to be the predominant item to which the<i> </i>sales-based royalties relate, including milestone payments based on the level of sales, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has <em style="font: inherit;">not</em> recognized any royalty revenue resulting from any of its sublicensing arrangements.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We invoice customers based on our contractual arrangements with each customer, which <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be consistent with the period that revenues are recognized. When there is a timing difference between when we invoice customers and when revenues are recognized, we record either a contract asset (unbilled accounts receivable) or a contract liability (deferred research and development obligations), as appropriate. If upfront fees or considerations related to sublicensing agreement are received prior to the technology transfer, the Company will record the amount received as deferred revenue from licensing agreement.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We are <em style="font: inherit;">not</em> required to disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of <em style="font: inherit;">one</em> year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company adopted a practical expedient to expense sales commissions when incurred because the amortization period would be <em style="font: inherit;">one</em> year or less.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"/> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i/></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Research and Development Costs </i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Research and development (“R&amp;D”) costs are expensed as incurred. R&amp;D costs are for the Company’s internally funded pharmaceutical programs and other governmental and commercial projects.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Research and development costs consist of personnel-related costs, facilities, research-related overhead, services from independent contract research organizations, and other external costs. Research and development costs, including related party, during the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2021 </em>and <em style="font: inherit;">2020</em> were as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three Months Ended March 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2020</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Unaudited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Unaudited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outside contracted services</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,659,194</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">613,790</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Personnel related costs</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">148,162</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">123,638</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Facilities, overhead and other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">742</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">18,025</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,808,098</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">755,453</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i/></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Foreign Currency Transaction Gain or Loss</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company and its foreign subsidiary use the U.S. dollar as its functional currency, and initially measure the foreign currency denominated assets and liabilities at the transaction date. Monetary assets and liabilities are then re-measured at exchange rates in effect at the end of each period, and property and non-monetary assets and liabilities are converted at historical rates.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i/></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Fair Value Measurements</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company applies fair value accounting for certain financial instruments that are recognized or disclosed at fair value in the financial statements. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into <em style="font: inherit;">three</em> levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;"><tbody><tr><td style="width: 3%; vertical-align: top;"> </td><td style="width: 3%; vertical-align: top;"><i>•</i></td><td style="width: 94%; vertical-align: top;"><i>Level <em style="font: inherit;">1</em></i> – Quoted prices in active markets for identical assets or liabilities.</td></tr> <tr><td style="width: 3%; vertical-align: top;"> </td><td style="width: 3%; vertical-align: top;"><i>•</i></td><td style="width: 94%; vertical-align: top;"><i>Level <em style="font: inherit;">2</em></i> – Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</td></tr> <tr><td style="width: 3%; vertical-align: top;"> </td><td style="width: 3%; vertical-align: top;"><i>•</i></td><td style="width: 94%; vertical-align: top;"><i>Level <em style="font: inherit;">3</em></i> – Inputs that are generally unobservable and typically reflect management’s estimate of assumptions that market participants would use in pricing the asset or liability.</td></tr> </tbody></table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company’s financial instruments included cash and cash equivalents, investment in debt securities, accounts receivable, accounts payable and accrued expenses, accrued payroll and related liabilities, deferred research and development obligations and deposits. The carrying amount of these financial instruments, except for investment in debt securities, approximates fair value due to the short-term maturities of these instruments. The Company’s short-term and long-term investments in debt securities are recorded at amortized cost, and their estimated fair value amounts are provided by the <em style="font: inherit;">third</em>-party broker service for disclosure purposes.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 17pt;"><b><i/></b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 17pt;"><b><i>Non-Marketable Investments</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company also holds investments in non-marketable equity securities of privately-held companies, which usually do <em style="font: inherit;">not</em> have a readily determinable fair value. Our policy is to measure these investments at cost less impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer such observable price changes <em style="font: inherit;"> may </em>include instances where the investee issues equity securities to new investors, thus creating a new indicator of fair value, as an example. On a quarterly basis, we perform a qualitative assessment considering impairment indicators to evaluate whether these investments are impaired and also monitor for any observable price changes. If indicators of impairment exist, we will prepare a quantitative assessment of the fair value of our equity investments, which <em style="font: inherit;"> may </em>include using both the market and income approaches which require judgment and the use of estimates, including discount rates, investee revenues and costs, and available comparable market data of private and public companies, among others. Valuations of such privately-held companies are inherently complex and uncertain due to the lack of liquid market for the company’s securities. In addition, such investments are inherently risky in that such companies are typically at an early stage of development, <em style="font: inherit;"> may </em>have <em style="font: inherit;">no</em> or limited revenues, <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be or <em style="font: inherit;"> may </em>never become profitable, <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be able to secure additional funding or their technologies, services or products <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be successfully developed or introduced into the market.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i/></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Income Taxes</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Tax Cuts and Jobs Act (“TCJA”) was enacted on <em style="font: inherit;"> December 22, 2017 </em>and became effective <em style="font: inherit;"> January 1, 2018. </em>The TCJA contains several key provisions, including a reduction in the U.S. federal corporate income tax rate from <em style="font: inherit;">35%</em> to <em style="font: inherit;">21%</em> and repeal of the corporate alternative minimum tax (“AMT”). The TCJA’s reduction in the U.S. statutory tax rate had <em style="font: inherit;">no</em> additional impact on the consolidated financial statement for the year ended <em style="font: inherit;"> December 31, 2020</em>.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">For the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2021</em>, there were <span style="-sec-ix-hidden:c73543846"><span style="-sec-ix-hidden:c73543847">no</span></span> provision for income taxes and unrecognized tax benefits recorded. As of <em style="font: inherit;"> March 31, 2021</em> and <em style="font: inherit;"> December 31, 2020</em>, deferred tax assets were approximately $10.2 million and $9.4 million, respectively. Due to the Company’s history of operating losses and the uncertainty regarding our ability to generate taxable income in the future, the Company has established a 100% valuation allowance against deferred tax assets as of <em style="font: inherit;"> March 31, 2021</em> and <em style="font: inherit;"> December 31, 2020</em>.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i/></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Comprehensive Income (Loss)</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Comprehensive income (loss) includes net income (loss) and other revenue, expenses, gains and losses that are recorded as an element of shareholders’ equity but are excluded from net income (loss) under GAAP. The Company does <em style="font: inherit;">not</em> have any significant transactions that are required to be reported in other comprehensive income (loss), and therefore, does <em style="font: inherit;">not</em> separately present a statement of comprehensive income (loss) in its consolidated financial statements.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i/></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Stock-Based Compensation</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We recognize all share-based payments to employees, consultants, and our board of directors (“Board of Directors”), as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statement of operations based on the grant date fair values of such payments. Stock-based compensation expense recognized each period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i/></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Net Loss Per Share</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common stock shares outstanding during the reporting period. Diluted net loss per share adjusts the weighted average number of common stock shares outstanding for the potential dilution that could occur if common stock equivalents, such as stock options were exercised and converted into common stock, calculated by applying the treasury stock method.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">For the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2021 </em>and <em style="font: inherit;">2020</em>, the effect of the potential exercise of options to purchase 5,324,215 and 4,663,390 shares of common stock, respectively, were excluded from the computation of diluted net loss per share as their effect would have been anti-dilutive.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-indent: 9pt;"><b><i/></b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-indent: 9pt;"><b><i>Recently Adopted Accounting Pronouncements</i></b> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In <em style="font: inherit;"> June 2016, </em>the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> <i>Financial Instruments - Credit Losses (Topic <em style="font: inherit;">326</em>): Measurement of Credit Losses on Financial Instruments</i>, which modifies the measurement of expected credit losses of certain financial instruments. ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> will be effective for the Company beginning in the <em style="font: inherit;">first</em> quarter of <em style="font: inherit;">2023.</em> The Company does <em style="font: inherit;">not</em> expect ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> to have a material impact on our consolidated financial positions, results of operations, and cash flows.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In <em style="font: inherit;"> December 2019, </em>the FASB issued ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2019</em>-<em style="font: inherit;">12,</em> <i>Income Taxes (Topic <em style="font: inherit;">740</em>): Simplifying the Accounting for Income Taxes</i>. The amendments of this update simplify the accounting for income taxes by removing certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The Company adopted ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">12</em> on <em style="font: inherit;"> January 1, 2021, </em>and adoption of ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">12</em> did <em style="font: inherit;">not</em> have any material impact on our consolidated financial positions, results of operations, cash flows and related disclosures.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Other pronouncements issued by the FASB or other authoritative accounting standards group with future effective dates are either <em style="font: inherit;">not</em> applicable or <em style="font: inherit;">not</em> significant to our consolidated financial statements.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"/> <p style="text-indent: 9pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin: 0"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Impact of COVID-<em style="font: inherit;">19</em></i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The outbreak of COVID-<em style="font: inherit;">19</em> has led to adverse impacts on the U.S. and global economies and created uncertainty regarding the potential impact to the Company’s employees, operations, and research projects.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">To date, some of our employees are still working remotely. The extent to which the COVID-<em style="font: inherit;">19</em> pandemic will directly or indirectly impact our business will depend on future developments that are highly uncertain, including as a result of new information that <em style="font: inherit;"> may </em>emerge concerning the severe acute respiratory syndrome coronavirus <em style="font: inherit;">2</em> (SARS-CoV-<em style="font: inherit;">2</em>) and its variants and the actions taken and the level of success to contain or treat the SARS-CoV-<em style="font: inherit;">2</em> virus and its variants, the economic impact on local, regional, national and international business partners and markets, delays or disruptions in our on-going research projects, and unavailability of the employees of the Company or <em style="font: inherit;">third</em>-party contract research organizations with whom we conduct business, due to illness or quarantines, all of which are highly uncertain and cannot be predicted at this time. Management is actively monitoring this situation and the possible effects on its financial condition, liquidity, operations, vendors, industry, and workforce. Even after the COVID-<em style="font: inherit;">19</em> pandemic has subsided, the Company <em style="font: inherit;"> may </em>continue to experience adverse impacts to its business because of economic recession or depression that has occurred or <em style="font: inherit;"> may </em>occur in the future. Given the daily evolution of the COVID-<em style="font: inherit;">19</em> outbreak and the ongoing response to curb its spread (including government travel and meeting restrictions) currently we are <em style="font: inherit;">not</em> able to accurately estimate the effects of the COVID-<em style="font: inherit;">19</em> outbreak to our results of operations, financial condition, or liquidity.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">We rely on our existing cash and cash equivalents, investments in debt securities, and operating cash flow to provide the working capital needs for our operations. We believe that our existing cash position and investment in investment grade securities will be adequate to meet our operational, business, and other liquidity requirements for at least the next <em style="font: inherit;">twelve</em> (<em style="font: inherit;">12</em>) months. However, in the event our financing needs for the foreseeable future are <em style="font: inherit;">not</em> able to be met by our existing cash, cash equivalents and investments, we would seek to raise funds through public or private equity offerings, and through other means to meet our financing requirements. Additionally, the Company <em style="font: inherit;"> may </em>decide to fund all of a Phase I clinical trial to demonstrate the safety in humans of a protein produced from the <em style="font: inherit;">C1</em> expression platform in humans. There is <em style="font: inherit;">no</em> assurance that external funding will be available at acceptable terms, if at all, and the Company <em style="font: inherit;"> may, </em>therefore, self-fund these vital projects.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b>Basis of Presentation </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The accompanying unaudited condensed consolidated financial statements, including the accounts of the Company and its wholly owned subsidiaries, have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and footnote disclosures normally included in consolidated financial statements have been condensed or omitted pursuant to such rules and regulations. All significant intra-entity transactions and balances have been eliminated in consolidation. The information included in this Quarterly Report on Form <em style="font: inherit;">10</em>-Q should be read in conjunction with the audited consolidated financial statements and footnotes as of and for the year ended <em style="font: inherit;"> December </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2020,</em> included in our Form <em style="font: inherit;">10</em>-K which was filed with the SEC on <em style="font: inherit;"> March </em><em style="font: inherit;">30,</em> <em style="font: inherit;">2021.</em><b><i> </i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In the opinion of management, the accompanying unaudited interim consolidated financial statements reflect all adjustments, which are of a normal recurring nature, considered necessary for a fair presentation of all periods presented. The results of the Company’s operations for any interim periods are <em style="font: inherit;">not</em> necessarily indicative of the results of operations for any other interim period or for a full fiscal year.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Since concluding the DuPont Transaction, the Company has conducted business in <span style="-sec-ix-hidden:c73543760">one</span> operating segment, which is identified by the Company based on how resources are allocated, and operating decisions are made. Management evaluates performance and allocates resources based on the Company as a whole.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Use of Estimates</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The preparation of these consolidated financial statements in accordance with GAAP requires management to make estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the applicable period. Actual results <em style="font: inherit;"> may </em>differ from these estimates under different assumptions or conditions. Such differences could be material to the consolidated financial statements.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Concentrations and Credit Risk</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company’s financial instruments that are potentially subject to concentrations of credit risk consist primarily of cash and cash equivalents, investment securities, and accounts receivable. At times, the Company has cash, cash equivalents, and investment securities at financial institutions exceeding the Federal Depository Insurance Company (“FDIC”) and the Securities Investor Protection Corporation (“SIPC”) insured limit on domestic currency and the Netherlands’ FDIC counterpart for foreign currency. The Company only deals with reputable financial institutions and has <em style="font: inherit;">not</em> experienced any losses in such accounts.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">For the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2021 </em>and <em style="font: inherit;">2020</em>, the Company’s revenue was generated from <span style="-sec-ix-hidden:c73543764">eight</span> and <span style="-sec-ix-hidden:c73543765">five</span> customers, respectively. As of <em style="font: inherit;"> March 31, 2021</em> and <em style="font: inherit;"> December 31, 2020</em>, the Company’s accounts receivable was from <span style="-sec-ix-hidden:c73543766">seven</span> and <span style="-sec-ix-hidden:c73543767">nine</span> customers, respectively. The loss of business from <em style="font: inherit;">one</em> or a combination of the Company’s customers could adversely affect its operations.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company conducts operations in the Netherlands through its foreign subsidiary and generates a portion of its revenues from customers that are located outside of the United States. For the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2021</em>, the Company had six customers outside of the United States (i.e. European and Asian customers) that accounted for approximately 76.7% or $353,000 of the revenue. For the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2020</em>, the Company had three customers outside of the United States that accounted for approximately 58.0% or $183,000 of the revenue. As of the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2021</em>, the Company had four customers outside of the United States (i.e. European and Asian customers) that accounted for approximately 46.0% or $174,000 of accounts receivable. As of <em style="font: inherit;"> December 31, 2020</em>, the Company had seven customers outside of the United States that accounted for approximately 41.6% or $123,000 of accounts receivable.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company uses several contract research organizations (“CROs”) to conduct its research projects. As of and for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2021</em>, <span style="-sec-ix-hidden:c73543786">three</span> CROs accounted for approximately $2,017,000 or 98.1% of total research services we purchased and $1,324,000 or 89.8% of the accounts payable. For the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2020, </em><span style="-sec-ix-hidden:c73543792">one</span> CRO accounted for approximately $855,000, or 100% of total research services we purchased. As of <em style="font: inherit;"> December 31, 2020</em>, <span style="-sec-ix-hidden:c73543795">one</span> CRO accounted for approximately $690,000 or 68.1% of the accounts payable. The loss of this CRO or a combination of the Company’s CROs could adversely affect its operations.</p> 6 0.767 353000 3 0.580 183000 4 0.460 174000 7 0.416 123000 2017000 0.981 1324000 0.898 855000 1 690000 0.681 <p style="margin-left: 18pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt"><b><i>Cash and Cash Equivalents</i></b></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 18pt; text-indent: 18pt;">We treat highly liquid investments with original maturities of <em style="font: inherit;">three</em> months or less when purchased as cash equivalents, including money market funds, which are unrestricted for withdrawal or use.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Investment Securities</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company invests excess cash balances in short-term and long-term investment grade securities. Short-term investment securities mature within <em style="font: inherit;">twelve</em> (<em style="font: inherit;">12</em>) months or less, and long-term investment securities mature over <em style="font: inherit;">twelve</em> (<em style="font: inherit;">12</em>) months from the applicable reporting date. Management determines the appropriate classification of its investments at the time of purchase and reevaluates the classifications at each balance sheet date. The Company’s investments in debt securities have been classified and accounted for as held-to-maturity. Held-to-maturity securities are those securities that the Company has the ability and intent to hold until maturity. Held-to-maturity securities are recorded at amortized cost, adjusted for the amortization or accretion of premiums or discounts. Premiums and discounts are amortized over the life of the related held-to-maturity security. When a debt security is purchased at a premium, both the face value of the debt and premium amount are reflected as investing outflow. Other-than-temporary impairment charges, if incurred, will be included in other income (expense).</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company’s investments in money market funds have been classified and accounted for as available-for-sale securities and presented as cash equivalents on the consolidated balance sheets. As of <em style="font: inherit;"> March 31, 2021</em> and <em style="font: inherit;"> December 31, 2020</em>, all of our money market funds were invested in U.S. Government money market funds. The Company did <em style="font: inherit;">not</em> have any investment securities classified as trading as of <em style="font: inherit;"> March 31, 2021</em> or <em style="font: inherit;"> December 31, 2020</em>.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Accounts Receivable</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Accounts receivable consist of billed receivables currently due from customers and unbilled receivables. Unbilled receivables represent the excess of contract revenue (or amounts reimbursable under contracts) over billings to date. Such amounts become billable in accordance with the contract terms, which usually consider the passage of time, achievement of certain milestones or completion of the project.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Outstanding account balances are reviewed individually for collectability. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing accounts receivable. Substantially all of our accounts receivable were current and include unbilled amounts that will be billed and collected over the next <em style="font: inherit;">twelve</em> (<em style="font: inherit;">12</em>) months. There was <span style="-sec-ix-hidden:c73543806"><span style="-sec-ix-hidden:c73543807">no</span></span> allowance for doubtful accounts as of <em style="font: inherit;"> March 31, 2021</em> and <em style="font: inherit;"> December 31, 2020</em>.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Accounts receivable consist of the following:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">March 31, 2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31, 2020</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Unaudited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Audited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Billed receivable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">293,323</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">130,532</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Unbilled receivable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">91,640</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">163,667</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">384,963</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">294,199</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">March 31, 2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31, 2020</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Unaudited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Audited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Billed receivable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">293,323</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">130,532</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Unbilled receivable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">91,640</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">163,667</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">384,963</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">294,199</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 293323 130532 91640 163667 384963 294199 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Prepaid Expenses and Other Current Assets</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Prepaid expenses and other current assets consist of the following:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">March 31, 2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31, 2020</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Unaudited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Audited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Prepaid insurance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">94,841</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">204,988</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Prepaid expenses - various</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">120,534</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">72,403</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Prepaid taxes</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">814</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,164</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">216,189</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">280,555</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">March 31, 2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31, 2020</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Unaudited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Audited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Prepaid insurance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">94,841</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">204,988</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Prepaid expenses - various</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">120,534</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">72,403</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Prepaid taxes</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">814</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,164</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">216,189</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">280,555</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 94841 204988 120534 72403 814 3164 216189 280555 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Accounts Payable</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Accounts payable consist of the following:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">March 31, 2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31, 2020</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Unaudited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Audited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Research and development expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,337,755</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">904,572</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Legal expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">93,071</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">24,496</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">42,987</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">84,031</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,473,813</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,013,099</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">March 31, 2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31, 2020</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Unaudited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Audited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Research and development expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,337,755</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">904,572</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Legal expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">93,071</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">24,496</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">42,987</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">84,031</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,473,813</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,013,099</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 1337755 904572 93071 24496 42987 84031 1473813 1013099 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Accrued Expenses</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Accrued expenses consist of the following:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">March 31, 2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31, 2020</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Unaudited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Audited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Employee wages and benefits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">175,210</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">447,881</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Research and development expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">42,006</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">28,508</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">60,452</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">13,367</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">277,668</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">489,756</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">March 31, 2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">December 31, 2020</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Unaudited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Audited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Employee wages and benefits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">175,210</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">447,881</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Research and development expenses</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">42,006</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">28,508</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">60,452</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">13,367</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">277,668</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">489,756</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 175210 447881 42006 28508 60452 13367 277668 489756 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b><i>Revenue Recognition </i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company has <em style="font: inherit;">no</em> pharmaceutical products approved for sale at this point, and all of our revenue to date has been research revenue from <em style="font: inherit;">third</em>-party collaborations and government grants. The Company is expected to generate future revenue from license agreements and collaborative arrangements, which <em style="font: inherit;"> may </em>include upfront payments for licenses or options to obtain a license, payment for research and development services and milestone payments, in the form of cash or non-cash considerations (e.g., minority equity interest).</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Revenue related to research collaborations and agreements: </i>The Company typically performs research and development services as specified in each respective agreement on a best efforts basis, and recognizes revenue from research funding under collaboration agreements in accordance with the <em style="font: inherit;">5</em>-step process outlined in ASC Topic <em style="font: inherit;">606</em> (“Topic <em style="font: inherit;">606”</em>): (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We recognize revenue when we satisfy a performance obligation by transferring control of the service to a customer in an amount that reflects the consideration that we expect to receive. Since the performance obligation under our collaboration agreements is generally satisfied over time, we elected to use the input method under Topic <em style="font: inherit;">606</em> to measure the progress toward complete satisfaction of a performance obligation.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Under the input methods, revenue will be recognized on the basis of the entity’s efforts or inputs to the satisfaction of a performance obligation (e.g., resources consumed, labor hours expended, costs incurred, or time elapsed) relative to the total expected inputs to the satisfaction of that performance obligation. The Company believes that the cost-based input method is the best measure of progress to reflect how the Company transfers its performance obligation to a customer. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to budgeted costs to fulfill the performance obligation. These costs consist primarily of full-time equivalent effort and <em style="font: inherit;">third</em>-party contract costs. Revenue will be recognized based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligations.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company’s performance obligations. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete the Company’s performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"><i>Revenue related to grants: </i>The Company <em style="font: inherit;"> may </em>receive grants from governments, agencies, and other private and <em style="font: inherit;">not</em>-for-profit organizations. These grants are intended to be used to partially or fully fund the Company’s research collaborations, including opportunities arising in connection with COVID-<em style="font: inherit;">19</em> that the Company is pursuing with certain collaborators. However, most, if <em style="font: inherit;">not</em> all, of such potential grant revenues, if received, is expected to be earmarked for <em style="font: inherit;">third</em> parties to advance the research required, including preclinical and clinical trials for SARS-CoV-<em style="font: inherit;">2</em> vaccines and/or antibodies candidates.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Revenue related to sublicensing agreements: </i>If the sublicense to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue allocated to the license when technology is transferred to the customer and the customer is able to use and benefit from the license.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Milestone payments: </i>At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Company evaluates whether the achievement of the milestones is considered probable and estimates the amount to be included in the transaction price. If the milestone payment is in exchange for a sublicense and is based on the sublicensee’s subsequent sale of product, the Company recognizes milestone payment by applying the accounting guidance for royalties. To date, the Company has <em style="font: inherit;">not</em> recognized any milestone payment revenue resulting from any of its sublicensing arrangements.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Royalties: </i>With respect to licenses deemed to be the predominant item to which the<i> </i>sales-based royalties relate, including milestone payments based on the level of sales, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has <em style="font: inherit;">not</em> recognized any royalty revenue resulting from any of its sublicensing arrangements.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We invoice customers based on our contractual arrangements with each customer, which <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be consistent with the period that revenues are recognized. When there is a timing difference between when we invoice customers and when revenues are recognized, we record either a contract asset (unbilled accounts receivable) or a contract liability (deferred research and development obligations), as appropriate. If upfront fees or considerations related to sublicensing agreement are received prior to the technology transfer, the Company will record the amount received as deferred revenue from licensing agreement.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We are <em style="font: inherit;">not</em> required to disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of <em style="font: inherit;">one</em> year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company adopted a practical expedient to expense sales commissions when incurred because the amortization period would be <em style="font: inherit;">one</em> year or less.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Research and Development Costs </i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Research and development (“R&amp;D”) costs are expensed as incurred. R&amp;D costs are for the Company’s internally funded pharmaceutical programs and other governmental and commercial projects.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Research and development costs consist of personnel-related costs, facilities, research-related overhead, services from independent contract research organizations, and other external costs. Research and development costs, including related party, during the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2021 </em>and <em style="font: inherit;">2020</em> were as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three Months Ended March 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2020</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Unaudited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Unaudited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outside contracted services</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,659,194</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">613,790</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Personnel related costs</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">148,162</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">123,638</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Facilities, overhead and other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">742</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">18,025</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,808,098</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">755,453</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three Months Ended March 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2020</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Unaudited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Unaudited)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outside contracted services</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,659,194</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">613,790</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Personnel related costs</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">148,162</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">123,638</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Facilities, overhead and other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">742</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">18,025</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,808,098</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">755,453</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 1659194 613790 148162 123638 742 18025 1808098 755453 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Foreign Currency Transaction Gain or Loss</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company and its foreign subsidiary use the U.S. dollar as its functional currency, and initially measure the foreign currency denominated assets and liabilities at the transaction date. Monetary assets and liabilities are then re-measured at exchange rates in effect at the end of each period, and property and non-monetary assets and liabilities are converted at historical rates.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Fair Value Measurements</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company applies fair value accounting for certain financial instruments that are recognized or disclosed at fair value in the financial statements. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into <em style="font: inherit;">three</em> levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;"><tbody><tr><td style="width: 3%; vertical-align: top;"> </td><td style="width: 3%; vertical-align: top;"><i>•</i></td><td style="width: 94%; vertical-align: top;"><i>Level <em style="font: inherit;">1</em></i> – Quoted prices in active markets for identical assets or liabilities.</td></tr> <tr><td style="width: 3%; vertical-align: top;"> </td><td style="width: 3%; vertical-align: top;"><i>•</i></td><td style="width: 94%; vertical-align: top;"><i>Level <em style="font: inherit;">2</em></i> – Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</td></tr> <tr><td style="width: 3%; vertical-align: top;"> </td><td style="width: 3%; vertical-align: top;"><i>•</i></td><td style="width: 94%; vertical-align: top;"><i>Level <em style="font: inherit;">3</em></i> – Inputs that are generally unobservable and typically reflect management’s estimate of assumptions that market participants would use in pricing the asset or liability.</td></tr> </tbody></table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company’s financial instruments included cash and cash equivalents, investment in debt securities, accounts receivable, accounts payable and accrued expenses, accrued payroll and related liabilities, deferred research and development obligations and deposits. The carrying amount of these financial instruments, except for investment in debt securities, approximates fair value due to the short-term maturities of these instruments. The Company’s short-term and long-term investments in debt securities are recorded at amortized cost, and their estimated fair value amounts are provided by the <em style="font: inherit;">third</em>-party broker service for disclosure purposes.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 17pt;"><b><i>Non-Marketable Investments</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company also holds investments in non-marketable equity securities of privately-held companies, which usually do <em style="font: inherit;">not</em> have a readily determinable fair value. Our policy is to measure these investments at cost less impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer such observable price changes <em style="font: inherit;"> may </em>include instances where the investee issues equity securities to new investors, thus creating a new indicator of fair value, as an example. On a quarterly basis, we perform a qualitative assessment considering impairment indicators to evaluate whether these investments are impaired and also monitor for any observable price changes. If indicators of impairment exist, we will prepare a quantitative assessment of the fair value of our equity investments, which <em style="font: inherit;"> may </em>include using both the market and income approaches which require judgment and the use of estimates, including discount rates, investee revenues and costs, and available comparable market data of private and public companies, among others. Valuations of such privately-held companies are inherently complex and uncertain due to the lack of liquid market for the company’s securities. In addition, such investments are inherently risky in that such companies are typically at an early stage of development, <em style="font: inherit;"> may </em>have <em style="font: inherit;">no</em> or limited revenues, <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be or <em style="font: inherit;"> may </em>never become profitable, <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be able to secure additional funding or their technologies, services or products <em style="font: inherit;"> may </em><em style="font: inherit;">not</em> be successfully developed or introduced into the market.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Income Taxes</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Tax Cuts and Jobs Act (“TCJA”) was enacted on <em style="font: inherit;"> December 22, 2017 </em>and became effective <em style="font: inherit;"> January 1, 2018. </em>The TCJA contains several key provisions, including a reduction in the U.S. federal corporate income tax rate from <em style="font: inherit;">35%</em> to <em style="font: inherit;">21%</em> and repeal of the corporate alternative minimum tax (“AMT”). The TCJA’s reduction in the U.S. statutory tax rate had <em style="font: inherit;">no</em> additional impact on the consolidated financial statement for the year ended <em style="font: inherit;"> December 31, 2020</em>.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">For the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2021</em>, there were <span style="-sec-ix-hidden:c73543846"><span style="-sec-ix-hidden:c73543847">no</span></span> provision for income taxes and unrecognized tax benefits recorded. As of <em style="font: inherit;"> March 31, 2021</em> and <em style="font: inherit;"> December 31, 2020</em>, deferred tax assets were approximately $10.2 million and $9.4 million, respectively. Due to the Company’s history of operating losses and the uncertainty regarding our ability to generate taxable income in the future, the Company has established a 100% valuation allowance against deferred tax assets as of <em style="font: inherit;"> March 31, 2021</em> and <em style="font: inherit;"> December 31, 2020</em>.</p> 10200000 9400000 1 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Comprehensive Income (Loss)</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Comprehensive income (loss) includes net income (loss) and other revenue, expenses, gains and losses that are recorded as an element of shareholders’ equity but are excluded from net income (loss) under GAAP. The Company does <em style="font: inherit;">not</em> have any significant transactions that are required to be reported in other comprehensive income (loss), and therefore, does <em style="font: inherit;">not</em> separately present a statement of comprehensive income (loss) in its consolidated financial statements.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Stock-Based Compensation</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We recognize all share-based payments to employees, consultants, and our board of directors (“Board of Directors”), as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statement of operations based on the grant date fair values of such payments. Stock-based compensation expense recognized each period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Net Loss Per Share</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common stock shares outstanding during the reporting period. Diluted net loss per share adjusts the weighted average number of common stock shares outstanding for the potential dilution that could occur if common stock equivalents, such as stock options were exercised and converted into common stock, calculated by applying the treasury stock method.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">For the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2021 </em>and <em style="font: inherit;">2020</em>, the effect of the potential exercise of options to purchase 5,324,215 and 4,663,390 shares of common stock, respectively, were excluded from the computation of diluted net loss per share as their effect would have been anti-dilutive.</p> 5324215 4663390 <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 8pt; text-indent: 9pt;"><b><i>Recently Adopted Accounting Pronouncements</i></b> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In <em style="font: inherit;"> June 2016, </em>the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> <i>Financial Instruments - Credit Losses (Topic <em style="font: inherit;">326</em>): Measurement of Credit Losses on Financial Instruments</i>, which modifies the measurement of expected credit losses of certain financial instruments. ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> will be effective for the Company beginning in the <em style="font: inherit;">first</em> quarter of <em style="font: inherit;">2023.</em> The Company does <em style="font: inherit;">not</em> expect ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> to have a material impact on our consolidated financial positions, results of operations, and cash flows.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In <em style="font: inherit;"> December 2019, </em>the FASB issued ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2019</em>-<em style="font: inherit;">12,</em> <i>Income Taxes (Topic <em style="font: inherit;">740</em>): Simplifying the Accounting for Income Taxes</i>. The amendments of this update simplify the accounting for income taxes by removing certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The Company adopted ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">12</em> on <em style="font: inherit;"> January 1, 2021, </em>and adoption of ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">12</em> did <em style="font: inherit;">not</em> have any material impact on our consolidated financial positions, results of operations, cash flows and related disclosures.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Other pronouncements issued by the FASB or other authoritative accounting standards group with future effective dates are either <em style="font: inherit;">not</em> applicable or <em style="font: inherit;">not</em> significant to our consolidated financial statements.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">2:</em></b>    <b>Cash, Cash Equivalent, and Investments </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company’s investments in debt securities are classified as held-to-maturity and are recorded at amortized cost, and its investments in money market funds are classified as cash equivalents. The following table shows the Company’s cash, available-for-sale securities, and investment securities by major security type as of <em style="font: inherit;"> March 31, 2021</em>, and <em style="font: inherit;"> December 31, 2020</em>:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="17" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 49%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">March 31, 2021 (Unaudited)</em></em></em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 10%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Gross</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Gross</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Level</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Unrealized</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Unrealized</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">(1)</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Fair Value</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Holding Gains</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Holding Losses</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Adjusted Cost</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Cash and Cash Equivalents</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 10%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 10%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,217,419</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,217,419</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Money Market Funds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">1</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11,838,139</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11,838,139</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Subtotal</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center; width: 10%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">13,055,558</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">13,055,558</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Short-Term Investment Securities <sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center; width: 10%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Corporate Bonds <sup style="vertical-align:top;line-height:120%;font-size:pt">(3)</sup></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">2</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">14,161,252</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,658</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(17,847</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">14,177,441</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Total</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 10%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; width: 1%;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">27,216,810</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,658</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(17,847</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">27,232,999</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="17" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">December 31, 2020 (Audited)</em></em></em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Gross</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Gross</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Level</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Unrealized</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Unrealized</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">(1)</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Fair Value</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Holding Gains</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Holding Losses</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Adjusted Cost</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Cash and Cash Equivalents</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">149,015</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">149,015</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Money Market Funds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">1</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">20,488,030</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">20,488,030</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Subtotal</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">20,637,045</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">20,637,045</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Short-Term Investment Securities <sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Corporate Bonds <sup style="vertical-align:top;line-height:120%;font-size:pt">(3)</sup></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">2</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">8,473,461</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">22,473</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">(6,463</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">8,457,451</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Total</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">29,110,506</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">22,473</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(6,463</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">29,094,496</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">_________________</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Notes:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(<em style="font: inherit;">1</em>) Definition of the <em style="font: inherit;">three</em>-level fair value hierarchy:</p> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> </td><td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">•</p> </td><td> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">Level <em style="font: inherit;">1</em> - Quoted prices (unadjusted) in active markets for identical assets or liabilities</p> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> </td><td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">•</p> </td><td> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">Level <em style="font: inherit;">2</em> - Other inputs that are directly or indirectly observable in the markets</p> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> </td><td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">•</p> </td><td> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">Level <em style="font: inherit;">3</em> - Inputs that are generally unobservable</p> </td></tr> </tbody></table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(<em style="font: inherit;">2</em>) Short-term investment securities will mature within <em style="font: inherit;">12</em> months or less, from the applicable reporting date.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(<em style="font: inherit;">3</em>) The premium paid to purchase held-to-maturity investment securities was $283,940 and $196,385 for the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2021 </em>and <em style="font: inherit;">2020</em>, respectively. The premium paid to purchase held-to-maturity investment securities was $282,946 for the year ended <em style="font: inherit;"> December 31, 2020</em>.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company considers the declines in market value of its investment portfolio to be temporary in nature. The Company’s investment policy requires investment securities to be investment grade and held to maturity with the primary objective to maintain a high degree of liquidity while maximizing yield. When evaluating an investment for other-than-temporary impairment, the Company reviews factors such as the length of time and extent to which fair value has been below its cost basis, the financial condition of the issuer and any changes thereto, changes in market interest rates, and whether it is more likely than <em style="font: inherit;">not</em> the Company will be required to sell the investment before recovery of the investment’s cost basis. As of <em style="font: inherit;"> March 31, 2021</em>, the Company does <em style="font: inherit;">not</em> consider any of its investments to be other-than-temporarily impaired.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="17" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 49%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">March 31, 2021 (Unaudited)</em></em></em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 10%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Gross</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Gross</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Level</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Unrealized</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Unrealized</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">(1)</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Fair Value</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Holding Gains</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Holding Losses</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Adjusted Cost</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Cash and Cash Equivalents</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 10%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash</p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 10%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,217,419</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,217,419</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Money Market Funds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">1</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11,838,139</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">11,838,139</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Subtotal</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center; width: 10%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">13,055,558</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">13,055,558</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Short-Term Investment Securities <sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center; width: 10%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 9%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Corporate Bonds <sup style="vertical-align:top;line-height:120%;font-size:pt">(3)</sup></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">2</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">14,161,252</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,658</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(17,847</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">14,177,441</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Total</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 10%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; width: 1%;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">27,216,810</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,658</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(17,847</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">27,232,999</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="17" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">December 31, 2020 (Audited)</em></em></em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Gross</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Gross</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Level</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Unrealized</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Unrealized</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td></tr> <tr class="finHeading" style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="1" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">(1)</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Fair Value</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Holding Gains</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Holding Losses</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Adjusted Cost</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Cash and Cash Equivalents</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash</p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">149,015</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">149,015</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Money Market Funds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">1</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">20,488,030</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">20,488,030</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Subtotal</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">20,637,045</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">—</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">20,637,045</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Short-Term Investment Securities <sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; text-align: center;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"><b> </b></td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Corporate Bonds <sup style="vertical-align:top;line-height:120%;font-size:pt">(3)</sup></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">2</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">8,473,461</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">22,473</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">(6,463</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0);">8,457,451</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Total</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">29,110,506</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">22,473</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(6,463</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">29,094,496</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 1217419 1217419 11838139 11838139 13055558 13055558 14161252 1658 17847 14177441 27216810 1658 17847 27232999 149015 149015 20488030 20488030 20637045 20637045 8473461 22473 6463 8457451 29110506 22473 6463 29094496 283940 196385 282946 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">3:</em></b>    <b>Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately-Held Companies</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>BDI </i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">On <em style="font: inherit;"> June 30, 2017, </em>the Company entered into a strategic Research Services Agreement (the “RSA”) with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U. (“BDI Pharma”), and a Service Framework Agreement (the “SFA”, and together with the RSA, the “R&amp;D Agreements”), with VLP The Vaccines Company, S.L.U. (“VLPbio”), both of which are subsidiaries of Biotechnology Developments for Industry, S.L., a Spanish biotechnology company (“BDI Holdings” and together with BDI Pharma and VLPbio, “BDI”). </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The R&amp;D Agreements provide a framework under which the parties will engage in a research and development collaboration encompassing several different projects over approximately a <span style="-sec-ix-hidden:c73544044">two</span>-year period, with a focus on advancing Dyadic’s proprietary <em style="font: inherit;">C1</em> technology in the development of next generation biological vaccines and drugs. Dyadic expects to leverage the BDI team’s previous <em style="font: inherit;">C1</em> gene expression and industrial fermentation scale-up and commercialization experience with yeast and filamentous fungi processes to further advance Dyadic’s proprietary <em style="font: inherit;">C1</em> technology with the potential to commercialize certain biopharmaceutical product(s). All of the data and any products developed from the funded research projects will be owned by Dyadic.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Upon closing of the BDI transaction, the Company paid EUR <em style="font: inherit;">€1.0</em> million (the “RSA Initial Payment”) in cash to engage BDI to develop designated <em style="font: inherit;">C1</em> based product candidates and further improve the <em style="font: inherit;">C1</em> manufacturing process, in consideration of which Dyadic also received a 16.1% equity interest in BDI Holdings and a 3.3% equity interest in VLPbio. BDI is obligated to spend a minimum amount of EUR <span style="-sec-ix-hidden:c73544054">€936,000</span> over <span style="-sec-ix-hidden:c73544055">two</span> years in the conduct of the research and development project under the RSA. If the research and development activities produce a product that is selected for additional development and commercialization, then Dyadic expects to share with BDI a range of between 50% and 75% of the net income from such selected product, depending upon the amount of BDI’s aggregate spend in the development of the selected product, with a minimum aggregate spend by BDI of EUR <span style="-sec-ix-hidden:c73544058">€1</span> million for a 50% share and EUR <em style="font: inherit;">€<span style="-sec-ix-hidden:c73544061">8.0</span></em> million for a 75% share. If BDI does <em style="font: inherit;">not</em> enter into an agreement with Dyadic for such additional development and commercialization of the selected product, then Dyadic will pay to BDI EUR <span style="-sec-ix-hidden:c73544064">€1.5</span> million of the net income from Dyadic’s commercialization, if any, of the selected product. In addition, under the SFA, Dyadic agreed to purchase from BDI at least USD $1.0 million (the “SFA Commitment”) in contract research services specified by Dyadic over <span style="-sec-ix-hidden:c73544066">two</span> years since the closing of the BDI transaction.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company has concluded that BDI is <em style="font: inherit;">not</em> a Variable Interest Entity (“VIE”), because BDI has sufficient equity to finance its activities without additional subordinated financial support and its at-risk equity holders have the characteristics of a controlling financial interest. Additionally, Dyadic is <em style="font: inherit;">not</em> the primary beneficiary of BDI as Dyadic does <em style="font: inherit;">not</em> have the power to control or direct the activities of BDI or its operations. As a result, the Company does <em style="font: inherit;">not</em> consolidate its investments in BDI, and the financial results of BDI are <em style="font: inherit;">not</em> included in the Company’s consolidated financial results.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company performed a valuation analysis of the components of the transaction and allocated the consideration based on the relative fair value of each component. As the fair value of BDI equity interest was considered immaterial, the RSA Initial Payment of approximately USD <em style="font: inherit;"><span style="-sec-ix-hidden:c73544074">$1.1</span></em> million (EUR <em style="font: inherit;">€1.0</em> million) was accounted for as a prepaid research and development collaboration payment on our consolidated balance sheet, and both the collaboration payment under the RSA and the SFA Commitment of USD $1.0 million paid by Dyadic were expensed as the related research services were performed by BDI. In <em style="font: inherit;"> June 2019, </em>BDI has completed its services under the RSA and the entire amount of the RSA Initial Payment was expensed. Dyadic had fulfilled its SFA commitment and completed all research projects under the SFA in <em style="font: inherit;">2019.</em></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">On <em style="font: inherit;"> February 18, 2021, </em>the Company entered into a separate service agreement with BDI to perform a research project unrelated to the R&amp;D Agreements. For the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2021</em>, approximately $15,000 recorded in the cost of research and development revenue was associated with this new service agreement.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b><i>Novovet and Luina Bio </i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On <em style="font: inherit;"> April 26, 2019, </em>the Company entered into a sub-license agreement (the “Luina Bio Sub-License Agreement”) with Luina Bio Pty Ltd. (“Luina Bio”) and Novovet Pty Ltd (“Novovet”). Under the terms of the Luina Bio Sub-License Agreement, the Company has granted to Novovet, subject to the terms of the license agreement entered into between the Company and Danisco US, Inc. on <em style="font: inherit;"> December 31, 2015, </em>a worldwide sub-license to certain patent rights and know-how related to Dyadic’s proprietary <em style="font: inherit;">C1</em> gene expression platform for the exclusive and sole purpose of commercializing certain targeted antigen and biological products for the prevention and treatment of various ailments for companion animals.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In consideration of the license granted pursuant to the Luina Bio Sub-License Agreement, Dyadic received a 20% equity interest in Novovet (“Novovet Up-Front Consideration”) in accordance with the terms of Novovet’s Shareholder Agreement, and will receive a percentage of royalties on future net sales and non-sales revenue, if any, which incorporates Dyadic’s proprietary <em style="font: inherit;">C1</em> gene expression platform.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company evaluated the nature of its equity interest investment in Novovet and determined that Novovet is a VIE, because Novovet does <em style="font: inherit;">not</em> have sufficient equity to finance its activities without additional financial support from <em style="font: inherit;">third</em> party investors or lenders. However, the Company is <em style="font: inherit;">not</em> the primary beneficiary of Novovet as Dyadic does <em style="font: inherit;">not</em> have the power to control or direct the activities of Novovet that most significantly impact the VIE. As a result, the Company will <em style="font: inherit;">not</em> consolidate its investment in Novovet, but account for under the equity method investment, given that it has the ability to exercise significant influence, but <em style="font: inherit;">not</em> control, over Novovet.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">To date Novovet has <em style="font: inherit;">not</em> raised the capital required to move this opportunity forward, and therefore, the Company has <em style="font: inherit;">not</em> transferred its <em style="font: inherit;">C1</em> technology to Novovet. Therefore, the Novovet Up-Front Consideration received under the Luina Bio Sub-License Agreement, in the form of a 20% equity interest in Novovet, does <em style="font: inherit;">not</em> yet meet the revenue recognition criteria under ASC <em style="font: inherit;">606.</em> The Company will account for its investment in Novovet and the related income under the equity method of accounting, once the transfer of its <em style="font: inherit;">C1</em> technology is completed and Novovet receives adequate financing required to commence its research and development activities. The Company intends to terminate the Luina Bio Sub-License Agreement in <em style="font: inherit;">2021</em> should Novovet be unable to raise the required funding.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b><i>Alphazyme </i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On <em style="font: inherit;"> May 5, 2019, </em>the Company entered into a sub-license agreement (the “Alphazyme Sub-License Agreement”) with Alphazyme, LLC (“Alphazyme”). Under the terms of the Alphazyme Sub-License Agreement, the Company has granted to Alphazyme, subject to the terms of the license agreement entered into between the Company and Danisco US, Inc. on <em style="font: inherit;"> December 31, 2015, </em>a sub-license to certain patent rights and know-how related to Dyadic’s proprietary <em style="font: inherit;">C1</em> gene expression platform for the purpose of commercializing certain pharmaceutical products that are used as reagents to catalyze a chemical reaction to detect, measure, or be used as a process intermediate to produce a nucleic acid as a therapeutic or diagnostic agent.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">On <em style="font: inherit;"> June 24, 2020, </em>the Company entered into an Amended and Restated Non-Exclusive Sub-License Agreement (the “Amended Sub-License Agreement”) with Alphazyme. Pursuant to the Amended Sub-License Agreement and in consideration of Dyadic’s transfer of its <em style="font: inherit;">C1</em> technology, Alphazyme issued 2.50% of the Class A shares of Alphazyme to Dyadic, and Dyadic became a party to the Alphazyme Limited Liability Company Agreement pursuant to which the Company has agreed to certain customary rights, covenants and obligations. In addition, and subject to achieving certain milestones, Alphazyme is obligated to pay a potential milestone payment and royalties, based on net sales, if any, which incorporate Dyadic’s proprietary <em style="font: inherit;">C1</em> gene expression platform. </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">On <em style="font: inherit;"> December 1, 2020, </em>the Company entered into an Amended and Restated Limited Liability Company Agreement with Alphazyme (the “Amended Alphazyme LLC Agreement”) was entered into. Under the Amended Alphazyme LLC Agreement, Alphazyme obtained an additional capital contribution and Dyadic’s ownership was diluted to 1.99%.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company evaluated the nature of its equity interest investment in Alphazyme and determined that Alphazyme is a VIE due to the capital structure of the entity. However, the Company is <em style="font: inherit;">not</em> the primary beneficiary of Alphazyme as Dyadic does <em style="font: inherit;">not</em> have the power to control or direct the activities of Alphazyme that most significantly impact the VIE. As a result, the Company does <em style="font: inherit;">not</em> consolidate its investment in Alphazyme. The Company reports its investment in Alphazyme under the cost method of accounting, given that it does <em style="font: inherit;">not</em> have the ability to exercise significant influence or control,</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">For the year ended <em style="font: inherit;"> December 31, 2020, </em>the Company recorded a gain of <span style="-sec-ix-hidden:c73544106">$284,709</span> from its investment in Alphazyme as a result of a <em style="font: inherit;">third</em>-party additional capital contribution obtained by Alphazyme. As of <em style="font: inherit;">March31,</em> <em style="font: inherit;">2021</em>, the Company does <em style="font: inherit;">not</em> consider its investment in Alphazyme to be impaired.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 17pt;"><b><i>IDBiologics, Inc.</i></b> </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">On <em style="font: inherit;"> July 8, 2020, </em>the Company entered into a Common Stock Purchase Agreement (the “IDBiologics Agreement”) with IDBiologics, Inc (“IDBiologics”). IDBiologics is a private biotechnology company focused on the development of human monoclonal antibodies for the treatment and prevention of serious infectious diseases. The Company was founded in <em style="font: inherit;">2017</em> and seeded by Vanderbilt University Medical Center in response to the repeated threats of epidemics around the world, including Ebola in West Africa and Zika in the Americas. IDBiologics is developing a portfolio of monoclonal antibodies against SARS-CoV-<em style="font: inherit;">2,</em> influenza and Zika viruses.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Under the term of the IDBiologics Agreement, Dyadic agreed to receive 129,611 shares of IDBiologics’ common stock, which represent 0.37% of IDBiologics’ outstanding equity, in exchange for the services to be provided by Dyadic. Such services include the use of Dyadic’s <em style="font: inherit;">C1</em> technology to express a SARS-CoV-<em style="font: inherit;">2</em> monoclonal antibody which IDBiologics licensed from the Vanderbilt Vaccine Center. The shares of common stock of IDBiologics vested 50% upon the signing of the IDBiologics Agreement, 25% will vest upon the completion of Step <em style="font: inherit;">3</em> of a feasibility study required by the IDBiologics Agreement, and 25% will vest at the end of the project.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The Company evaluated the nature of its equity interest in IDBiologics and determined that IDBiologics is a VIE due to the capital structure of the entity. However, the Company is <em style="font: inherit;">not</em> the primary beneficiary of IDBiologics as Dyadic does <em style="font: inherit;">not</em> have the power to control or direct the activities of IDBiologics that most significantly impact the VIE. As a result, the Company does <em style="font: inherit;">not</em> consolidate its investment in IDBiologics. Upon receipt its shares, Dyadic will account for the equity interest in IDBiologics under the cost method. <em style="font: inherit;">No</em> revenue from the IDBiologics Agreement was recorded during the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March </em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em>, because the amount of consideration received was immaterial.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 0.161 0.033 0.50 0.75 0.50 0.75 1000000.0 1000000.0 15000 0.20 0.20 0.0250 0.0199 129611 0.0037 0.50 0.25 0.25 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">4:</em></b>    <b>Commitments and Contingencies</b></p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b><i>Legal Proceedings</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We are <em style="font: inherit;">not</em> currently involved in any litigation that we believe could have a materially adverse effect in our financial condition or results of operations. From time to time, the Company is subject to legal proceedings, asserted claims and investigations in the ordinary course of business, including commercial claims, employment and other matters, which management considers immaterial, individually and in the aggregate. The Company makes a provision for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The requirement for these provisions is reviewed at least quarterly and adjusted to reflect the impact of negotiations, settlements, rulings, advice of legal counsel and other information and events pertaining to a particular case. Litigation is inherently unpredictable and costly. Protracted litigation and/or an unfavorable resolution of <em style="font: inherit;">one</em> or more of proceedings, claims or investigations against the Company could have a material adverse effect on the Company’s consolidated financial position, cash flows or results of operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">5:</em></b>    <b>Share-Based Compensation</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Description of Equity Plans</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The <em style="font: inherit;">2011</em> Equity Incentive Plan (the <em style="font: inherit;">“2011</em> Plan”) was adopted by the Company’s Board of Directors on <em style="font: inherit;"> April 28, 2011 </em>and approved by the Company’s stockholders on <em style="font: inherit;"> June 15, 2011. </em>The <em style="font: inherit;">2011</em> Plan serves as the successor to the Company’s <em style="font: inherit;">2006</em> Stock Option Plan (the <em style="font: inherit;">“2006</em> Plan”). Since the effective date of the <em style="font: inherit;">2011</em> Plan, all equity awards were made from the <em style="font: inherit;">2011</em> Plan, and <em style="font: inherit;">no</em> additional awards will be granted under the <em style="font: inherit;">2006</em> plan. Under the <em style="font: inherit;">2011</em> Plan, 3,000,000 shares of the Company’s common stock were initially reserved for issuance pursuant to a variety of share-based compensation awards, plus any shares available for issuance under the <em style="font: inherit;">2006</em> Plan or are subject to awards under the <em style="font: inherit;">2006</em> Plan which are forfeited or lapse unexercised and which following the effective date are <em style="font: inherit;">not</em> issued under the <em style="font: inherit;">2006</em> Plan. In accordance with the provisions of the <em style="font: inherit;">2011</em> Plan, the Board of Directors approved an increase of 1,500,000 shares to the plan on <em style="font: inherit;"> January 1, 2019 </em>and <em style="font: inherit;">2020.</em></p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">At our <em style="font: inherit;">2021</em> Virtual Annual Meeting of Shareholders (“Annual Meeting”) to be held on <em style="font: inherit;"> June 11, 2021, </em>shareholders will be asked to approve the Company’s <em style="font: inherit;">2021</em> Equity Incentive Award Plan (the <em style="font: inherit;">“2021</em> Plan”), which was adopted, subject to shareholder approval, by the Board of Directors on <em style="font: inherit;"> April 9, 2021. </em>We are seeking stockholder approval of the <em style="font: inherit;">2021</em> Plan to increase the number of shares available for the grant of stock options, restricted stock awards and other awards by 3,000,000 in addition to the number of shares remaining available for the grant of new awards under the <em style="font: inherit;">2011</em> Plan as of <em style="font: inherit;"> April 16, 2021. </em>If this proposal is approved by our shareholders, the <em style="font: inherit;">2021</em> Plan will become effective as of the date of the Annual Meeting and as of such date, <em style="font: inherit;">no</em> additional awards will be granted under the <em style="font: inherit;">2011</em> Plan. If our shareholders do <em style="font: inherit;">not</em> approve this proposal, the <em style="font: inherit;">2021</em> Plan will <em style="font: inherit;">not</em> become effective and the <em style="font: inherit;">2011</em> Plan will continue to be effective in accordance with its terms, until its expiration date.</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As of <em style="font: inherit;"> March 31, 2021</em>, the Company had 5,324,215 stock options outstanding and an additional 1,388,386 shares of common stock available for grant under the <em style="font: inherit;">2011</em> Plan. As of <em style="font: inherit;"> December 31, 2020</em>, there were 4,638,390 stock options outstanding and 2,134,211 shares of common stock available for grant under the <em style="font: inherit;">2011</em> Plan.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Stock Options </i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Options are granted to purchase common stock at prices that are equal to the fair value of the common stock on the date the option is granted. Vesting is determined by the Board of Directors at the time of grant. The term of any stock option awards under the Company’s <em style="font: inherit;">2011</em> Plan is <span style="-sec-ix-hidden:c73544184">ten</span> years except for certain options granted to the contractors which are <span style="-sec-ix-hidden:c73544185">one</span> or <span style="-sec-ix-hidden:c73544186">three</span> years.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The grant-date fair value of each option grant is estimated using the Black-Scholes option pricing model and amortized on a straight-line basis over the requisite service period, which is generally the vesting period, for each separately vesting portion of the award as if the award was, in substance, multiple awards. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs, including the following:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Risk-free interest rate</i>. The risk-free interest rate is based on U.S. Treasury rates with securities approximating the expected lives of options at the date of grant.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Expected dividend yield</i>. The expected dividend yield is zero, as the Company has never paid dividends to common shareholders and does <em style="font: inherit;">not</em> currently anticipate paying any in the foreseeable future.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Expected stock price volatility.</i> The expected stock price volatility was calculated based on the Company’s own volatility after the DuPont Transaction. The Company reviews its volatility assumption on an annual basis and has used the Company’s historical volatility since <em style="font: inherit;">2016,</em> as the DuPont Transaction resulted in significant changes in the Company’s business and capital structure.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"><i>Expected life of option. </i>The expected life of option was based on the contractual term of the option and expected employee exercise and post-vesting employment termination behavior. The Company uses the weighted average vesting period and contractual term of the option as the best estimate of the expected life of a new option, except for the options granted to the CEO (i.e., <span style="-sec-ix-hidden:c73544190">5</span> or 10 years) and certain contractors (i.e., 2 or <em style="font: inherit;"><span style="-sec-ix-hidden:c73544194">3</span>years</em>).</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The assumptions used in the Black-Scholes option pricing model for stock options granted during the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2021</em> are as follows:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Risk-Free interest rate</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.13%-0.55%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected dividend yield</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">—%</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected stock price volatility</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">54.52%-56.07%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected life of options (in years)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.00-6.25</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The following table summarizes the stock option activities during the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2021</em>:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 10%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 11%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted-Average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 10%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 10%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted-Average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Remaining Contractual</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Aggregate Intrinsic</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Shares</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Exercise Price</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Term (Years)</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Value</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,638,390</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.44</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.64</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13,701,610</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted (1)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">745,825</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.25</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 13%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 10%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercised (2)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(60,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.93</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 13%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 10%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 11%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 13%;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 10%;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Canceled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 13%;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 10%;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at March 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,324,215</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2.84</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6.03</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,209,431</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="width: 44%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 10%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 11%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 13%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 10%;"> </td><td style="width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercisable at March 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,016,141</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2.28</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5.09</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,927,908</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">_________________</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Notes:</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(<em style="font: inherit;">1</em>) Represents the following stock options granted:</p> <table cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; margin-right: 0pt;"><tbody><tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">•</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Annual share-based compensation awards on <em style="font: inherit;"> January 4, </em><em style="font: inherit;">2021</em>, including: (a) 417,500 stock options with an exercise price of $5.16 per share granted to executives and key personnel, upon <span style="-sec-ix-hidden:c73544201">one</span> year anniversary, or vesting annually in equal installments over <span style="-sec-ix-hidden:c73544202">four</span> years, (b) 227,500 stock options with an exercise price of $5.16 per share granted to members of the Board of Directors, vesting upon <span style="-sec-ix-hidden:c73544205">one</span> year anniversary, (c) 23,325 stock options with an exercise price of $5.16 per share granted to employees, vesting annually in equal installments over <span style="-sec-ix-hidden:c73544208">four</span> years and (d) 5,000 stock options with an exercise price of $5.16 per share granted to a consultant, vesting upon <span style="-sec-ix-hidden:c73544211">one</span> year anniversary.</p> </td></tr> <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">•</p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">One-time award on <em style="font: inherit;"> January 8, </em><em style="font: inherit;">2021</em>, 35,000 stock options with an exercise price of $5.50 per share granted to a new member of the Board of Directors, vesting in <span style="-sec-ix-hidden:c73544215">one</span> year from the grant date.</p> </td></tr> <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">•</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">One-time award on <em style="font: inherit;"> January 21, 2021, </em>7,500 stock options with an exercise price of $5.65 per share granted to a consultant, vesting in <span style="-sec-ix-hidden:c73544218">one</span> year from the grant date.</p> </td></tr> <tr style="vertical-align: top; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </td><td style="width: 18pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">•</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">One-time award on <em style="font: inherit;"> March 22, 2021, </em>30,000 stock options with an exercise price of $6.87 per share granted to a consultant, vesting in <span style="-sec-ix-hidden:c73544221">one</span> year from the grant date.</p> </td></tr> </tbody></table> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-indent: 27pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">(<em style="font: inherit;">2</em>) Represents the following stock options exercised:</p> <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 18pt;"> </td><td style="width: 18pt;"> <p style="margin: 0pt; text-align: justify; font-family: Times New Roman; font-size: 10pt;">•</p> </td><td> <p style="margin: 0pt; text-align: justify; font-family: Times New Roman; font-size: 10pt;">A total of 60,000 stock options exercised with a weighted average exercise price of $1.93.</p> </td></tr> </tbody></table> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Compensation Expenses</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We recognize all share-based payments to employees and our Board of Directors, as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statement of operations, and these charges had <em style="font: inherit;">no</em> impact on the Company’s reported cash flows. Stock-based compensation expense is calculated on the grant date fair values of such awards, and recognized each period based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Total non-cash stock option compensation expense was allocated among the following expense categories:    </p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three Months Ended March 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2020</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">General and administrative</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">377,052</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">380,251</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Research and development</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">44,019</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">46,688</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">421,071</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">426,939</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </p> 3000000 1500000 3000000 5324215 1388386 4638390 2134211 P10Y P2Y <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 85%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Risk-Free interest rate</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.13%-0.55%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected dividend yield</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">—%</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected stock price volatility</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">54.52%-56.07%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected life of options (in years)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.00-6.25</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 0.0013 0.0055 0.5452 0.5607 P2Y P6Y3M <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 10%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 11%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted-Average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 10%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 10%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Weighted-Average</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Remaining Contractual</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Aggregate Intrinsic</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Shares</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Exercise Price</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Term (Years)</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Value</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,638,390</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.44</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.64</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13,701,610</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted (1)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">745,825</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">5.25</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 13%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 10%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercised (2)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(60,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.93</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 13%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt; width: 10%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 11%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 13%;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 10%;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Canceled</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 11%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 13%;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 10%;"><em style="font: inherit;"> </em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at March 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,324,215</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2.84</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6.03</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">14,209,431</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="width: 44%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 10%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 11%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 13%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 1%;"> </td><td style="width: 10%;"> </td><td style="width: 1%;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercisable at March 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,016,141</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 11%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2.28</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td><td style="width: 13%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5.09</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">12,927,908</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 4638390 2.44 P5Y7M20D 13701610 745825 5.25 60000 1.93 0 0 0 0 5324215 2.84 P6Y10D 14209431 4016141 2.28 P5Y1M2D 12927908 417500 5.16 227500 5.16 23325 5.16 5000 5.16 35000 5.50 7500 5.65 30000 6.87 60000 1.93 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;">Three Months Ended March 31,</em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2021</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">2020</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">General and administrative</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">377,052</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">380,251</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Research and development</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">44,019</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">46,688</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">421,071</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">426,939</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> 377052 380251 44019 46688 421071 426939 <b>Note <em style="font: inherit;">6:</em></b>     <b>Shareholders</b>’ <b> Equity</b> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Issuances of Common Stock</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"> </p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">For the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2021</em>, there were 60,000 shares of the Company’s common stock issued as a result of the exercise of stock options with a weighted average issue price of $1.93 per share. For the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> March 31, 2020</em>, there were 100,000 shares of the Company’s common stock issued as a result of the exercise of stock options with a weighted average issue price of $1.78 per share.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:54pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"><b><i>Changes in Stockholders Equity</i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 12%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Three Months Ended March 31, 2021 (Unaudited)</em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"><b> </b></td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Common Stock</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Treasury Stock</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Additional Paid-In Capital</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Accumulated Deficit</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Total</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">January 1, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">39,748</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(18,929,915</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">98,013,079</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(50,676,351</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">28,446,561</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock-based compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">421,071</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">421,071</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock issued</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">60</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">115,740</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">115,800</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,294,949</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,294,949</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">March 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">39,808</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">(18,929,915</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">98,549,890</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">(53,971,300</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">25,688,483</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:18pt;"> </p> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 12%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Three Months Ended March 31, 2020 (Unaudited)</em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"><b> </b></td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Common Stock</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Treasury Stock</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Additional Paid-In Capital</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Accumulated Deficit</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Total</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">January 1, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">39,613</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(18,929,915</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">96,105,851</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(41,351,078</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">35,864,471</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock-based compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">426,939</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">426,939</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%">Stock issued</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt">100</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt">174,900</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt">175,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,214,139</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,214,139</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">March 31, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">39,713</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">(18,929,915</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">96,707,690</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">(43,565,217</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">34,252,271</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <p style="margin: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Treasury Stock </i></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As of <em style="font: inherit;"> March 31, 2021</em>, and <em style="font: inherit;"> December 31, 2020</em>, there were 12,253,502 shares of common stock held in treasury, at a cost of approximately $18.9 million, representing the purchase price on the date the shares were surrendered to the Company.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><b><i>Open Market Sale Agreement</i></b>℠</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On <em style="font: inherit;"> August 13, 2020, </em>we entered into an Open Market Sale Agreement℠ with Jefferies LLC, or Jefferies, with respect to an at the market offering program under which we <em style="font: inherit;"> may </em>offer and sell, from time to time at our sole discretion, shares of our common stock, par value $0.001 per share, having an aggregate offering price of up to $50.0 million through Jefferies as our sales agent or principal.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We have <em style="font: inherit;">not</em> and are <em style="font: inherit;">not</em> obligated to sell any shares under the sale agreement. Subject to the terms and conditions of the sale agreement, Jefferies will use commercially reasonable efforts, consistent with its normal trading and sales practices and applicable laws and regulations, to sell shares of our common stock from time to time based upon our instructions, including any price, time or size limits or other customary parameters or conditions we specify, subject to certain limitations. Under the sale agreement, Jefferies <em style="font: inherit;"> may </em>sell shares of our common stock by any method permitted by law deemed to be an “at the market offering” as defined in Rule <em style="font: inherit;">415</em>(a)(<em style="font: inherit;">4</em>) under the Securities Act of <em style="font: inherit;">1933,</em> as amended.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We will pay Jefferies a commission equal to 3.0% of the gross proceeds from each sale of shares of our common stock sold through Jefferies under the sale agreement and will provide Jefferies with customary indemnification and contribution rights. In addition, we agreed to reimburse certain legal expenses and fees by Jefferies in connection with the offering up to a maximum of $50,000, in addition to certain ongoing disbursements of Jefferies’ counsel, if required. The sale agreement will terminate upon the sale of all $50.0 million of shares under the sale agreement, unless earlier terminated by either party as permitted therein.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The issuance and sale, if any, of shares of our common stock by us under the sale agreement will be made pursuant to a registration statement on Form S-<em style="font: inherit;">3</em> filed with the SEC on <em style="font: inherit;"> August 13, 2020 </em>and declared effective by the SEC on <em style="font: inherit;"> August 25, 2020 </em>and the accompanying Prospectus, as supplemented by a Prospectus Supplement. As of the date of this filing, there have been <em style="font: inherit;">no</em> sales made under the Open Market Sale Agreement℠.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> 60000 1.93 100000 1.78 <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 12%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Three Months Ended March 31, 2021 (Unaudited)</em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"><b> </b></td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Common Stock</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Treasury Stock</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Additional Paid-In Capital</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Accumulated Deficit</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Total</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">January 1, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">39,748</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(18,929,915</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">98,013,079</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(50,676,351</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">28,446,561</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock-based compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">421,071</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">421,071</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock issued</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">60</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">115,740</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">115,800</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,294,949</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,294,949</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">March 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">39,808</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">(18,929,915</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">98,549,890</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">(53,971,300</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">25,688,483</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 12%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"><b> </b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 31%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">Three Months Ended March 31, 2020 (Unaudited)</em></em></em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 9%;"><em style="font: inherit;"> </em></td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"><b> </b></td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Common Stock</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Treasury Stock</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Additional Paid-In Capital</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Accumulated Deficit</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><em style="font: inherit;">Total</em></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">January 1, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">39,613</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(18,929,915</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">96,105,851</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(41,351,078</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">35,864,471</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock-based compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">426,939</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">426,939</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%">Stock issued</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt">100</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt">174,900</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt">—</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt">175,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">—</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,214,139</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,214,139</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 28%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">March 31, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">39,713</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">(18,929,915</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">96,707,690</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">(43,565,217</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double black;">34,252,271</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> </tbody></table> 39748 -18929915 98013079 -50676351 28446561 0 0 421071 0 421071 60 0 115740 0 115800 0 0 0 -3294949 -3294949 39808 -18929915 98549890 -53971300 25688483 39613 -18929915 96105851 -41351078 35864471 0 0 426939 0 426939 100 0 174900 0 175000 0 0 0 -2214139 -2214139 39713 -18929915 96707690 -43565217 34252271 12253502 18900000 0.001 50000000.0 0.030 50000 50000000.0 <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Note <em style="font: inherit;">7:</em></b>    <b>Subsequent Events </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Management continues to actively monitor the COVID-<em style="font: inherit;">19</em> pandemic and its development, and the possible effects on the Company’s financial condition, liquidity, operations, vendors, industry, and workforce.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">For purpose of disclosure in the consolidated financial statements, the Company has evaluated subsequent events through <em style="font: inherit;"> May 13, 2021</em>, the date the consolidated financial statements were available to be issued. Management is <em style="font: inherit;">not</em> aware of any material events that have occurred subsequent to the balance sheet date that would require adjustment to, or disclosure in the accompanying financial statements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> Represents the following stock options granted: Annual share-based compensation awards on January 4, 2021, including: (a) 417,500 stock options with an exercise price of $5.16 per share granted to executives and key personnel, upon one year anniversary, or vesting annually in equal installments over four years, (b) 227,500 stock options with an exercise price of $5.16 per share granted to members of the Board of Directors, vesting upon one year anniversary, (c) 23,325 stock options with an exercise price of $5.16 per share granted to employees, vesting annually in equal installments over four years and (d) 5,000 stock options with an exercise price of $5.16 per share granted to a consultant, vesting upon one year anniversary. One-time award on January 8, 2021, 35,000 stock options with an exercise price of $5.50 per share granted to a new member of the Board of Directors, vesting in one year from the grant date. One-time award on January 21, 2021, 7,500 stock options with an exercise price of $5.65 per share granted to a consultant, vesting in one year from the grant date. One-time award on March 22, 2021, 30,000 stock options with an exercise price of $6.87 per share granted to a consultant, vesting in one year from the grant date. Represents the following stock options exercised: A total of 60,000 stock options exercised with a weighted average exercise price of $1.93. The premium paid to purchase held-to-maturity investment securities was $283,940 and $196,385 for the three months ended March 31, 2021 and 2020, respectively. The premium paid to purchase held-to-maturity investment securities was $282,946 for the year ended December 31, 2020. Short-term investment securities will mature within 12 months or less, from the applicable reporting date. XML 13 R1.htm IDEA: XBRL DOCUMENT v3.21.1
Document And Entity Information - shares
3 Months Ended
Mar. 31, 2021
May 12, 2021
Document Information [Line Items]    
Entity Central Index Key 0001213809  
Entity Registrant Name DYADIC INTERNATIONAL INC  
Amendment Flag false  
Current Fiscal Year End Date --12-31  
Document Fiscal Period Focus Q1  
Document Fiscal Year Focus 2021  
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2021  
Document Transition Report false  
Entity File Number 000-55264  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 45-0486747  
Entity Address, Address Line One 140 Intracoastal Pointe Drive, Suite 404  
Entity Address, City or Town Jupiter  
Entity Address, State or Province FL  
Entity Address, Postal Zip Code 33477  
City Area Code 561  
Local Phone Number 743-8333  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Title of 12(b) Security Common Stock, par value $0.001 per share  
Trading Symbol DYAI  
Security Exchange Name NASDAQ  
Entity Common Stock, Shares Outstanding   27,554,157

XML 14 R2.htm IDEA: XBRL DOCUMENT v3.21.1
Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
Mar. 31, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 13,055,558 $ 20,637,045
Short-term investment securities 14,177,441 8,457,452
Interest receivable 157,201 112,247
Accounts receivable 384,963 294,199
Prepaid expenses and other current assets 216,189 280,555
Total current assets 27,991,352 29,781,498
Non-current assets:    
Investment in Alphazyme 284,709 284,709
Other assets 6,151 6,225
Total assets 28,282,212 30,072,432
Current liabilities:    
Accounts payable 1,473,813 1,013,099
Accrued expenses 277,668 489,756
Deferred research and development obligations 842,248 123,016
Total current liabilities 2,593,729 1,625,871
Commitments and contingencies (Note 4)
Stockholders’ equity:    
Preferred stock, $.0001 par value: Authorized shares - 5,000,000; none issued and outstanding 0 0
Common stock, $.001 par value: Authorized shares - 100,000,000; issued shares - 39,807,659 and 39,747,659, outstanding shares - 27,554,157 and 27,494,157 as of March 31, 2021 and December 31, 2020, respectively 39,808 39,748
Additional paid-in capital 98,549,890 98,013,079
Treasury stock, shares held at cost - 12,253,502 (18,929,915) (18,929,915)
Accumulated deficit (53,971,300) (50,676,351)
Total stockholders’ equity 25,688,483 28,446,561
Total liabilities and stockholders’ equity $ 28,282,212 $ 30,072,432
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.21.1
Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares
Mar. 31, 2021
Dec. 31, 2020
Preferred stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Preferred stock, shares authorized (in shares) 5,000,000 5,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized (in shares) 100,000,000 100,000,000
Common stock, shares issued (in shares) 39,807,659 39,747,659
Common stock, shares outstanding (in shares) 27,554,157 27,494,157
Treasury stock (in shares) 12,253,502 12,253,502
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.21.1
Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Revenues:    
Research and development revenue $ 460,520 $ 315,372
Costs and expenses:    
Costs of research and development revenue 390,762 278,182
Research and development 1,808,098 755,453
General and administrative 1,554,007 1,653,392
Foreign currency exchange loss (gain), net 28,272 10,867
Total costs and expenses 3,781,139 2,697,894
Loss from operations (3,320,619) (2,382,522)
Interest income 25,670 168,383
Net loss $ (3,294,949) $ (2,214,139)
Basic and diluted net loss per common share (in dollars per share) $ (0.12) $ (0.08)
Basic and diluted weighted-average common shares outstanding (in shares) 27,533,268 27,452,490
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.21.1
Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)
Common Stock [Member]
Treasury Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
Balance at Dec. 31, 2019 $ 39,613 $ (18,929,915) $ 96,105,851 $ (41,351,078) $ 35,864,471
Stock-based compensation $ 0 0 426,939 0 426,939
Exercise of stock options (in shares) 100,000        
Net loss $ 0 0 0 (2,214,139) (2,214,139)
Balance at Mar. 31, 2020 $ 39,713 $ (18,929,915) 96,707,690 (43,565,217) 34,252,271
Balance (in shares) at Dec. 31, 2020 39,747,659 (12,253,502)      
Balance at Dec. 31, 2020 $ 39,748 $ (18,929,915) 98,013,079 (50,676,351) 28,446,561
Stock-based compensation $ 0 $ 0 421,071 0 $ 421,071
Exercise of stock options (in shares) 60,000 0     60,000 [1]
Exercise of stock options $ 60 $ 0 115,740 0 $ 115,800
Net loss $ 0 $ 0 0 (3,294,949) (3,294,949)
Balance (in shares) at Mar. 31, 2021 39,807,659 (12,253,502)      
Balance at Mar. 31, 2021 $ 39,808 $ (18,929,915) $ 98,549,890 $ (53,971,300) $ 25,688,483
[1] Represents the following stock options exercised: A total of 60,000 stock options exercised with a weighted average exercise price of $1.93.
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.21.1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Cash flows from operating activities    
Net loss $ (3,294,949) $ (2,214,139)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation expense 421,071 426,939
Amortization of held-to-maturity securities, net 63,951 107,256
Foreign currency exchange loss (gain), net 28,272 10,867
Changes in operating assets and liabilities:    
Interest receivable (44,954) 102,565
Accounts receivable (131,800) 35,258
Prepaid expenses and other current assets 64,297 (10,529)
Accounts payable 480,455 (292,361)
Accrued expenses (212,088) (326,000)
Deferred research and development obligation 719,232 163,799
Net cash used in operating activities (1,906,513) (1,996,345)
Cash flows from investing activities    
Purchases of held-to-maturity investment securities (11,283,940) (11,652,385)
Proceeds from maturities of investment securities 5,500,000 13,350,000
Net cash (used in) provided by investing activities (5,783,940) 1,697,615
Cash flows from financing activities    
Proceeds from exercise of options 115,800 175,000
Net cash provided by financing activities 115,800 175,000
Effect of exchange rate changes on cash (6,834) (2,983)
Net decrease in cash and cash equivalents (7,581,487) (126,713)
Cash and cash equivalents at beginning of period 20,637,045 4,823,544
Cash and cash equivalents at end of period $ 13,055,558 $ 4,696,831
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.21.1
Note 1 - Organization and Summary of Significant Accounting Policies
3 Months Ended
Mar. 31, 2021
Notes to Financial Statements  
Business Description and Accounting Policies [Text Block]

Note 1:    Organization and Summary of Significant Accounting Policies

 

Description of Business

 

Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) is a global biotechnology platform company based in Jupiter, Florida with operations in the United States, a satellite office in the Netherlands and predominantly three research organizations performing services in the Netherlands, Finland and Israel. Over the past two plus decades, the Company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has previously licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica (formerly known as Myceliophthora thermophila) fungus, which the Company named C1. The C1 technology is a robust and versatile fungal expression system for the development and production of enzymes and other proteins.

 

On December 31, 2015, the Company sold its industrial technology business to Danisco USA (“Danisco”), the industrial biosciences business of DuPont (NYSE: DD) (the “DuPont Transaction”). As part of the DuPont Transaction, Dyadic retained co-exclusive rights to the C1 technology for use in all human and animal pharmaceutical applications, and currently has the exclusive ability to enter into sub-license agreements (subject to the terms of the license and to certain exceptions). Danisco retained certain rights to utilize the C1 technology in pharmaceutical applications, including the development and production of pharmaceutical products, for which it will be required to make royalty payments to Dyadic upon commercialization. In certain circumstances, Dyadic may owe a royalty to either Danisco or certain licensors of Danisco, depending upon whether Dyadic elects to utilize certain patents either owned by Danisco or licensed in by Danisco.

 

After the DuPont Transaction, the Company has been focused on the biopharmaceutical industry, specifically in further improving and applying the proprietary C1 technology into a safe and efficient gene expression platform to help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs and other biological products at flexible commercial scales. Currently, the Company is involved in multiple funded research collaborations with animal and human pharmaceutical companies to leverage its C1 technology to help develop products such as innovative vaccines and drugs, biosimilars and/or biobetters. The Company is also working on several COVID-19 related vaccine and antibody opportunities, including its proprietary COVID-19 vaccine candidate, DYAI-100, towards a first-in-human Phase 1 clinical trial. 

 

Effective April 17, 2019, our common stock began trading on the NASDAQ Stock Market LLC’s NASDAQ Capital Market, under the symbol “DYAI”.

 

Impact of COVID-19

 

The outbreak of COVID-19 has led to adverse impacts on the U.S. and global economies and created uncertainty regarding the potential impact to the Company’s employees, operations, and research projects.

 

To date, some of our employees are still working remotely. The extent to which the COVID-19 pandemic will directly or indirectly impact our business will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants and the actions taken and the level of success to contain or treat the SARS-CoV-2 virus and its variants, the economic impact on local, regional, national and international business partners and markets, delays or disruptions in our on-going research projects, and unavailability of the employees of the Company or third-party contract research organizations with whom we conduct business, due to illness or quarantines, all of which are highly uncertain and cannot be predicted at this time. Management is actively monitoring this situation and the possible effects on its financial condition, liquidity, operations, vendors, industry, and workforce. Even after the COVID-19 pandemic has subsided, the Company may continue to experience adverse impacts to its business because of economic recession or depression that has occurred or may occur in the future. Given the daily evolution of the COVID-19 outbreak and the ongoing response to curb its spread (including government travel and meeting restrictions) currently we are not able to accurately estimate the effects of the COVID-19 outbreak to our results of operations, financial condition, or liquidity.

 

We rely on our existing cash and cash equivalents, investments in debt securities, and operating cash flow to provide the working capital needs for our operations. We believe that our existing cash position and investment in investment grade securities will be adequate to meet our operational, business, and other liquidity requirements for at least the next twelve (12) months. However, in the event our financing needs for the foreseeable future are not able to be met by our existing cash, cash equivalents and investments, we would seek to raise funds through public or private equity offerings, and through other means to meet our financing requirements. Additionally, the Company may decide to fund all of a Phase I clinical trial to demonstrate the safety in humans of a protein produced from the C1 expression platform in humans. There is no assurance that external funding will be available at acceptable terms, if at all, and the Company may, therefore, self-fund these vital projects.

 

Summary of Significant Accounting Policies

 

Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements, including the accounts of the Company and its wholly owned subsidiaries, have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and footnote disclosures normally included in consolidated financial statements have been condensed or omitted pursuant to such rules and regulations. All significant intra-entity transactions and balances have been eliminated in consolidation. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and footnotes as of and for the year ended December 31, 2020, included in our Form 10-K which was filed with the SEC on March 30, 2021.

 

In the opinion of management, the accompanying unaudited interim consolidated financial statements reflect all adjustments, which are of a normal recurring nature, considered necessary for a fair presentation of all periods presented. The results of the Company’s operations for any interim periods are not necessarily indicative of the results of operations for any other interim period or for a full fiscal year.

 

Since concluding the DuPont Transaction, the Company has conducted business in one operating segment, which is identified by the Company based on how resources are allocated, and operating decisions are made. Management evaluates performance and allocates resources based on the Company as a whole.

 

Use of Estimates

 

The preparation of these consolidated financial statements in accordance with GAAP requires management to make estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the applicable period. Actual results may differ from these estimates under different assumptions or conditions. Such differences could be material to the consolidated financial statements.

 

Concentrations and Credit Risk

 

The Company’s financial instruments that are potentially subject to concentrations of credit risk consist primarily of cash and cash equivalents, investment securities, and accounts receivable. At times, the Company has cash, cash equivalents, and investment securities at financial institutions exceeding the Federal Depository Insurance Company (“FDIC”) and the Securities Investor Protection Corporation (“SIPC”) insured limit on domestic currency and the Netherlands’ FDIC counterpart for foreign currency. The Company only deals with reputable financial institutions and has not experienced any losses in such accounts.

 

For the three months ended  March 31, 2021 and 2020, the Company’s revenue was generated from eight and five customers, respectively. As of  March 31, 2021 and  December 31, 2020, the Company’s accounts receivable was from seven and nine customers, respectively. The loss of business from one or a combination of the Company’s customers could adversely affect its operations.

 

The Company conducts operations in the Netherlands through its foreign subsidiary and generates a portion of its revenues from customers that are located outside of the United States. For the three months ended  March 31, 2021, the Company had six customers outside of the United States (i.e. European and Asian customers) that accounted for approximately 76.7% or $353,000 of the revenue. For the three months ended  March 31, 2020, the Company had three customers outside of the United States that accounted for approximately 58.0% or $183,000 of the revenue. As of the three months ended  March 31, 2021, the Company had four customers outside of the United States (i.e. European and Asian customers) that accounted for approximately 46.0% or $174,000 of accounts receivable. As of  December 31, 2020, the Company had seven customers outside of the United States that accounted for approximately 41.6% or $123,000 of accounts receivable.

 

The Company uses several contract research organizations (“CROs”) to conduct its research projects. As of and for the three months ended  March 31, 2021, three CROs accounted for approximately $2,017,000 or 98.1% of total research services we purchased and $1,324,000 or 89.8% of the accounts payable. For the three months ended March 31, 2020, one CRO accounted for approximately $855,000, or 100% of total research services we purchased. As of  December 31, 2020, one CRO accounted for approximately $690,000 or 68.1% of the accounts payable. The loss of this CRO or a combination of the Company’s CROs could adversely affect its operations.

Cash and Cash Equivalents

We treat highly liquid investments with original maturities of three months or less when purchased as cash equivalents, including money market funds, which are unrestricted for withdrawal or use.

 

Investment Securities

 

The Company invests excess cash balances in short-term and long-term investment grade securities. Short-term investment securities mature within twelve (12) months or less, and long-term investment securities mature over twelve (12) months from the applicable reporting date. Management determines the appropriate classification of its investments at the time of purchase and reevaluates the classifications at each balance sheet date. The Company’s investments in debt securities have been classified and accounted for as held-to-maturity. Held-to-maturity securities are those securities that the Company has the ability and intent to hold until maturity. Held-to-maturity securities are recorded at amortized cost, adjusted for the amortization or accretion of premiums or discounts. Premiums and discounts are amortized over the life of the related held-to-maturity security. When a debt security is purchased at a premium, both the face value of the debt and premium amount are reflected as investing outflow. Other-than-temporary impairment charges, if incurred, will be included in other income (expense).

 

The Company’s investments in money market funds have been classified and accounted for as available-for-sale securities and presented as cash equivalents on the consolidated balance sheets. As of  March 31, 2021 and  December 31, 2020, all of our money market funds were invested in U.S. Government money market funds. The Company did not have any investment securities classified as trading as of  March 31, 2021 or  December 31, 2020.

 

Accounts Receivable

 

Accounts receivable consist of billed receivables currently due from customers and unbilled receivables. Unbilled receivables represent the excess of contract revenue (or amounts reimbursable under contracts) over billings to date. Such amounts become billable in accordance with the contract terms, which usually consider the passage of time, achievement of certain milestones or completion of the project.

 

Outstanding account balances are reviewed individually for collectability. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing accounts receivable. Substantially all of our accounts receivable were current and include unbilled amounts that will be billed and collected over the next twelve (12) months. There was no allowance for doubtful accounts as of  March 31, 2021 and  December 31, 2020.

 

Accounts receivable consist of the following:

 

  

March 31, 2021

  

December 31, 2020

 
  

(Unaudited)

  

(Audited)

 

Billed receivable

 $293,323  $130,532 

Unbilled receivable

  91,640   163,667 
  $384,963  $294,199 

 

Prepaid Expenses and Other Current Assets

 

Prepaid expenses and other current assets consist of the following:

 

  

March 31, 2021

  

December 31, 2020

 
  

(Unaudited)

  

(Audited)

 

Prepaid insurance

 $94,841  $204,988 

Prepaid expenses - various

  120,534   72,403 

Prepaid taxes

  814   3,164 
  $216,189  $280,555 

 

Accounts Payable

 

Accounts payable consist of the following:

 

  

March 31, 2021

  

December 31, 2020

 
  

(Unaudited)

  

(Audited)

 

Research and development expenses

 $1,337,755  $904,572 

Legal expenses

  93,071   24,496 

Other

  42,987   84,031 
  $1,473,813  $1,013,099 

 

Accrued Expenses

 

Accrued expenses consist of the following:

 

  

March 31, 2021

  

December 31, 2020

 
  

(Unaudited)

  

(Audited)

 

Employee wages and benefits

 $175,210  $447,881 

Research and development expenses

  42,006   28,508 

Other

  60,452   13,367 
  $277,668  $489,756 

 

Revenue Recognition

 

The Company has no pharmaceutical products approved for sale at this point, and all of our revenue to date has been research revenue from third-party collaborations and government grants. The Company is expected to generate future revenue from license agreements and collaborative arrangements, which may include upfront payments for licenses or options to obtain a license, payment for research and development services and milestone payments, in the form of cash or non-cash considerations (e.g., minority equity interest).

 

Revenue related to research collaborations and agreements: The Company typically performs research and development services as specified in each respective agreement on a best efforts basis, and recognizes revenue from research funding under collaboration agreements in accordance with the 5-step process outlined in ASC Topic 606 (“Topic 606”): (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We recognize revenue when we satisfy a performance obligation by transferring control of the service to a customer in an amount that reflects the consideration that we expect to receive. Since the performance obligation under our collaboration agreements is generally satisfied over time, we elected to use the input method under Topic 606 to measure the progress toward complete satisfaction of a performance obligation.

 

Under the input methods, revenue will be recognized on the basis of the entity’s efforts or inputs to the satisfaction of a performance obligation (e.g., resources consumed, labor hours expended, costs incurred, or time elapsed) relative to the total expected inputs to the satisfaction of that performance obligation. The Company believes that the cost-based input method is the best measure of progress to reflect how the Company transfers its performance obligation to a customer. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to budgeted costs to fulfill the performance obligation. These costs consist primarily of full-time equivalent effort and third-party contract costs. Revenue will be recognized based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligations.

 

A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company’s performance obligations. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete the Company’s performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.

 

Revenue related to grants: The Company may receive grants from governments, agencies, and other private and not-for-profit organizations. These grants are intended to be used to partially or fully fund the Company’s research collaborations, including opportunities arising in connection with COVID-19 that the Company is pursuing with certain collaborators. However, most, if not all, of such potential grant revenues, if received, is expected to be earmarked for third parties to advance the research required, including preclinical and clinical trials for SARS-CoV-2 vaccines and/or antibodies candidates.

 

Revenue related to sublicensing agreements: If the sublicense to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue allocated to the license when technology is transferred to the customer and the customer is able to use and benefit from the license.

 

Milestone payments: At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Company evaluates whether the achievement of the milestones is considered probable and estimates the amount to be included in the transaction price. If the milestone payment is in exchange for a sublicense and is based on the sublicensee’s subsequent sale of product, the Company recognizes milestone payment by applying the accounting guidance for royalties. To date, the Company has not recognized any milestone payment revenue resulting from any of its sublicensing arrangements.

 

Royalties: With respect to licenses deemed to be the predominant item to which the sales-based royalties relate, including milestone payments based on the level of sales, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its sublicensing arrangements.

 

We invoice customers based on our contractual arrangements with each customer, which may not be consistent with the period that revenues are recognized. When there is a timing difference between when we invoice customers and when revenues are recognized, we record either a contract asset (unbilled accounts receivable) or a contract liability (deferred research and development obligations), as appropriate. If upfront fees or considerations related to sublicensing agreement are received prior to the technology transfer, the Company will record the amount received as deferred revenue from licensing agreement.

 

We are not required to disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.

 

The Company adopted a practical expedient to expense sales commissions when incurred because the amortization period would be one year or less.

 

Research and Development Costs

 

Research and development (“R&D”) costs are expensed as incurred. R&D costs are for the Company’s internally funded pharmaceutical programs and other governmental and commercial projects.

 

Research and development costs consist of personnel-related costs, facilities, research-related overhead, services from independent contract research organizations, and other external costs. Research and development costs, including related party, during the three months ended March 31, 2021 and 2020 were as follows:

 

  

Three Months Ended March 31,

 
  

2021

  

2020

 
  

(Unaudited)

  

(Unaudited)

 

Outside contracted services

 $1,659,194  $613,790 

Personnel related costs

  148,162   123,638 

Facilities, overhead and other

  742   18,025 
  $1,808,098  $755,453 

 

Foreign Currency Transaction Gain or Loss

 

The Company and its foreign subsidiary use the U.S. dollar as its functional currency, and initially measure the foreign currency denominated assets and liabilities at the transaction date. Monetary assets and liabilities are then re-measured at exchange rates in effect at the end of each period, and property and non-monetary assets and liabilities are converted at historical rates.

 

Fair Value Measurements

 

The Company applies fair value accounting for certain financial instruments that are recognized or disclosed at fair value in the financial statements. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:

 

 Level 1 – Quoted prices in active markets for identical assets or liabilities.
 Level 2 – Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
 Level 3 – Inputs that are generally unobservable and typically reflect management’s estimate of assumptions that market participants would use in pricing the asset or liability.

 

The Company’s financial instruments included cash and cash equivalents, investment in debt securities, accounts receivable, accounts payable and accrued expenses, accrued payroll and related liabilities, deferred research and development obligations and deposits. The carrying amount of these financial instruments, except for investment in debt securities, approximates fair value due to the short-term maturities of these instruments. The Company’s short-term and long-term investments in debt securities are recorded at amortized cost, and their estimated fair value amounts are provided by the third-party broker service for disclosure purposes.

 

Non-Marketable Investments

 

The Company also holds investments in non-marketable equity securities of privately-held companies, which usually do not have a readily determinable fair value. Our policy is to measure these investments at cost less impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer such observable price changes may include instances where the investee issues equity securities to new investors, thus creating a new indicator of fair value, as an example. On a quarterly basis, we perform a qualitative assessment considering impairment indicators to evaluate whether these investments are impaired and also monitor for any observable price changes. If indicators of impairment exist, we will prepare a quantitative assessment of the fair value of our equity investments, which may include using both the market and income approaches which require judgment and the use of estimates, including discount rates, investee revenues and costs, and available comparable market data of private and public companies, among others. Valuations of such privately-held companies are inherently complex and uncertain due to the lack of liquid market for the company’s securities. In addition, such investments are inherently risky in that such companies are typically at an early stage of development, may have no or limited revenues, may not be or may never become profitable, may not be able to secure additional funding or their technologies, services or products may not be successfully developed or introduced into the market.

 

Income Taxes

 

The Tax Cuts and Jobs Act (“TCJA”) was enacted on December 22, 2017 and became effective January 1, 2018. The TCJA contains several key provisions, including a reduction in the U.S. federal corporate income tax rate from 35% to 21% and repeal of the corporate alternative minimum tax (“AMT”). The TCJA’s reduction in the U.S. statutory tax rate had no additional impact on the consolidated financial statement for the year ended  December 31, 2020.

 

For the three months ended March 31, 2021, there were no provision for income taxes and unrecognized tax benefits recorded. As of  March 31, 2021 and  December 31, 2020, deferred tax assets were approximately $10.2 million and $9.4 million, respectively. Due to the Company’s history of operating losses and the uncertainty regarding our ability to generate taxable income in the future, the Company has established a 100% valuation allowance against deferred tax assets as of  March 31, 2021 and  December 31, 2020.

 

Comprehensive Income (Loss)

 

Comprehensive income (loss) includes net income (loss) and other revenue, expenses, gains and losses that are recorded as an element of shareholders’ equity but are excluded from net income (loss) under GAAP. The Company does not have any significant transactions that are required to be reported in other comprehensive income (loss), and therefore, does not separately present a statement of comprehensive income (loss) in its consolidated financial statements.

 

Stock-Based Compensation

 

We recognize all share-based payments to employees, consultants, and our board of directors (“Board of Directors”), as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statement of operations based on the grant date fair values of such payments. Stock-based compensation expense recognized each period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur.

 

Net Loss Per Share

 

Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common stock shares outstanding during the reporting period. Diluted net loss per share adjusts the weighted average number of common stock shares outstanding for the potential dilution that could occur if common stock equivalents, such as stock options were exercised and converted into common stock, calculated by applying the treasury stock method.

 

For the three months ended March 31, 2021 and 2020, the effect of the potential exercise of options to purchase 5,324,215 and 4,663,390 shares of common stock, respectively, were excluded from the computation of diluted net loss per share as their effect would have been anti-dilutive.

 

Recently Adopted Accounting Pronouncements 

 

In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which modifies the measurement of expected credit losses of certain financial instruments. ASU 2016-13 will be effective for the Company beginning in the first quarter of 2023. The Company does not expect ASU 2016-13 to have a material impact on our consolidated financial positions, results of operations, and cash flows.

 

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The amendments of this update simplify the accounting for income taxes by removing certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The Company adopted ASU 2019-12 on  January 1, 2021, and adoption of ASU 2019-12 did not have any material impact on our consolidated financial positions, results of operations, cash flows and related disclosures.

 

Other pronouncements issued by the FASB or other authoritative accounting standards group with future effective dates are either not applicable or not significant to our consolidated financial statements.

 

XML 20 R8.htm IDEA: XBRL DOCUMENT v3.21.1
Note 2 - Cash, Cash Equivalent, and Investments
3 Months Ended
Mar. 31, 2021
Notes to Financial Statements  
Cash, Cash Equivalents, and Marketable Securities [Text Block]

Note 2:    Cash, Cash Equivalent, and Investments

 

The Company’s investments in debt securities are classified as held-to-maturity and are recorded at amortized cost, and its investments in money market funds are classified as cash equivalents. The following table shows the Company’s cash, available-for-sale securities, and investment securities by major security type as of  March 31, 2021, and  December 31, 2020:

 

  

March 31, 2021 (Unaudited)

 
         

Gross

  

Gross

     
  

Level

      

Unrealized

  

Unrealized

     
  

(1)

  

Fair Value

  

Holding Gains

  

Holding Losses

  

Adjusted Cost

 

Cash and Cash Equivalents

                   

Cash

    $1,217,419  $  $  $1,217,419 

Money Market Funds

 1   11,838,139         11,838,139 

Subtotal

     13,055,558         13,055,558 

Short-Term Investment Securities (2)

                   

Corporate Bonds (3)

 2   14,161,252   1,658   (17,847)  14,177,441 

Total

    $27,216,810  $1,658  $(17,847) $27,232,999 

 

 

  

December 31, 2020 (Audited)

 
         

Gross

  

Gross

     
  

Level

      

Unrealized

  

Unrealized

     
  

(1)

  

Fair Value

  

Holding Gains

  

Holding Losses

  

Adjusted Cost

 

Cash and Cash Equivalents

                   

Cash

    $149,015  $  $  $149,015 

Money Market Funds

 1   20,488,030         20,488,030 

Subtotal

     20,637,045         20,637,045 

Short-Term Investment Securities (2)

                   

Corporate Bonds (3)

 2   8,473,461   22,473   (6,463)  8,457,451 

Total

    $29,110,506  $22,473  $(6,463) $29,094,496 

_________________

Notes:

(1) Definition of the three-level fair value hierarchy:

 

Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities

 

Level 2 - Other inputs that are directly or indirectly observable in the markets

 

Level 3 - Inputs that are generally unobservable

(2) Short-term investment securities will mature within 12 months or less, from the applicable reporting date.

(3) The premium paid to purchase held-to-maturity investment securities was $283,940 and $196,385 for the three months ended March 31, 2021 and 2020, respectively. The premium paid to purchase held-to-maturity investment securities was $282,946 for the year ended  December 31, 2020.

 

The Company considers the declines in market value of its investment portfolio to be temporary in nature. The Company’s investment policy requires investment securities to be investment grade and held to maturity with the primary objective to maintain a high degree of liquidity while maximizing yield. When evaluating an investment for other-than-temporary impairment, the Company reviews factors such as the length of time and extent to which fair value has been below its cost basis, the financial condition of the issuer and any changes thereto, changes in market interest rates, and whether it is more likely than not the Company will be required to sell the investment before recovery of the investment’s cost basis. As of  March 31, 2021, the Company does not consider any of its investments to be other-than-temporarily impaired.

 

XML 21 R9.htm IDEA: XBRL DOCUMENT v3.21.1
Note 3 - Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately-held Companies
3 Months Ended
Mar. 31, 2021
Notes to Financial Statements  
Collaborative Arrangement Disclosure [Text Block]

Note 3:    Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately-Held Companies

 

BDI 

 

On June 30, 2017, the Company entered into a strategic Research Services Agreement (the “RSA”) with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U. (“BDI Pharma”), and a Service Framework Agreement (the “SFA”, and together with the RSA, the “R&D Agreements”), with VLP The Vaccines Company, S.L.U. (“VLPbio”), both of which are subsidiaries of Biotechnology Developments for Industry, S.L., a Spanish biotechnology company (“BDI Holdings” and together with BDI Pharma and VLPbio, “BDI”). 

 

The R&D Agreements provide a framework under which the parties will engage in a research and development collaboration encompassing several different projects over approximately a two-year period, with a focus on advancing Dyadic’s proprietary C1 technology in the development of next generation biological vaccines and drugs. Dyadic expects to leverage the BDI team’s previous C1 gene expression and industrial fermentation scale-up and commercialization experience with yeast and filamentous fungi processes to further advance Dyadic’s proprietary C1 technology with the potential to commercialize certain biopharmaceutical product(s). All of the data and any products developed from the funded research projects will be owned by Dyadic.

 

Upon closing of the BDI transaction, the Company paid EUR €1.0 million (the “RSA Initial Payment”) in cash to engage BDI to develop designated C1 based product candidates and further improve the C1 manufacturing process, in consideration of which Dyadic also received a 16.1% equity interest in BDI Holdings and a 3.3% equity interest in VLPbio. BDI is obligated to spend a minimum amount of EUR €936,000 over two years in the conduct of the research and development project under the RSA. If the research and development activities produce a product that is selected for additional development and commercialization, then Dyadic expects to share with BDI a range of between 50% and 75% of the net income from such selected product, depending upon the amount of BDI’s aggregate spend in the development of the selected product, with a minimum aggregate spend by BDI of EUR €1 million for a 50% share and EUR 8.0 million for a 75% share. If BDI does not enter into an agreement with Dyadic for such additional development and commercialization of the selected product, then Dyadic will pay to BDI EUR €1.5 million of the net income from Dyadic’s commercialization, if any, of the selected product. In addition, under the SFA, Dyadic agreed to purchase from BDI at least USD $1.0 million (the “SFA Commitment”) in contract research services specified by Dyadic over two years since the closing of the BDI transaction.

 

The Company has concluded that BDI is not a Variable Interest Entity (“VIE”), because BDI has sufficient equity to finance its activities without additional subordinated financial support and its at-risk equity holders have the characteristics of a controlling financial interest. Additionally, Dyadic is not the primary beneficiary of BDI as Dyadic does not have the power to control or direct the activities of BDI or its operations. As a result, the Company does not consolidate its investments in BDI, and the financial results of BDI are not included in the Company’s consolidated financial results.

 

The Company performed a valuation analysis of the components of the transaction and allocated the consideration based on the relative fair value of each component. As the fair value of BDI equity interest was considered immaterial, the RSA Initial Payment of approximately USD $1.1 million (EUR €1.0 million) was accounted for as a prepaid research and development collaboration payment on our consolidated balance sheet, and both the collaboration payment under the RSA and the SFA Commitment of USD $1.0 million paid by Dyadic were expensed as the related research services were performed by BDI. In June 2019, BDI has completed its services under the RSA and the entire amount of the RSA Initial Payment was expensed. Dyadic had fulfilled its SFA commitment and completed all research projects under the SFA in 2019.

 

On February 18, 2021, the Company entered into a separate service agreement with BDI to perform a research project unrelated to the R&D Agreements. For the three months ended March 31, 2021, approximately $15,000 recorded in the cost of research and development revenue was associated with this new service agreement.

 

Novovet and Luina Bio 

 

On April 26, 2019, the Company entered into a sub-license agreement (the “Luina Bio Sub-License Agreement”) with Luina Bio Pty Ltd. (“Luina Bio”) and Novovet Pty Ltd (“Novovet”). Under the terms of the Luina Bio Sub-License Agreement, the Company has granted to Novovet, subject to the terms of the license agreement entered into between the Company and Danisco US, Inc. on December 31, 2015, a worldwide sub-license to certain patent rights and know-how related to Dyadic’s proprietary C1 gene expression platform for the exclusive and sole purpose of commercializing certain targeted antigen and biological products for the prevention and treatment of various ailments for companion animals.

 

In consideration of the license granted pursuant to the Luina Bio Sub-License Agreement, Dyadic received a 20% equity interest in Novovet (“Novovet Up-Front Consideration”) in accordance with the terms of Novovet’s Shareholder Agreement, and will receive a percentage of royalties on future net sales and non-sales revenue, if any, which incorporates Dyadic’s proprietary C1 gene expression platform.

 

The Company evaluated the nature of its equity interest investment in Novovet and determined that Novovet is a VIE, because Novovet does not have sufficient equity to finance its activities without additional financial support from third party investors or lenders. However, the Company is not the primary beneficiary of Novovet as Dyadic does not have the power to control or direct the activities of Novovet that most significantly impact the VIE. As a result, the Company will not consolidate its investment in Novovet, but account for under the equity method investment, given that it has the ability to exercise significant influence, but not control, over Novovet.

 

To date Novovet has not raised the capital required to move this opportunity forward, and therefore, the Company has not transferred its C1 technology to Novovet. Therefore, the Novovet Up-Front Consideration received under the Luina Bio Sub-License Agreement, in the form of a 20% equity interest in Novovet, does not yet meet the revenue recognition criteria under ASC 606. The Company will account for its investment in Novovet and the related income under the equity method of accounting, once the transfer of its C1 technology is completed and Novovet receives adequate financing required to commence its research and development activities. The Company intends to terminate the Luina Bio Sub-License Agreement in 2021 should Novovet be unable to raise the required funding.

 

Alphazyme 

 

On May 5, 2019, the Company entered into a sub-license agreement (the “Alphazyme Sub-License Agreement”) with Alphazyme, LLC (“Alphazyme”). Under the terms of the Alphazyme Sub-License Agreement, the Company has granted to Alphazyme, subject to the terms of the license agreement entered into between the Company and Danisco US, Inc. on December 31, 2015, a sub-license to certain patent rights and know-how related to Dyadic’s proprietary C1 gene expression platform for the purpose of commercializing certain pharmaceutical products that are used as reagents to catalyze a chemical reaction to detect, measure, or be used as a process intermediate to produce a nucleic acid as a therapeutic or diagnostic agent.

 

On June 24, 2020, the Company entered into an Amended and Restated Non-Exclusive Sub-License Agreement (the “Amended Sub-License Agreement”) with Alphazyme. Pursuant to the Amended Sub-License Agreement and in consideration of Dyadic’s transfer of its C1 technology, Alphazyme issued 2.50% of the Class A shares of Alphazyme to Dyadic, and Dyadic became a party to the Alphazyme Limited Liability Company Agreement pursuant to which the Company has agreed to certain customary rights, covenants and obligations. In addition, and subject to achieving certain milestones, Alphazyme is obligated to pay a potential milestone payment and royalties, based on net sales, if any, which incorporate Dyadic’s proprietary C1 gene expression platform. 

 

On December 1, 2020, the Company entered into an Amended and Restated Limited Liability Company Agreement with Alphazyme (the “Amended Alphazyme LLC Agreement”) was entered into. Under the Amended Alphazyme LLC Agreement, Alphazyme obtained an additional capital contribution and Dyadic’s ownership was diluted to 1.99%.

 

The Company evaluated the nature of its equity interest investment in Alphazyme and determined that Alphazyme is a VIE due to the capital structure of the entity. However, the Company is not the primary beneficiary of Alphazyme as Dyadic does not have the power to control or direct the activities of Alphazyme that most significantly impact the VIE. As a result, the Company does not consolidate its investment in Alphazyme. The Company reports its investment in Alphazyme under the cost method of accounting, given that it does not have the ability to exercise significant influence or control,

 

For the year ended December 31, 2020, the Company recorded a gain of $284,709 from its investment in Alphazyme as a result of a third-party additional capital contribution obtained by Alphazyme. As of March31, 2021, the Company does not consider its investment in Alphazyme to be impaired.

 

IDBiologics, Inc. 

 

On July 8, 2020, the Company entered into a Common Stock Purchase Agreement (the “IDBiologics Agreement”) with IDBiologics, Inc (“IDBiologics”). IDBiologics is a private biotechnology company focused on the development of human monoclonal antibodies for the treatment and prevention of serious infectious diseases. The Company was founded in 2017 and seeded by Vanderbilt University Medical Center in response to the repeated threats of epidemics around the world, including Ebola in West Africa and Zika in the Americas. IDBiologics is developing a portfolio of monoclonal antibodies against SARS-CoV-2, influenza and Zika viruses.

 

Under the term of the IDBiologics Agreement, Dyadic agreed to receive 129,611 shares of IDBiologics’ common stock, which represent 0.37% of IDBiologics’ outstanding equity, in exchange for the services to be provided by Dyadic. Such services include the use of Dyadic’s C1 technology to express a SARS-CoV-2 monoclonal antibody which IDBiologics licensed from the Vanderbilt Vaccine Center. The shares of common stock of IDBiologics vested 50% upon the signing of the IDBiologics Agreement, 25% will vest upon the completion of Step 3 of a feasibility study required by the IDBiologics Agreement, and 25% will vest at the end of the project.

 

The Company evaluated the nature of its equity interest in IDBiologics and determined that IDBiologics is a VIE due to the capital structure of the entity. However, the Company is not the primary beneficiary of IDBiologics as Dyadic does not have the power to control or direct the activities of IDBiologics that most significantly impact the VIE. As a result, the Company does not consolidate its investment in IDBiologics. Upon receipt its shares, Dyadic will account for the equity interest in IDBiologics under the cost method. No revenue from the IDBiologics Agreement was recorded during the three months ended March 31, 2021, because the amount of consideration received was immaterial.

 

XML 22 R10.htm IDEA: XBRL DOCUMENT v3.21.1
Note 4 - Commitments and Contingencies
3 Months Ended
Mar. 31, 2021
Notes to Financial Statements  
Commitments and Contingencies Disclosure [Text Block]

Note 4:    Commitments and Contingencies

 

Legal Proceedings

 

We are not currently involved in any litigation that we believe could have a materially adverse effect in our financial condition or results of operations. From time to time, the Company is subject to legal proceedings, asserted claims and investigations in the ordinary course of business, including commercial claims, employment and other matters, which management considers immaterial, individually and in the aggregate. The Company makes a provision for a liability when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. The requirement for these provisions is reviewed at least quarterly and adjusted to reflect the impact of negotiations, settlements, rulings, advice of legal counsel and other information and events pertaining to a particular case. Litigation is inherently unpredictable and costly. Protracted litigation and/or an unfavorable resolution of one or more of proceedings, claims or investigations against the Company could have a material adverse effect on the Company’s consolidated financial position, cash flows or results of operations.

 

XML 23 R11.htm IDEA: XBRL DOCUMENT v3.21.1
Note 5 - Share-based Compensation
3 Months Ended
Mar. 31, 2021
Notes to Financial Statements  
Share-based Payment Arrangement [Text Block]

Note 5:    Share-Based Compensation

 

Description of Equity Plans

 

The 2011 Equity Incentive Plan (the “2011 Plan”) was adopted by the Company’s Board of Directors on April 28, 2011 and approved by the Company’s stockholders on June 15, 2011. The 2011 Plan serves as the successor to the Company’s 2006 Stock Option Plan (the “2006 Plan”). Since the effective date of the 2011 Plan, all equity awards were made from the 2011 Plan, and no additional awards will be granted under the 2006 plan. Under the 2011 Plan, 3,000,000 shares of the Company’s common stock were initially reserved for issuance pursuant to a variety of share-based compensation awards, plus any shares available for issuance under the 2006 Plan or are subject to awards under the 2006 Plan which are forfeited or lapse unexercised and which following the effective date are not issued under the 2006 Plan. In accordance with the provisions of the 2011 Plan, the Board of Directors approved an increase of 1,500,000 shares to the plan on January 1, 2019 and 2020.

 

At our 2021 Virtual Annual Meeting of Shareholders (“Annual Meeting”) to be held on June 11, 2021, shareholders will be asked to approve the Company’s 2021 Equity Incentive Award Plan (the “2021 Plan”), which was adopted, subject to shareholder approval, by the Board of Directors on April 9, 2021. We are seeking stockholder approval of the 2021 Plan to increase the number of shares available for the grant of stock options, restricted stock awards and other awards by 3,000,000 in addition to the number of shares remaining available for the grant of new awards under the 2011 Plan as of April 16, 2021. If this proposal is approved by our shareholders, the 2021 Plan will become effective as of the date of the Annual Meeting and as of such date, no additional awards will be granted under the 2011 Plan. If our shareholders do not approve this proposal, the 2021 Plan will not become effective and the 2011 Plan will continue to be effective in accordance with its terms, until its expiration date.

 

As of  March 31, 2021, the Company had 5,324,215 stock options outstanding and an additional 1,388,386 shares of common stock available for grant under the 2011 Plan. As of  December 31, 2020, there were 4,638,390 stock options outstanding and 2,134,211 shares of common stock available for grant under the 2011 Plan.

 

Stock Options

 

Options are granted to purchase common stock at prices that are equal to the fair value of the common stock on the date the option is granted. Vesting is determined by the Board of Directors at the time of grant. The term of any stock option awards under the Company’s 2011 Plan is ten years except for certain options granted to the contractors which are one or three years.

 

The grant-date fair value of each option grant is estimated using the Black-Scholes option pricing model and amortized on a straight-line basis over the requisite service period, which is generally the vesting period, for each separately vesting portion of the award as if the award was, in substance, multiple awards. Use of a valuation model requires management to make certain assumptions with respect to selected model inputs, including the following:

 

Risk-free interest rate. The risk-free interest rate is based on U.S. Treasury rates with securities approximating the expected lives of options at the date of grant.

 

Expected dividend yield. The expected dividend yield is zero, as the Company has never paid dividends to common shareholders and does not currently anticipate paying any in the foreseeable future.

 

Expected stock price volatility. The expected stock price volatility was calculated based on the Company’s own volatility after the DuPont Transaction. The Company reviews its volatility assumption on an annual basis and has used the Company’s historical volatility since 2016, as the DuPont Transaction resulted in significant changes in the Company’s business and capital structure.

 

Expected life of option. The expected life of option was based on the contractual term of the option and expected employee exercise and post-vesting employment termination behavior. The Company uses the weighted average vesting period and contractual term of the option as the best estimate of the expected life of a new option, except for the options granted to the CEO (i.e., 5 or 10 years) and certain contractors (i.e., 2 or 3years).

 

The assumptions used in the Black-Scholes option pricing model for stock options granted during the three months ended March 31, 2021 are as follows:

 

Risk-Free interest rate

  0.13%-0.55% 

Expected dividend yield

  —% 

Expected stock price volatility

  54.52%-56.07% 

Expected life of options (in years)

  2.00-6.25 

 

The following table summarizes the stock option activities during the three months ended March 31, 2021:

 

          

Weighted-Average

     
      

Weighted-Average

  

Remaining Contractual

  

Aggregate Intrinsic

 
  

Shares

  

Exercise Price

  

Term (Years)

  

Value

 

Outstanding at December 31, 2020

  4,638,390  $2.44   5.64  $13,701,610 

Granted (1)

  745,825   5.25         

Exercised (2)

  (60,000)  1.93         

Expired

              

Canceled

              

Outstanding at March 31, 2021

  5,324,215  $2.84   6.03  $14,209,431 
                 

Exercisable at March 31, 2021

  4,016,141  $2.28   5.09  $12,927,908 

_________________

Notes:

(1) Represents the following stock options granted:

 

Annual share-based compensation awards on January 4, 2021, including: (a) 417,500 stock options with an exercise price of $5.16 per share granted to executives and key personnel, upon one year anniversary, or vesting annually in equal installments over four years, (b) 227,500 stock options with an exercise price of $5.16 per share granted to members of the Board of Directors, vesting upon one year anniversary, (c) 23,325 stock options with an exercise price of $5.16 per share granted to employees, vesting annually in equal installments over four years and (d) 5,000 stock options with an exercise price of $5.16 per share granted to a consultant, vesting upon one year anniversary.

 

One-time award on January 8, 2021, 35,000 stock options with an exercise price of $5.50 per share granted to a new member of the Board of Directors, vesting in one year from the grant date.

 

One-time award on January 21, 2021, 7,500 stock options with an exercise price of $5.65 per share granted to a consultant, vesting in one year from the grant date.

 

One-time award on March 22, 2021, 30,000 stock options with an exercise price of $6.87 per share granted to a consultant, vesting in one year from the grant date.

 

(2) Represents the following stock options exercised:

 

A total of 60,000 stock options exercised with a weighted average exercise price of $1.93.

 

Compensation Expenses

 

We recognize all share-based payments to employees and our Board of Directors, as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statement of operations, and these charges had no impact on the Company’s reported cash flows. Stock-based compensation expense is calculated on the grant date fair values of such awards, and recognized each period based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur.

 

Total non-cash stock option compensation expense was allocated among the following expense categories:    

 

  

Three Months Ended March 31,

 
  

2021

  

2020

 

General and administrative

 $377,052  $380,251 

Research and development

  44,019   46,688 

Total

 $421,071  $426,939 

 

 

XML 24 R12.htm IDEA: XBRL DOCUMENT v3.21.1
Note 6 - Shareholders' Equity
3 Months Ended
Mar. 31, 2021
Notes to Financial Statements  
Stockholders' Equity Note Disclosure [Text Block] Note 6:     Shareholders Equity

 

Issuances of Common Stock

 

For the three months ended March 31, 2021, there were 60,000 shares of the Company’s common stock issued as a result of the exercise of stock options with a weighted average issue price of $1.93 per share. For the three months ended March 31, 2020, there were 100,000 shares of the Company’s common stock issued as a result of the exercise of stock options with a weighted average issue price of $1.78 per share.

 

Changes in Stockholders Equity

 

      

Three Months Ended March 31, 2021 (Unaudited)

     
  

Common Stock

  

Treasury Stock

  

Additional Paid-In Capital

  

Accumulated Deficit

  

Total

 

January 1, 2021

 $39,748  $(18,929,915) $98,013,079  $(50,676,351) $28,446,561 

Stock-based compensation

        421,071      421,071 

Stock issued

  60      115,740      115,800 

Net loss

           (3,294,949)  (3,294,949)

March 31, 2021

 $39,808  $(18,929,915) $98,549,890  $(53,971,300) $25,688,483 

 

      

Three Months Ended March 31, 2020 (Unaudited)

     
  

Common Stock

  

Treasury Stock

  

Additional Paid-In Capital

  

Accumulated Deficit

  

Total

 

January 1, 2020

 $39,613  $(18,929,915) $96,105,851  $(41,351,078) $35,864,471 

Stock-based compensation

        426,939      426,939 
Stock issued  100      174,900      175,000 

Net loss

           (2,214,139)  (2,214,139)

March 31, 2020

 $39,713  $(18,929,915) $96,707,690  $(43,565,217) $34,252,271 

 

Treasury Stock

 

As of  March 31, 2021, and  December 31, 2020, there were 12,253,502 shares of common stock held in treasury, at a cost of approximately $18.9 million, representing the purchase price on the date the shares were surrendered to the Company.

 

Open Market Sale Agreement

 

On August 13, 2020, we entered into an Open Market Sale Agreement℠ with Jefferies LLC, or Jefferies, with respect to an at the market offering program under which we may offer and sell, from time to time at our sole discretion, shares of our common stock, par value $0.001 per share, having an aggregate offering price of up to $50.0 million through Jefferies as our sales agent or principal.

 

We have not and are not obligated to sell any shares under the sale agreement. Subject to the terms and conditions of the sale agreement, Jefferies will use commercially reasonable efforts, consistent with its normal trading and sales practices and applicable laws and regulations, to sell shares of our common stock from time to time based upon our instructions, including any price, time or size limits or other customary parameters or conditions we specify, subject to certain limitations. Under the sale agreement, Jefferies may sell shares of our common stock by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended.

 

We will pay Jefferies a commission equal to 3.0% of the gross proceeds from each sale of shares of our common stock sold through Jefferies under the sale agreement and will provide Jefferies with customary indemnification and contribution rights. In addition, we agreed to reimburse certain legal expenses and fees by Jefferies in connection with the offering up to a maximum of $50,000, in addition to certain ongoing disbursements of Jefferies’ counsel, if required. The sale agreement will terminate upon the sale of all $50.0 million of shares under the sale agreement, unless earlier terminated by either party as permitted therein.

 

The issuance and sale, if any, of shares of our common stock by us under the sale agreement will be made pursuant to a registration statement on Form S-3 filed with the SEC on August 13, 2020 and declared effective by the SEC on August 25, 2020 and the accompanying Prospectus, as supplemented by a Prospectus Supplement. As of the date of this filing, there have been no sales made under the Open Market Sale Agreement℠.

 

XML 25 R13.htm IDEA: XBRL DOCUMENT v3.21.1
Note 7 - Subsequent Events
3 Months Ended
Mar. 31, 2021
Notes to Financial Statements  
Subsequent Events [Text Block]

Note 7:    Subsequent Events

 

Management continues to actively monitor the COVID-19 pandemic and its development, and the possible effects on the Company’s financial condition, liquidity, operations, vendors, industry, and workforce.

 

For purpose of disclosure in the consolidated financial statements, the Company has evaluated subsequent events through May 13, 2021, the date the consolidated financial statements were available to be issued. Management is not aware of any material events that have occurred subsequent to the balance sheet date that would require adjustment to, or disclosure in the accompanying financial statements.

 

XML 26 R14.htm IDEA: XBRL DOCUMENT v3.21.1
Significant Accounting Policies (Policies)
3 Months Ended
Mar. 31, 2021
Accounting Policies [Abstract]  
Impact of COVID-19, Policy [Policy Text Block]

Impact of COVID-19

 

The outbreak of COVID-19 has led to adverse impacts on the U.S. and global economies and created uncertainty regarding the potential impact to the Company’s employees, operations, and research projects.

 

To date, some of our employees are still working remotely. The extent to which the COVID-19 pandemic will directly or indirectly impact our business will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants and the actions taken and the level of success to contain or treat the SARS-CoV-2 virus and its variants, the economic impact on local, regional, national and international business partners and markets, delays or disruptions in our on-going research projects, and unavailability of the employees of the Company or third-party contract research organizations with whom we conduct business, due to illness or quarantines, all of which are highly uncertain and cannot be predicted at this time. Management is actively monitoring this situation and the possible effects on its financial condition, liquidity, operations, vendors, industry, and workforce. Even after the COVID-19 pandemic has subsided, the Company may continue to experience adverse impacts to its business because of economic recession or depression that has occurred or may occur in the future. Given the daily evolution of the COVID-19 outbreak and the ongoing response to curb its spread (including government travel and meeting restrictions) currently we are not able to accurately estimate the effects of the COVID-19 outbreak to our results of operations, financial condition, or liquidity.

 

We rely on our existing cash and cash equivalents, investments in debt securities, and operating cash flow to provide the working capital needs for our operations. We believe that our existing cash position and investment in investment grade securities will be adequate to meet our operational, business, and other liquidity requirements for at least the next twelve (12) months. However, in the event our financing needs for the foreseeable future are not able to be met by our existing cash, cash equivalents and investments, we would seek to raise funds through public or private equity offerings, and through other means to meet our financing requirements. Additionally, the Company may decide to fund all of a Phase I clinical trial to demonstrate the safety in humans of a protein produced from the C1 expression platform in humans. There is no assurance that external funding will be available at acceptable terms, if at all, and the Company may, therefore, self-fund these vital projects.

 

Basis of Accounting, Policy [Policy Text Block]

Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements, including the accounts of the Company and its wholly owned subsidiaries, have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and footnote disclosures normally included in consolidated financial statements have been condensed or omitted pursuant to such rules and regulations. All significant intra-entity transactions and balances have been eliminated in consolidation. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and footnotes as of and for the year ended December 31, 2020, included in our Form 10-K which was filed with the SEC on March 30, 2021.

 

In the opinion of management, the accompanying unaudited interim consolidated financial statements reflect all adjustments, which are of a normal recurring nature, considered necessary for a fair presentation of all periods presented. The results of the Company’s operations for any interim periods are not necessarily indicative of the results of operations for any other interim period or for a full fiscal year.

 

Since concluding the DuPont Transaction, the Company has conducted business in one operating segment, which is identified by the Company based on how resources are allocated, and operating decisions are made. Management evaluates performance and allocates resources based on the Company as a whole.

Use of Estimates, Policy [Policy Text Block]

Use of Estimates

 

The preparation of these consolidated financial statements in accordance with GAAP requires management to make estimates and judgments that affect the reported amount of assets and liabilities and related disclosure of contingent assets and liabilities at the date of our consolidated financial statements and the reported amounts of revenues and expenses during the applicable period. Actual results may differ from these estimates under different assumptions or conditions. Such differences could be material to the consolidated financial statements.

Concentration Risk, Credit Risk, Policy [Policy Text Block]

Concentrations and Credit Risk

 

The Company’s financial instruments that are potentially subject to concentrations of credit risk consist primarily of cash and cash equivalents, investment securities, and accounts receivable. At times, the Company has cash, cash equivalents, and investment securities at financial institutions exceeding the Federal Depository Insurance Company (“FDIC”) and the Securities Investor Protection Corporation (“SIPC”) insured limit on domestic currency and the Netherlands’ FDIC counterpart for foreign currency. The Company only deals with reputable financial institutions and has not experienced any losses in such accounts.

 

For the three months ended  March 31, 2021 and 2020, the Company’s revenue was generated from eight and five customers, respectively. As of  March 31, 2021 and  December 31, 2020, the Company’s accounts receivable was from seven and nine customers, respectively. The loss of business from one or a combination of the Company’s customers could adversely affect its operations.

 

The Company conducts operations in the Netherlands through its foreign subsidiary and generates a portion of its revenues from customers that are located outside of the United States. For the three months ended  March 31, 2021, the Company had six customers outside of the United States (i.e. European and Asian customers) that accounted for approximately 76.7% or $353,000 of the revenue. For the three months ended  March 31, 2020, the Company had three customers outside of the United States that accounted for approximately 58.0% or $183,000 of the revenue. As of the three months ended  March 31, 2021, the Company had four customers outside of the United States (i.e. European and Asian customers) that accounted for approximately 46.0% or $174,000 of accounts receivable. As of  December 31, 2020, the Company had seven customers outside of the United States that accounted for approximately 41.6% or $123,000 of accounts receivable.

 

The Company uses several contract research organizations (“CROs”) to conduct its research projects. As of and for the three months ended  March 31, 2021, three CROs accounted for approximately $2,017,000 or 98.1% of total research services we purchased and $1,324,000 or 89.8% of the accounts payable. For the three months ended March 31, 2020, one CRO accounted for approximately $855,000, or 100% of total research services we purchased. As of  December 31, 2020, one CRO accounted for approximately $690,000 or 68.1% of the accounts payable. The loss of this CRO or a combination of the Company’s CROs could adversely affect its operations.

Cash and Cash Equivalents, Policy [Policy Text Block]

Cash and Cash Equivalents

We treat highly liquid investments with original maturities of three months or less when purchased as cash equivalents, including money market funds, which are unrestricted for withdrawal or use.

 

Investment, Policy [Policy Text Block]

Investment Securities

 

The Company invests excess cash balances in short-term and long-term investment grade securities. Short-term investment securities mature within twelve (12) months or less, and long-term investment securities mature over twelve (12) months from the applicable reporting date. Management determines the appropriate classification of its investments at the time of purchase and reevaluates the classifications at each balance sheet date. The Company’s investments in debt securities have been classified and accounted for as held-to-maturity. Held-to-maturity securities are those securities that the Company has the ability and intent to hold until maturity. Held-to-maturity securities are recorded at amortized cost, adjusted for the amortization or accretion of premiums or discounts. Premiums and discounts are amortized over the life of the related held-to-maturity security. When a debt security is purchased at a premium, both the face value of the debt and premium amount are reflected as investing outflow. Other-than-temporary impairment charges, if incurred, will be included in other income (expense).

 

The Company’s investments in money market funds have been classified and accounted for as available-for-sale securities and presented as cash equivalents on the consolidated balance sheets. As of  March 31, 2021 and  December 31, 2020, all of our money market funds were invested in U.S. Government money market funds. The Company did not have any investment securities classified as trading as of  March 31, 2021 or  December 31, 2020.

Accounts Receivable [Policy Text Block]

Accounts Receivable

 

Accounts receivable consist of billed receivables currently due from customers and unbilled receivables. Unbilled receivables represent the excess of contract revenue (or amounts reimbursable under contracts) over billings to date. Such amounts become billable in accordance with the contract terms, which usually consider the passage of time, achievement of certain milestones or completion of the project.

 

Outstanding account balances are reviewed individually for collectability. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in the Company’s existing accounts receivable. Substantially all of our accounts receivable were current and include unbilled amounts that will be billed and collected over the next twelve (12) months. There was no allowance for doubtful accounts as of  March 31, 2021 and  December 31, 2020.

 

Accounts receivable consist of the following:

 

  

March 31, 2021

  

December 31, 2020

 
  

(Unaudited)

  

(Audited)

 

Billed receivable

 $293,323  $130,532 

Unbilled receivable

  91,640   163,667 
  $384,963  $294,199 

 

Prepaid Expenses and Other Current Assets, Policy [Policy Text Block]

Prepaid Expenses and Other Current Assets

 

Prepaid expenses and other current assets consist of the following:

 

  

March 31, 2021

  

December 31, 2020

 
  

(Unaudited)

  

(Audited)

 

Prepaid insurance

 $94,841  $204,988 

Prepaid expenses - various

  120,534   72,403 

Prepaid taxes

  814   3,164 
  $216,189  $280,555 

 

Accounts Payable, Policy [Policy Text Block]

Accounts Payable

 

Accounts payable consist of the following:

 

  

March 31, 2021

  

December 31, 2020

 
  

(Unaudited)

  

(Audited)

 

Research and development expenses

 $1,337,755  $904,572 

Legal expenses

  93,071   24,496 

Other

  42,987   84,031 
  $1,473,813  $1,013,099 

 

Accrued Expenses, Policy [Policy Text Block]

Accrued Expenses

 

Accrued expenses consist of the following:

 

  

March 31, 2021

  

December 31, 2020

 
  

(Unaudited)

  

(Audited)

 

Employee wages and benefits

 $175,210  $447,881 

Research and development expenses

  42,006   28,508 

Other

  60,452   13,367 
  $277,668  $489,756 

 

Revenue from Contract with Customer [Policy Text Block]

Revenue Recognition

 

The Company has no pharmaceutical products approved for sale at this point, and all of our revenue to date has been research revenue from third-party collaborations and government grants. The Company is expected to generate future revenue from license agreements and collaborative arrangements, which may include upfront payments for licenses or options to obtain a license, payment for research and development services and milestone payments, in the form of cash or non-cash considerations (e.g., minority equity interest).

 

Revenue related to research collaborations and agreements: The Company typically performs research and development services as specified in each respective agreement on a best efforts basis, and recognizes revenue from research funding under collaboration agreements in accordance with the 5-step process outlined in ASC Topic 606 (“Topic 606”): (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. We recognize revenue when we satisfy a performance obligation by transferring control of the service to a customer in an amount that reflects the consideration that we expect to receive. Since the performance obligation under our collaboration agreements is generally satisfied over time, we elected to use the input method under Topic 606 to measure the progress toward complete satisfaction of a performance obligation.

 

Under the input methods, revenue will be recognized on the basis of the entity’s efforts or inputs to the satisfaction of a performance obligation (e.g., resources consumed, labor hours expended, costs incurred, or time elapsed) relative to the total expected inputs to the satisfaction of that performance obligation. The Company believes that the cost-based input method is the best measure of progress to reflect how the Company transfers its performance obligation to a customer. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to budgeted costs to fulfill the performance obligation. These costs consist primarily of full-time equivalent effort and third-party contract costs. Revenue will be recognized based on actual costs incurred as a percentage of total budgeted costs as the Company completes its performance obligations.

 

A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company’s performance obligations. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete the Company’s performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.

 

Revenue related to grants: The Company may receive grants from governments, agencies, and other private and not-for-profit organizations. These grants are intended to be used to partially or fully fund the Company’s research collaborations, including opportunities arising in connection with COVID-19 that the Company is pursuing with certain collaborators. However, most, if not all, of such potential grant revenues, if received, is expected to be earmarked for third parties to advance the research required, including preclinical and clinical trials for SARS-CoV-2 vaccines and/or antibodies candidates.

 

Revenue related to sublicensing agreements: If the sublicense to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue allocated to the license when technology is transferred to the customer and the customer is able to use and benefit from the license.

 

Milestone payments: At the inception of each arrangement that includes development, commercialization, and regulatory milestone payments, the Company evaluates whether the achievement of the milestones is considered probable and estimates the amount to be included in the transaction price. If the milestone payment is in exchange for a sublicense and is based on the sublicensee’s subsequent sale of product, the Company recognizes milestone payment by applying the accounting guidance for royalties. To date, the Company has not recognized any milestone payment revenue resulting from any of its sublicensing arrangements.

 

Royalties: With respect to licenses deemed to be the predominant item to which the sales-based royalties relate, including milestone payments based on the level of sales, the Company recognizes revenue at the later of (i) when the related sales occur or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from any of its sublicensing arrangements.

 

We invoice customers based on our contractual arrangements with each customer, which may not be consistent with the period that revenues are recognized. When there is a timing difference between when we invoice customers and when revenues are recognized, we record either a contract asset (unbilled accounts receivable) or a contract liability (deferred research and development obligations), as appropriate. If upfront fees or considerations related to sublicensing agreement are received prior to the technology transfer, the Company will record the amount received as deferred revenue from licensing agreement.

 

We are not required to disclose the value of unsatisfied performance obligations for (i) contracts with an original expected length of one year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.

 

The Company adopted a practical expedient to expense sales commissions when incurred because the amortization period would be one year or less.

Research and Development Expense, Policy [Policy Text Block]

Research and Development Costs

 

Research and development (“R&D”) costs are expensed as incurred. R&D costs are for the Company’s internally funded pharmaceutical programs and other governmental and commercial projects.

 

Research and development costs consist of personnel-related costs, facilities, research-related overhead, services from independent contract research organizations, and other external costs. Research and development costs, including related party, during the three months ended March 31, 2021 and 2020 were as follows:

 

  

Three Months Ended March 31,

 
  

2021

  

2020

 
  

(Unaudited)

  

(Unaudited)

 

Outside contracted services

 $1,659,194  $613,790 

Personnel related costs

  148,162   123,638 

Facilities, overhead and other

  742   18,025 
  $1,808,098  $755,453 

 

Foreign Currency Transactions and Translations Policy [Policy Text Block]

Foreign Currency Transaction Gain or Loss

 

The Company and its foreign subsidiary use the U.S. dollar as its functional currency, and initially measure the foreign currency denominated assets and liabilities at the transaction date. Monetary assets and liabilities are then re-measured at exchange rates in effect at the end of each period, and property and non-monetary assets and liabilities are converted at historical rates.

Fair Value Measurement, Policy [Policy Text Block]

Fair Value Measurements

 

The Company applies fair value accounting for certain financial instruments that are recognized or disclosed at fair value in the financial statements. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is estimated by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:

 

 Level 1 – Quoted prices in active markets for identical assets or liabilities.
 Level 2 – Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
 Level 3 – Inputs that are generally unobservable and typically reflect management’s estimate of assumptions that market participants would use in pricing the asset or liability.

 

The Company’s financial instruments included cash and cash equivalents, investment in debt securities, accounts receivable, accounts payable and accrued expenses, accrued payroll and related liabilities, deferred research and development obligations and deposits. The carrying amount of these financial instruments, except for investment in debt securities, approximates fair value due to the short-term maturities of these instruments. The Company’s short-term and long-term investments in debt securities are recorded at amortized cost, and their estimated fair value amounts are provided by the third-party broker service for disclosure purposes.

Equity Securities without Readily Determinable Fair Value [Policy Text Block]

Non-Marketable Investments

 

The Company also holds investments in non-marketable equity securities of privately-held companies, which usually do not have a readily determinable fair value. Our policy is to measure these investments at cost less impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer such observable price changes may include instances where the investee issues equity securities to new investors, thus creating a new indicator of fair value, as an example. On a quarterly basis, we perform a qualitative assessment considering impairment indicators to evaluate whether these investments are impaired and also monitor for any observable price changes. If indicators of impairment exist, we will prepare a quantitative assessment of the fair value of our equity investments, which may include using both the market and income approaches which require judgment and the use of estimates, including discount rates, investee revenues and costs, and available comparable market data of private and public companies, among others. Valuations of such privately-held companies are inherently complex and uncertain due to the lack of liquid market for the company’s securities. In addition, such investments are inherently risky in that such companies are typically at an early stage of development, may have no or limited revenues, may not be or may never become profitable, may not be able to secure additional funding or their technologies, services or products may not be successfully developed or introduced into the market.

 

Income Tax, Policy [Policy Text Block]

Income Taxes

 

The Tax Cuts and Jobs Act (“TCJA”) was enacted on December 22, 2017 and became effective January 1, 2018. The TCJA contains several key provisions, including a reduction in the U.S. federal corporate income tax rate from 35% to 21% and repeal of the corporate alternative minimum tax (“AMT”). The TCJA’s reduction in the U.S. statutory tax rate had no additional impact on the consolidated financial statement for the year ended  December 31, 2020.

 

For the three months ended March 31, 2021, there were no provision for income taxes and unrecognized tax benefits recorded. As of  March 31, 2021 and  December 31, 2020, deferred tax assets were approximately $10.2 million and $9.4 million, respectively. Due to the Company’s history of operating losses and the uncertainty regarding our ability to generate taxable income in the future, the Company has established a 100% valuation allowance against deferred tax assets as of  March 31, 2021 and  December 31, 2020.

Comprehensive Income, Policy [Policy Text Block]

Comprehensive Income (Loss)

 

Comprehensive income (loss) includes net income (loss) and other revenue, expenses, gains and losses that are recorded as an element of shareholders’ equity but are excluded from net income (loss) under GAAP. The Company does not have any significant transactions that are required to be reported in other comprehensive income (loss), and therefore, does not separately present a statement of comprehensive income (loss) in its consolidated financial statements.

 

Share-based Payment Arrangement [Policy Text Block]

Stock-Based Compensation

 

We recognize all share-based payments to employees, consultants, and our board of directors (“Board of Directors”), as non-cash compensation expense, in research and development expenses or general and administrative expenses in the consolidated statement of operations based on the grant date fair values of such payments. Stock-based compensation expense recognized each period is based on the value of the portion of share-based payment awards that is ultimately expected to vest during the period. Forfeitures are recorded as they occur.

Earnings Per Share, Policy [Policy Text Block]

Net Loss Per Share

 

Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common stock shares outstanding during the reporting period. Diluted net loss per share adjusts the weighted average number of common stock shares outstanding for the potential dilution that could occur if common stock equivalents, such as stock options were exercised and converted into common stock, calculated by applying the treasury stock method.

 

For the three months ended March 31, 2021 and 2020, the effect of the potential exercise of options to purchase 5,324,215 and 4,663,390 shares of common stock, respectively, were excluded from the computation of diluted net loss per share as their effect would have been anti-dilutive.

New Accounting Pronouncements, Policy [Policy Text Block]

Recently Adopted Accounting Pronouncements 

 

In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which modifies the measurement of expected credit losses of certain financial instruments. ASU 2016-13 will be effective for the Company beginning in the first quarter of 2023. The Company does not expect ASU 2016-13 to have a material impact on our consolidated financial positions, results of operations, and cash flows.

 

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The amendments of this update simplify the accounting for income taxes by removing certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The Company adopted ASU 2019-12 on  January 1, 2021, and adoption of ASU 2019-12 did not have any material impact on our consolidated financial positions, results of operations, cash flows and related disclosures.

 

Other pronouncements issued by the FASB or other authoritative accounting standards group with future effective dates are either not applicable or not significant to our consolidated financial statements.

XML 27 R15.htm IDEA: XBRL DOCUMENT v3.21.1
Note 1 - Organization and Summary of Significant Accounting Policies (Tables)
3 Months Ended
Mar. 31, 2021
Notes Tables  
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]
  

March 31, 2021

  

December 31, 2020

 
  

(Unaudited)

  

(Audited)

 

Billed receivable

 $293,323  $130,532 

Unbilled receivable

  91,640   163,667 
  $384,963  $294,199 
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]
  

March 31, 2021

  

December 31, 2020

 
  

(Unaudited)

  

(Audited)

 

Prepaid insurance

 $94,841  $204,988 

Prepaid expenses - various

  120,534   72,403 

Prepaid taxes

  814   3,164 
  $216,189  $280,555 
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]
  

March 31, 2021

  

December 31, 2020

 
  

(Unaudited)

  

(Audited)

 

Research and development expenses

 $1,337,755  $904,572 

Legal expenses

  93,071   24,496 

Other

  42,987   84,031 
  $1,473,813  $1,013,099 
Schedule of Accrued Liabilities [Table Text Block]
  

March 31, 2021

  

December 31, 2020

 
  

(Unaudited)

  

(Audited)

 

Employee wages and benefits

 $175,210  $447,881 

Research and development expenses

  42,006   28,508 

Other

  60,452   13,367 
  $277,668  $489,756 
Schedule of Research and Development Costs [Table Text Block]
  

Three Months Ended March 31,

 
  

2021

  

2020

 
  

(Unaudited)

  

(Unaudited)

 

Outside contracted services

 $1,659,194  $613,790 

Personnel related costs

  148,162   123,638 

Facilities, overhead and other

  742   18,025 
  $1,808,098  $755,453 
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.21.1
Note 2 - Cash, Cash Equivalent, and Investments (Tables)
3 Months Ended
Mar. 31, 2021
Notes Tables  
Cash, Cash Equivalents and Investments [Table Text Block]
  

March 31, 2021 (Unaudited)

 
         

Gross

  

Gross

     
  

Level

      

Unrealized

  

Unrealized

     
  

(1)

  

Fair Value

  

Holding Gains

  

Holding Losses

  

Adjusted Cost

 

Cash and Cash Equivalents

                   

Cash

    $1,217,419  $  $  $1,217,419 

Money Market Funds

 1   11,838,139         11,838,139 

Subtotal

     13,055,558         13,055,558 

Short-Term Investment Securities (2)

                   

Corporate Bonds (3)

 2   14,161,252   1,658   (17,847)  14,177,441 

Total

    $27,216,810  $1,658  $(17,847) $27,232,999 
  

December 31, 2020 (Audited)

 
         

Gross

  

Gross

     
  

Level

      

Unrealized

  

Unrealized

     
  

(1)

  

Fair Value

  

Holding Gains

  

Holding Losses

  

Adjusted Cost

 

Cash and Cash Equivalents

                   

Cash

    $149,015  $  $  $149,015 

Money Market Funds

 1   20,488,030         20,488,030 

Subtotal

     20,637,045         20,637,045 

Short-Term Investment Securities (2)

                   

Corporate Bonds (3)

 2   8,473,461   22,473   (6,463)  8,457,451 

Total

    $29,110,506  $22,473  $(6,463) $29,094,496 
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.21.1
Note 5 - Share-based Compensation (Tables)
3 Months Ended
Mar. 31, 2021
Notes Tables  
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

Risk-Free interest rate

  0.13%-0.55% 

Expected dividend yield

  —% 

Expected stock price volatility

  54.52%-56.07% 

Expected life of options (in years)

  2.00-6.25 
Share-based Payment Arrangement, Option, Activity [Table Text Block]
          

Weighted-Average

     
      

Weighted-Average

  

Remaining Contractual

  

Aggregate Intrinsic

 
  

Shares

  

Exercise Price

  

Term (Years)

  

Value

 

Outstanding at December 31, 2020

  4,638,390  $2.44   5.64  $13,701,610 

Granted (1)

  745,825   5.25         

Exercised (2)

  (60,000)  1.93         

Expired

              

Canceled

              

Outstanding at March 31, 2021

  5,324,215  $2.84   6.03  $14,209,431 
                 

Exercisable at March 31, 2021

  4,016,141  $2.28   5.09  $12,927,908 
Share-based Payment Arrangement, Activity [Table Text Block]
  

Three Months Ended March 31,

 
  

2021

  

2020

 

General and administrative

 $377,052  $380,251 

Research and development

  44,019   46,688 

Total

 $421,071  $426,939 
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.21.1
Note 6 - Shareholders' Equity (Tables)
3 Months Ended
Mar. 31, 2021
Notes Tables  
Schedule of Stockholders Equity [Table Text Block]
      

Three Months Ended March 31, 2021 (Unaudited)

     
  

Common Stock

  

Treasury Stock

  

Additional Paid-In Capital

  

Accumulated Deficit

  

Total

 

January 1, 2021

 $39,748  $(18,929,915) $98,013,079  $(50,676,351) $28,446,561 

Stock-based compensation

        421,071      421,071 

Stock issued

  60      115,740      115,800 

Net loss

           (3,294,949)  (3,294,949)

March 31, 2021

 $39,808  $(18,929,915) $98,549,890  $(53,971,300) $25,688,483 
      

Three Months Ended March 31, 2020 (Unaudited)

     
  

Common Stock

  

Treasury Stock

  

Additional Paid-In Capital

  

Accumulated Deficit

  

Total

 

January 1, 2020

 $39,613  $(18,929,915) $96,105,851  $(41,351,078) $35,864,471 

Stock-based compensation

        426,939      426,939 
Stock issued  100      174,900      175,000 

Net loss

           (2,214,139)  (2,214,139)

March 31, 2020

 $39,713  $(18,929,915) $96,707,690  $(43,565,217) $34,252,271 
XML 31 R19.htm IDEA: XBRL DOCUMENT v3.21.1
Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual)
3 Months Ended 12 Months Ended
Mar. 31, 2021
USD ($)
shares
Mar. 31, 2020
USD ($)
shares
Dec. 31, 2020
USD ($)
Number of Research Organizations 3    
Number of Operating Segments 1    
Revenue from Contract with Customer, Excluding Assessed Tax, Total $ 460,520 $ 315,372  
Accounts Receivable, Allowance for Credit Loss, Ending Balance 0   $ 0
Unrecognized Tax Benefits, Ending Balance 0   0
Deferred Tax Assets, Net, Total $ 10,200,000   $ 9,400,000
Deferred Tax Assets, Valuation Allowance Coverage, Percent 100.00%   100.00%
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares 5,324,215 4,663,390  
Customer Concentration Risk [Member] | Revenue Benchmark [Member]      
Concentration Risk, Number of Customers 8 5  
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | Non-US [Member]      
Concentration Risk, Number of Customers 6 3  
Concentration Risk, Percentage 76.70% 58.00%  
Revenue from Contract with Customer, Excluding Assessed Tax, Total $ 353,000 $ 183,000  
Customer Concentration Risk [Member] | Accounts Receivable [Member]      
Concentration Risk, Number of Customers 7   9
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Non-US [Member]      
Concentration Risk, Number of Customers 4   7
Concentration Risk, Percentage 46.00%   41.60%
Accounts Receivable, after Allowance for Credit Loss, Total $ 174,000   $ 123,000
Supplier Concentration Risk [Member] | Contract Research Organizations [Member]      
Concentration Risk, Percentage 98.10%    
Concentration Risk, Number of Suppliers 3 1  
Supplier Concentration Risk [Member] | Contract Research Organizations [Member] | Three CROs [Member]      
Research Services Purchased $ 2,017,000    
Supplier Concentration Risk [Member] | Contract Research Organizations [Member] | One CRO [Member]      
Concentration Risk, Percentage   100.00%  
Research Services Purchased   $ 855,000  
Supplier Concentration Risk [Member] | Accounts Payable [Member]      
Concentration Risk, Number of Suppliers     1
Supplier Concentration Risk [Member] | Accounts Payable [Member] | Three CROs [Member]      
Concentration Risk, Percentage 89.80%    
Accounts Payable, Total $ 1,324,000    
Supplier Concentration Risk [Member] | Accounts Payable [Member] | One CRO [Member]      
Concentration Risk, Percentage     68.10%
Accounts Payable, Total     $ 690,000
XML 32 R20.htm IDEA: XBRL DOCUMENT v3.21.1
Note 1 - Organization and Summary of Significant Accounting Policies - Accounts Receivable (Details) - USD ($)
Mar. 31, 2021
Dec. 31, 2020
Accounts receivable $ 384,963 $ 294,199
Billed Revenues [Member]    
Accounts receivable 293,323 130,532
Unbilled Revenues [Member]    
Accounts receivable $ 91,640 $ 163,667
XML 33 R21.htm IDEA: XBRL DOCUMENT v3.21.1
Note 1 - Organization and Summary of Significant Accounting Policies - Prepaid Expenses and Other Current Assets (Details) - USD ($)
Mar. 31, 2021
Dec. 31, 2020
Prepaid insurance $ 94,841 $ 204,988
Prepaid expenses - various 120,534 72,403
Prepaid taxes 814 3,164
Prepaid Expense and Other Assets, Current $ 216,189 $ 280,555
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.21.1
Note 1 - Organization and Summary of Significant Accounting Policies - Accounts Payable (Details) - USD ($)
Mar. 31, 2021
Dec. 31, 2020
Research and development expenses $ 1,337,755 $ 904,572
Legal expenses 93,071 24,496
Other 42,987 84,031
Accounts Payable, Current, Total $ 1,473,813 $ 1,013,099
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.21.1
Note 1 - Organization and Summary of Significant Accounting Policies - Accrued Expenses (Details) - USD ($)
Mar. 31, 2021
Dec. 31, 2020
Employee wages and benefits $ 175,210 $ 447,881
Research and development expenses 42,006 28,508
Other 60,452 13,367
Accrued Liabilities, Current, Total $ 277,668 $ 489,756
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.21.1
Note 1 - Organization and Summary of Significant Accounting Policies - Research and Development Costs (Details) - USD ($)
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Outside contracted services $ 1,659,194 $ 613,790
Personnel related costs 148,162 123,638
Facilities, overhead and other 742 18,025
Research And Development Expense, Including Related Party $ 1,808,098 $ 755,453
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.21.1
Note 2 - Cash, Cash Equivalent, and Investments (Details Textual) - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Corporate Debt Securities [Member]      
Debt Securities, Held-to-maturity, Premium Paid on Purchase $ 283,940 $ 196,385 $ 282,946
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.21.1
Note 2 - Cash, Cash Equivalent, and Investments - Major Security Type (Details) - USD ($)
Mar. 31, 2021
Dec. 31, 2020
Cash and cash equivalent, fair value $ 13,055,558 $ 20,637,045
Cash, adjusted cost 1,217,419 149,015
Money Market Funds, adjusted cost 11,838,139 20,488,030
Cash and cash equivalents, adjusted cost 13,055,558 20,637,045
Gross Unrealized Holding Gains 1,658 22,473
Gross Unrealized Holding Losses (17,847) (6,463)
Short-term investment securities 14,177,441 8,457,452
Total, fair value 27,216,810 29,110,506
Total, adjusted 27,232,999 29,094,496
Corporate Bond Securities [Member]    
Short-term investment securities [1],[2] 14,177,441 8,457,451
Fair Value, Inputs, Level 2 [Member] | Short-term Corporate Bonds [Member]    
Gross Unrealized Holding Gains [1],[2] 1,658 22,473
Cash [Member]    
Cash and cash equivalent, fair value 1,217,419 149,015
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]    
Cash and cash equivalent, fair value 11,838,139 20,488,030
Short-term Corporate Bonds [Member] | Fair Value, Inputs, Level 2 [Member]    
Corporate Bonds, fair value [1],[2] 14,161,252 8,473,461
Gross Unrealized Holding Losses [1],[2] $ (17,847) $ (6,463)
[1] Short-term investment securities will mature within 12 months or less, from the applicable reporting date.
[2] The premium paid to purchase held-to-maturity investment securities was $283,940 and $196,385 for the three months ended March 31, 2021 and 2020, respectively. The premium paid to purchase held-to-maturity investment securities was $282,946 for the year ended December 31, 2020.
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.21.1
Note 3 - Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately-held Companies (Details Textual)
€ in Millions
3 Months Ended
Jun. 24, 2020
Jun. 30, 2017
EUR (€)
Mar. 31, 2021
USD ($)
Mar. 31, 2020
USD ($)
Dec. 31, 2020
USD ($)
Dec. 01, 2020
Jul. 08, 2020
shares
Apr. 26, 2019
Jun. 30, 2017
USD ($)
Jun. 30, 2017
EUR (€)
Collaborative Arrangement, Duration Of Agreement (Year)   2 years                
Collaborative Arrangement, Payment for Research and Development Agreement | €   € 1.1                
Cost of Goods and Services Sold, Total     $ 390,762 $ 278,182            
Novovet [Member]                    
Equity Method Investment, Ownership Percentage               20.00%    
Alphazyme [Member]                    
Sale of Stock, Percentage of Ownership after Transaction 2.50%                  
Equity Securities without Readily Determinable Fair Value, Amount         $ 284,709          
Service Agreement to Perform Research Project [Member] | BDI [Member]                    
Cost of Goods and Services Sold, Total     $ 15,000              
Research Services Agreement [Member]                    
Collaborative Arrangement, Payment for Additional Development and Commercialization | €                   € 1.5
Service Framework Agreement [Member]                    
Collaborative Arrangement, Duration Of Agreement (Year)   2 years                
Collaborative Arrangement, Minimum Obligation For Research and Development                 $ 1,000,000.0  
Collaborative Arrangement, Outstanding Commitment                 1,000,000.0  
Alphazyme [Member]                    
Ownership Percentage           1.99%        
ID Biologics Inc [Member]                    
Collaborative Arrangement, Number of Shares To Be Received (in shares) | shares             129,611      
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners             0.37%      
ID Biologics Inc [Member] | Share-based Payment Arrangement, Tranche One [Member]                    
Collaborative Arrangement, Vesting Percentages             50.00%      
ID Biologics Inc [Member] | Share-based Payment Arrangement, Tranche Two [Member]                    
Collaborative Arrangement, Vesting Percentages             25.00%      
ID Biologics Inc [Member] | Share-based Payment Arrangement, Tranche Three [Member]                    
Collaborative Arrangement, Vesting Percentages             25.00%      
Research Services Agreement [Member]                    
Collaborative Arrangement, Payment for Research and Development Agreement | €   € 1.0                
Research Services Agreement [Member] | BDI Holdings [Member]                    
Collaborative Arrangement, Duration Of Agreement (Year)   2 years                
Collaborative Arrangement, Equity Interest Acquired   16.10%                
Collaborative Arrangement, Minimum Obligation For Research and Development                 $ 936,000  
Collaborative Arrangement, Maximum Obligation For Research and Development | €                   8.0
Research Services Agreement [Member] | BDI Holdings [Member] | Minimum [Member]                    
Collaborative Arrangement, Minimum Obligation For Research and Development | €                   € 1.0
Collaborative Arrangement, Revenue Sharing, Percentage   50.00%                
Research Services Agreement [Member] | BDI Holdings [Member] | Maximum [Member]                    
Collaborative Arrangement, Revenue Sharing, Percentage   75.00%                
Research Services Agreement [Member] | VL Pbio Member                    
Collaborative Arrangement, Equity Interest Acquired   3.30%                
XML 40 R28.htm IDEA: XBRL DOCUMENT v3.21.1
Note 5 - Share-based Compensation (Details Textual) - $ / shares
3 Months Ended
Apr. 16, 2021
Mar. 22, 2021
Jan. 21, 2021
Jan. 08, 2021
Jan. 04, 2021
Jan. 01, 2019
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Apr. 28, 2011
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)             5,324,215   4,638,390  
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) [1]             745,825      
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share) [1]             $ 5.25      
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares) [2]             60,000      
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price (in dollars per share)             $ 1.93 [2] $ 1.78    
Minimum [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year)             2 years      
Executives and Key Personnel [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)         417,500          
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)         $ 5.16          
Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period (Year)         1 year          
Director [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)       35,000 227,500          
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)       $ 5.50 $ 5.16          
Employees [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)         23,325          
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)         $ 5.16          
Consultant [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)   30,000 7,500   5,000          
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)   $ 6.87 $ 5.65   $ 5.16          
Share-based Payment Arrangement, Option [Member] | Director [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)       1 year 1 year          
Share-based Payment Arrangement, Option [Member] | Employees [Member] | Minimum [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)         4 years          
Share-based Payment Arrangement, Option [Member] | Consultant [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)   1 year 1 year   1 year          
Share-based Payment Arrangement, Option [Member] | Share-based Compensation Award Tranche Two through Five [Member] | Executives and Key Personnel [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)         4 years          
The 2011 Plan [Member]                    
Common Stock, Capital Shares Reserved for Future Issuance (in shares)                   3,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)           1,500,000        
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)             5,324,215   4,638,390  
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)             1,388,386   2,134,211  
The 2011 Plan [Member] | Share-based Payment Arrangement, Option [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)             10 years      
The 2011 Plan [Member] | Share-based Payment Arrangement, Option [Member] | Share-based Payment Arrangement, Tranche One [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)             1 year      
The 2011 Plan [Member] | Share-based Payment Arrangement, Option [Member] | Share-based Payment Arrangement, Tranche One [Member] | Contractor [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year)             2 years      
The 2011 Plan [Member] | Share-based Payment Arrangement, Option [Member] | Share-based Payment Arrangement, Tranche One [Member] | Chief Executive Officer [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year)             5 years      
The 2011 Plan [Member] | Share-based Payment Arrangement, Option [Member] | Share-based Payment Arrangement, Tranche Two [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)             3 years      
The 2011 Plan [Member] | Share-based Payment Arrangement, Option [Member] | Share-based Payment Arrangement, Tranche Two [Member] | Contractor [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year)             3 years      
The 2011 Plan [Member] | Share-based Payment Arrangement, Option [Member] | Share-based Payment Arrangement, Tranche Two [Member] | Chief Executive Officer [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year)             10 years      
The 2011 Plan [Member] | Subsequent Event [Member]                    
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares) 3,000,000                  
[1] Represents the following stock options granted: Annual share-based compensation awards on January 4, 2021, including: (a) 417,500 stock options with an exercise price of $5.16 per share granted to executives and key personnel, upon one year anniversary, or vesting annually in equal installments over four years, (b) 227,500 stock options with an exercise price of $5.16 per share granted to members of the Board of Directors, vesting upon one year anniversary, (c) 23,325 stock options with an exercise price of $5.16 per share granted to employees, vesting annually in equal installments over four years and (d) 5,000 stock options with an exercise price of $5.16 per share granted to a consultant, vesting upon one year anniversary. One-time award on January 8, 2021, 35,000 stock options with an exercise price of $5.50 per share granted to a new member of the Board of Directors, vesting in one year from the grant date. One-time award on January 21, 2021, 7,500 stock options with an exercise price of $5.65 per share granted to a consultant, vesting in one year from the grant date. One-time award on March 22, 2021, 30,000 stock options with an exercise price of $6.87 per share granted to a consultant, vesting in one year from the grant date.
[2] Represents the following stock options exercised: A total of 60,000 stock options exercised with a weighted average exercise price of $1.93.
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.21.1
Note 5 - Share-based Compensation - Black-Scholes Options Pricing Model (Details)
3 Months Ended
Mar. 31, 2021
Risk-Free interest rate, minimum 0.13%
Risk-Free interest rate, maximum 0.55%
Expected stock price volatility, minimum 54.52%
Expected stock price volatility, maximum 56.07%
Minimum [Member]  
Expected life of options (Year) 2 years
Maximum [Member]  
Expected life of options (Year) 6 years 3 months
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.21.1
Note 5 - Share-based Compensation - Stock Option Activity (Details) - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Outstanding, shares (in shares) 4,638,390    
Outstanding, weighted average exercise price (in dollars per share) $ 2.44    
Weighted-average remaining contractual term, outstanding (Year) 6 years 10 days   5 years 7 months 20 days
Aggregate intrinsic value, outstanding $ 14,209,431   $ 13,701,610
Granted, shares (in shares) [1] 745,825    
Granted, weighted average exercise price (in dollars per share) [1] $ 5.25    
Exercised, shares (in shares) [2] (60,000)    
Exercised, weighted average exercise price (in dollars per share) $ 1.93 [2] $ 1.78  
Expired, shares (in shares) 0    
Expired, weighted average exercise price (in dollars per share) $ 0    
Canceled, shares (in shares) 0    
Canceled, weighted average exercise price (in dollars per share) $ 0    
Outstanding, shares (in shares) 5,324,215   4,638,390
Outstanding, weighted average exercise price (in dollars per share) $ 2.84   $ 2.44
Exercisable, shares (in shares) 4,016,141    
Exercisable, weighted average exercise price (in dollars per share) $ 2.28    
Weighted-average remaining contractual term, exercisable (Year) 5 years 1 month 2 days    
Aggregate intrinsic value, exercisable $ 12,927,908    
[1] Represents the following stock options granted: Annual share-based compensation awards on January 4, 2021, including: (a) 417,500 stock options with an exercise price of $5.16 per share granted to executives and key personnel, upon one year anniversary, or vesting annually in equal installments over four years, (b) 227,500 stock options with an exercise price of $5.16 per share granted to members of the Board of Directors, vesting upon one year anniversary, (c) 23,325 stock options with an exercise price of $5.16 per share granted to employees, vesting annually in equal installments over four years and (d) 5,000 stock options with an exercise price of $5.16 per share granted to a consultant, vesting upon one year anniversary. One-time award on January 8, 2021, 35,000 stock options with an exercise price of $5.50 per share granted to a new member of the Board of Directors, vesting in one year from the grant date. One-time award on January 21, 2021, 7,500 stock options with an exercise price of $5.65 per share granted to a consultant, vesting in one year from the grant date. One-time award on March 22, 2021, 30,000 stock options with an exercise price of $6.87 per share granted to a consultant, vesting in one year from the grant date.
[2] Represents the following stock options exercised: A total of 60,000 stock options exercised with a weighted average exercise price of $1.93.
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.21.1
Note 5 - Share-based Compensation - Noncash Stock Option Compensation (Details) - USD ($)
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Stock-based compensation $ 421,071 $ 426,939
General and Administrative Expense [Member]    
Stock-based compensation 377,052 380,251
Research and Development Expense [Member]    
Stock-based compensation $ 44,019 $ 46,688
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.21.1
Note 6 - Shareholders' Equity (Details Textual) - USD ($)
3 Months Ended
Aug. 13, 2020
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares) [1]   60,000    
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price (in dollars per share)   $ 1.93 [1] $ 1.78  
Treasury Stock, Common, Shares (in shares)   12,253,502   12,253,502
Treasury Stock, Value, Ending Balance   $ 18,929,915   $ 18,929,915
Common Stock, Par or Stated Value Per Share (in dollars per share) $ 0.001 $ 0.001   $ 0.001
Open Market Sale Agreement [Member]        
Sale of Stock, Authorized Offering Amount $ 50,000,000.0      
Sale of Stock, Percentage of Commissions Paid of Gross Proceeds From Sale Of Each Share 3.00%      
Sale of Stock, Reimbursable Legal Expenses $ 50,000      
Sale of Stock, Termination Amount Under Agreement $ 50,000,000.0      
Common Stock [Member]        
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)   60,000 100,000  
[1] Represents the following stock options exercised: A total of 60,000 stock options exercised with a weighted average exercise price of $1.93.
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.21.1
Note 6 - Shareholders' Equity - Schedule of Stockholders Equity (Details) - USD ($)
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Balance $ 28,446,561 $ 35,864,471
Stock-based compensation 421,071 426,939
Stock issued 115,800 175,000
Net loss (3,294,949) (2,214,139)
Balance 25,688,483 34,252,271
Common Stock [Member]    
Balance 39,748 39,613
Stock-based compensation 0 0
Stock issued 60 100
Net loss 0 0
Balance 39,808 39,713
Treasury Stock [Member]    
Balance (18,929,915) (18,929,915)
Stock-based compensation 0 0
Stock issued 0 0
Net loss 0 0
Balance (18,929,915) (18,929,915)
Additional Paid-in Capital [Member]    
Balance 98,013,079 96,105,851
Stock-based compensation 421,071 426,939
Stock issued 115,740 174,900
Net loss 0 0
Balance 98,549,890 96,707,690
Retained Earnings [Member]    
Balance (50,676,351) (41,351,078)
Stock-based compensation 0 0
Stock issued 0 0
Net loss (3,294,949) (2,214,139)
Balance $ (53,971,300) $ (43,565,217)
EXCEL 46 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 47 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 48 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 49 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 123 277 1 true 52 0 false 7 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.dyadic.com/20210331/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Consolidated Balance Sheets (Current Period Unaudited) Sheet http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited- Consolidated Balance Sheets (Current Period Unaudited) Statements 2 false false R3.htm 002 - Statement - Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Sheet http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Consolidated Statements of Operations (Unaudited) Sheet http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 004 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited) Sheet http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-stockholders-equity-unaudited Consolidated Statements of Stockholders' Equity (Unaudited) Statements 5 false false R6.htm 005 - Statement - Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 006 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies Sheet http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies Note 1 - Organization and Summary of Significant Accounting Policies Notes 7 false false R8.htm 007 - Disclosure - Note 2 - Cash, Cash Equivalent, and Investments Sheet http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments- Note 2 - Cash, Cash Equivalent, and Investments Notes 8 false false R9.htm 008 - Disclosure - Note 3 - Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately-held Companies Sheet http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies Note 3 - Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately-held Companies Notes 9 false false R10.htm 009 - Disclosure - Note 4 - Commitments and Contingencies Sheet http://www.dyadic.com/20210331/role/statement-note-4-commitments-and-contingencies- Note 4 - Commitments and Contingencies Notes 10 false false R11.htm 010 - Disclosure - Note 5 - Share-based Compensation Sheet http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation- Note 5 - Share-based Compensation Notes 11 false false R12.htm 011 - Disclosure - Note 6 - Shareholders' Equity Sheet http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity- Note 6 - Shareholders' Equity Notes 12 false false R13.htm 012 - Disclosure - Note 7 - Subsequent Events Sheet http://www.dyadic.com/20210331/role/statement-note-7-subsequent-events- Note 7 - Subsequent Events Notes 13 false false R14.htm 013 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies 14 false false R15.htm 014 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies (Tables) Sheet http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables Note 1 - Organization and Summary of Significant Accounting Policies (Tables) Tables http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies 15 false false R16.htm 015 - Disclosure - Note 2 - Cash, Cash Equivalent, and Investments (Tables) Sheet http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-tables Note 2 - Cash, Cash Equivalent, and Investments (Tables) Tables http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments- 16 false false R17.htm 016 - Disclosure - Note 5 - Share-based Compensation (Tables) Sheet http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-tables Note 5 - Share-based Compensation (Tables) Tables http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation- 17 false false R18.htm 017 - Disclosure - Note 6 - Shareholders' Equity (Tables) Sheet http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-tables Note 6 - Shareholders' Equity (Tables) Tables http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity- 18 false false R19.htm 018 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual) Sheet http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual) Details http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables 19 false false R20.htm 019 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies - Accounts Receivable (Details) Sheet http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details Note 1 - Organization and Summary of Significant Accounting Policies - Accounts Receivable (Details) Details 20 false false R21.htm 020 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies - Prepaid Expenses and Other Current Assets (Details) Sheet http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details Note 1 - Organization and Summary of Significant Accounting Policies - Prepaid Expenses and Other Current Assets (Details) Details 21 false false R22.htm 021 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies - Accounts Payable (Details) Sheet http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details Note 1 - Organization and Summary of Significant Accounting Policies - Accounts Payable (Details) Details 22 false false R23.htm 022 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies - Accrued Expenses (Details) Sheet http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details Note 1 - Organization and Summary of Significant Accounting Policies - Accrued Expenses (Details) Details 23 false false R24.htm 023 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies - Research and Development Costs (Details) Sheet http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details Note 1 - Organization and Summary of Significant Accounting Policies - Research and Development Costs (Details) Details 24 false false R25.htm 024 - Disclosure - Note 2 - Cash, Cash Equivalent, and Investments (Details Textual) Sheet http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-details-textual Note 2 - Cash, Cash Equivalent, and Investments (Details Textual) Details http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-tables 25 false false R26.htm 025 - Disclosure - Note 2 - Cash, Cash Equivalent, and Investments - Major Security Type (Details) Sheet http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details Note 2 - Cash, Cash Equivalent, and Investments - Major Security Type (Details) Details 26 false false R27.htm 026 - Disclosure - Note 3 - Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately-held Companies (Details Textual) Sheet http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual Note 3 - Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately-held Companies (Details Textual) Details http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies 27 false false R28.htm 027 - Disclosure - Note 5 - Share-based Compensation (Details Textual) Sheet http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual Note 5 - Share-based Compensation (Details Textual) Details http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-tables 28 false false R29.htm 028 - Disclosure - Note 5 - Share-based Compensation - Black-Scholes Options Pricing Model (Details) Sheet http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-blackscholes-options-pricing-model-details Note 5 - Share-based Compensation - Black-Scholes Options Pricing Model (Details) Details 29 false false R30.htm 029 - Disclosure - Note 5 - Share-based Compensation - Stock Option Activity (Details) Sheet http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-stock-option-activity-details Note 5 - Share-based Compensation - Stock Option Activity (Details) Details 30 false false R31.htm 030 - Disclosure - Note 5 - Share-based Compensation - Noncash Stock Option Compensation (Details) Sheet http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-noncash-stock-option-compensation-details Note 5 - Share-based Compensation - Noncash Stock Option Compensation (Details) Details 31 false false R32.htm 031 - Disclosure - Note 6 - Shareholders' Equity (Details Textual) Sheet http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-details-textual Note 6 - Shareholders' Equity (Details Textual) Details http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-tables 32 false false R33.htm 032 - Disclosure - Note 6 - Shareholders' Equity - Schedule of Stockholders Equity (Details) Sheet http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-schedule-of-stockholders-equity-details Note 6 - Shareholders' Equity - Schedule of Stockholders Equity (Details) Details 33 false false All Reports Book All Reports dyai20210331_10q.htm dyai-20210331.xsd dyai-20210331_cal.xml dyai-20210331_def.xml dyai-20210331_lab.xml dyai-20210331_pre.xml ex_237822.htm ex_237823.htm ex_237824.htm ex_237825.htm dyai-20200930_g1copy.jpg http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/srt/2020-01-31 true true JSON 52 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "dyai20210331_10q.htm": { "axisCustom": 0, "axisStandard": 24, "contextCount": 123, "dts": { "calculationLink": { "local": [ "dyai-20210331_cal.xml" ] }, "definitionLink": { "local": [ "dyai-20210331_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "dyai20210331_10q.htm" ] }, "labelLink": { "local": [ "dyai-20210331_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "dyai-20210331_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "dyai-20210331.xsd" ], "remote": [ "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 350, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 41, "http://www.dyadic.com/20210331": 18, "http://xbrl.sec.gov/dei/2019-01-31": 6, "total": 65 }, "keyCustom": 35, "keyStandard": 242, "memberCustom": 20, "memberStandard": 29, "nsprefix": "dyai", "nsuri": "http://www.dyadic.com/20210331", "report": { "R1": { "firstAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "d_2021-01-01_2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://www.dyadic.com/20210331/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "d_2021-01-01_2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "d_2021-01-01_2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Note 4 - Commitments and Contingencies", "role": "http://www.dyadic.com/20210331/role/statement-note-4-commitments-and-contingencies-", "shortName": "Note 4 - Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "d_2021-01-01_2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "d_2021-01-01_2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Note 5 - Share-based Compensation", "role": "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-", "shortName": "Note 5 - Share-based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "d_2021-01-01_2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "d_2021-01-01_2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Note 6 - Shareholders' Equity", "role": "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-", "shortName": "Note 6 - Shareholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "d_2021-01-01_2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "d_2021-01-01_2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Note 7 - Subsequent Events", "role": "http://www.dyadic.com/20210331/role/statement-note-7-subsequent-events-", "shortName": "Note 7 - Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "d_2021-01-01_2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "d_2021-01-01_2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dyai:ImpactOfCOVID19PolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Significant Accounting Policies (Policies)", "role": "http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "d_2021-01-01_2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dyai:ImpactOfCOVID19PolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "us-gaap:TradeAndOtherAccountsReceivablePolicy", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "d_2021-01-01_2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies (Tables)", "role": "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables", "shortName": "Note 1 - Organization and Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:TradeAndOtherAccountsReceivablePolicy", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "d_2021-01-01_2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "d_2021-01-01_2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Note 2 - Cash, Cash Equivalent, and Investments (Tables)", "role": "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-tables", "shortName": "Note 2 - Cash, Cash Equivalent, and Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "d_2021-01-01_2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "d_2021-01-01_2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Note 5 - Share-based Compensation (Tables)", "role": "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-tables", "shortName": "Note 5 - Share-based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "d_2021-01-01_2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "d_2021-01-01_2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Note 6 - Shareholders' Equity (Tables)", "role": "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-tables", "shortName": "Note 6 - Shareholders' Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "d_2021-01-01_2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "d_2021-01-01_2021-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual)", "role": "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual", "shortName": "Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxPolicyTextBlock", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "i_2021-03-31", "decimals": "-5", "lang": null, "name": "us-gaap:DeferredTaxAssetsLiabilitiesNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "i_2021-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Consolidated Balance Sheets (Current Period Unaudited)", "role": "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-", "shortName": "Consolidated Balance Sheets (Current Period Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "i_2021-03-31", "decimals": "INF", "lang": null, "name": "us-gaap:InterestReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "i_2021-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies - Accounts Receivable (Details)", "role": "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details", "shortName": "Note 1 - Organization and Summary of Significant Accounting Policies - Accounts Receivable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "us-gaap:TradeAndOtherAccountsReceivablePolicy", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "i_2021-03-31_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis-BilledRevenuesMember", "decimals": "INF", "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "dyai:PrepaidExpensesAndOtherCurrentAssetsPolicyPolicyTextBlock", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "i_2021-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PrepaidInsurance", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies - Prepaid Expenses and Other Current Assets (Details)", "role": "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details", "shortName": "Note 1 - Organization and Summary of Significant Accounting Policies - Prepaid Expenses and Other Current Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "dyai:PrepaidExpensesAndOtherCurrentAssetsPolicyPolicyTextBlock", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "i_2021-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PrepaidInsurance", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "dyai:AccountsPayablePolicyPolicyTextBlock", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "i_2021-03-31", "decimals": "INF", "first": true, "lang": null, "name": "dyai:ResearchAndDevelopmentInProcessCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies - Accounts Payable (Details)", "role": "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details", "shortName": "Note 1 - Organization and Summary of Significant Accounting Policies - Accounts Payable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "dyai:AccountsPayablePolicyPolicyTextBlock", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "i_2021-03-31", "decimals": "INF", "first": true, "lang": null, "name": "dyai:ResearchAndDevelopmentInProcessCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "dyai:AccruedExpensesPolicyPolicyTextBlock", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "i_2021-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies - Accrued Expenses (Details)", "role": "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details", "shortName": "Note 1 - Organization and Summary of Significant Accounting Policies - Accrued Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "dyai:AccruedExpensesPolicyPolicyTextBlock", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "i_2021-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "dyai:ScheduleOfResearchAndDevelopmentCostsTableTextBlock", "us-gaap:ResearchAndDevelopmentExpensePolicy", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "d_2021-01-01_2021-03-31", "decimals": "INF", "first": true, "lang": null, "name": "dyai:ResearchAndDevelopmentExpenseOutsideContractedServices", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies - Research and Development Costs (Details)", "role": "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details", "shortName": "Note 1 - Organization and Summary of Significant Accounting Policies - Research and Development Costs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "dyai:ScheduleOfResearchAndDevelopmentCostsTableTextBlock", "us-gaap:ResearchAndDevelopmentExpensePolicy", "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "d_2021-01-01_2021-03-31", "decimals": "INF", "first": true, "lang": null, "name": "dyai:ResearchAndDevelopmentExpenseOutsideContractedServices", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "d_2021-01-01_2021-03-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember", "decimals": "INF", "first": true, "lang": null, "name": "dyai:DebtSecuritiesHeldtomaturityPremiumPaidOnPurchase", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Note 2 - Cash, Cash Equivalent, and Investments (Details Textual)", "role": "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-details-textual", "shortName": "Note 2 - Cash, Cash Equivalent, and Investments (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "d_2021-01-01_2021-03-31_FinancialInstrumentAxis-CorporateDebtSecuritiesMember", "decimals": "INF", "first": true, "lang": null, "name": "dyai:DebtSecuritiesHeldtomaturityPremiumPaidOnPurchase", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "i_2021-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Note 2 - Cash, Cash Equivalent, and Investments - Major Security Type (Details)", "role": "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details", "shortName": "Note 2 - Cash, Cash Equivalent, and Investments - Major Security Type (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "i_2021-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "d_2021-01-01_2021-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - Note 3 - Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately-held Companies (Details Textual)", "role": "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual", "shortName": "Note 3 - Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately-held Companies (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "i_2019-04-26_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis-NovovetMember", "decimals": "1", "lang": null, "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "i_2021-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Note 5 - Share-based Compensation (Details Textual)", "role": "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual", "shortName": "Note 5 - Share-based Compensation (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "d_2021-01-04_2021-01-04_TitleOfIndividualAxis-ExecutivesAndKeyPersonnelMember", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "d_2021-01-01_2021-03-31", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Note 5 - Share-based Compensation - Black-Scholes Options Pricing Model (Details)", "role": "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-blackscholes-options-pricing-model-details", "shortName": "Note 5 - Share-based Compensation - Black-Scholes Options Pricing Model (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "d_2021-01-01_2021-03-31", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)", "role": "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals", "shortName": "Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "i_2020-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - Note 5 - Share-based Compensation - Stock Option Activity (Details)", "role": "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-stock-option-activity-details", "shortName": "Note 5 - Share-based Compensation - Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "d_2021-01-01_2021-03-31", "decimals": null, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "d_2021-01-01_2021-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "030 - Disclosure - Note 5 - Share-based Compensation - Noncash Stock Option Compensation (Details)", "role": "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-noncash-stock-option-compensation-details", "shortName": "Note 5 - Share-based Compensation - Noncash Stock Option Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "d_2021-01-01_2021-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "d_2021-01-01_2021-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "031 - Disclosure - Note 6 - Shareholders' Equity (Details Textual)", "role": "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-details-textual", "shortName": "Note 6 - Shareholders' Equity (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "i_2020-08-13", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPerShare", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "i_2020-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "032 - Disclosure - Note 6 - Shareholders' Equity - Schedule of Stockholders Equity (Details)", "role": "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-schedule-of-stockholders-equity-details", "shortName": "Note 6 - Shareholders' Equity - Schedule of Stockholders Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "d_2021-01-01_2021-03-31", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueIssuedForServices", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "d_2021-01-01_2021-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Consolidated Statements of Operations (Unaudited)", "role": "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited", "shortName": "Consolidated Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "d_2021-01-01_2021-03-31", "decimals": "INF", "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Consolidated Statements of Stockholders' Equity (Unaudited)", "role": "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-stockholders-equity-unaudited", "shortName": "Consolidated Statements of Stockholders' Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember", "decimals": "INF", "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "d_2021-01-01_2021-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Consolidated Statements of Cash Flows (Unaudited)", "role": "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited", "shortName": "Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "d_2021-01-01_2021-03-31", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "d_2021-01-01_2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "006 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies", "role": "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies", "shortName": "Note 1 - Organization and Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "d_2021-01-01_2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "d_2021-01-01_2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "007 - Disclosure - Note 2 - Cash, Cash Equivalent, and Investments", "role": "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-", "shortName": "Note 2 - Cash, Cash Equivalent, and Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "d_2021-01-01_2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "d_2021-01-01_2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Note 3 - Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately-held Companies", "role": "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies", "shortName": "Note 3 - Research and Collaboration Agreements, Sublicense Agreements, and Investments in Privately-held Companies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "dyai20210331_10q.htm", "contextRef": "d_2021-01-01_2021-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 52, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-document-and-entity-information" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-document-and-entity-information" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-document-and-entity-information" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r360" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r361" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-document-and-entity-information" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-", "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited", "http://www.dyadic.com/20210331/role/statement-document-and-entity-information", "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies", "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details", "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details", "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details", "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual", "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details", "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details", "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables", "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-", "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-details-textual", "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details", "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-tables", "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies", "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual", "http://www.dyadic.com/20210331/role/statement-note-4-commitments-and-contingencies-", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-blackscholes-options-pricing-model-details", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-noncash-stock-option-compensation-details", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-stock-option-activity-details", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-tables", "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-", "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-details-textual", "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-schedule-of-stockholders-equity-details", "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-tables", "http://www.dyadic.com/20210331/role/statement-note-7-subsequent-events-", "http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-document-and-entity-information" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r362" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-", "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited", "http://www.dyadic.com/20210331/role/statement-document-and-entity-information", "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies", "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details", "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details", "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details", "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual", "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details", "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details", "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables", "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-", "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-details-textual", "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details", "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-tables", "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies", "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual", "http://www.dyadic.com/20210331/role/statement-note-4-commitments-and-contingencies-", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-blackscholes-options-pricing-model-details", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-noncash-stock-option-compensation-details", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-stock-option-activity-details", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-tables", "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-", "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-details-textual", "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-schedule-of-stockholders-equity-details", "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-tables", "http://www.dyadic.com/20210331/role/statement-note-7-subsequent-events-", "http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r358" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "dyai_AccountsPayablePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts payable.", "label": "Accounts Payable, Policy [Policy Text Block]" } } }, "localname": "AccountsPayablePolicyPolicyTextBlock", "nsuri": "http://www.dyadic.com/20210331", "presentation": [ "http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "dyai_AccruedExpensesPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accrued expenses.", "label": "Accrued Expenses, Policy [Policy Text Block]" } } }, "localname": "AccruedExpensesPolicyPolicyTextBlock", "nsuri": "http://www.dyadic.com/20210331", "presentation": [ "http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "dyai_AccruedResearchAndDevelopmentInProcessCurrent": { "auth_ref": [], "calculation": { "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details": { "order": 0.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents current accrued research and development in process.", "label": "dyai_AccruedResearchAndDevelopmentInProcessCurrent", "verboseLabel": "Research and development expenses" } } }, "localname": "AccruedResearchAndDevelopmentInProcessCurrent", "nsuri": "http://www.dyadic.com/20210331", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "dyai_AlphazymeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information related to Alphazyme.", "label": "Alphazyme [Member]" } } }, "localname": "AlphazymeMember", "nsuri": "http://www.dyadic.com/20210331", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies", "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual" ], "xbrltype": "domainItemType" }, "dyai_BDIHoldingsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information related to BDI Holdings.", "label": "BDI Holdings [Member]" } } }, "localname": "BDIHoldingsMember", "nsuri": "http://www.dyadic.com/20210331", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies", "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual" ], "xbrltype": "domainItemType" }, "dyai_BDIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information regarding Biotechnology Developments for Industry, S.L., a Spanish biotechnology company.", "label": "BDI [Member]" } } }, "localname": "BDIMember", "nsuri": "http://www.dyadic.com/20210331", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies", "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual" ], "xbrltype": "domainItemType" }, "dyai_CashCashEquivalentsAndInvestmentsFairValue": { "auth_ref": [], "calculation": { "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents fair value of cash, cash equivalents and investments.", "label": "dyai_CashCashEquivalentsAndInvestmentsFairValue", "totalLabel": "Total, fair value" } } }, "localname": "CashCashEquivalentsAndInvestmentsFairValue", "nsuri": "http://www.dyadic.com/20210331", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details" ], "xbrltype": "monetaryItemType" }, "dyai_CollaborativeArrangementDurationOfAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents duration of agreement for collaborative agreement.", "label": "dyai_CollaborativeArrangementDurationOfAgreement", "terseLabel": "Collaborative Arrangement, Duration Of Agreement (Year)" } } }, "localname": "CollaborativeArrangementDurationOfAgreement", "nsuri": "http://www.dyadic.com/20210331", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual" ], "xbrltype": "durationItemType" }, "dyai_CollaborativeArrangementEquityInterestAcquired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents equity interest acquired for collaborative agreement.", "label": "dyai_CollaborativeArrangementEquityInterestAcquired", "terseLabel": "Collaborative Arrangement, Equity Interest Acquired" } } }, "localname": "CollaborativeArrangementEquityInterestAcquired", "nsuri": "http://www.dyadic.com/20210331", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual" ], "xbrltype": "percentItemType" }, "dyai_CollaborativeArrangementMaximumObligationForResearchAndDevelopment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents maximum obligation for research and development for collaborative agreement.", "label": "dyai_CollaborativeArrangementMaximumObligationForResearchAndDevelopment", "terseLabel": "Collaborative Arrangement, Maximum Obligation For Research and Development" } } }, "localname": "CollaborativeArrangementMaximumObligationForResearchAndDevelopment", "nsuri": "http://www.dyadic.com/20210331", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual" ], "xbrltype": "monetaryItemType" }, "dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents minimum obligation for research and development for collaborative agreement.", "label": "dyai_CollaborativeArrangementMinimumObligationForResearchAndDevelopment", "terseLabel": "Collaborative Arrangement, Minimum Obligation For Research and Development" } } }, "localname": "CollaborativeArrangementMinimumObligationForResearchAndDevelopment", "nsuri": "http://www.dyadic.com/20210331", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual" ], "xbrltype": "monetaryItemType" }, "dyai_CollaborativeArrangementNumberOfSharesToBeReceived": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents number of shares to be received for collaborative arrangement.", "label": "dyai_CollaborativeArrangementNumberOfSharesToBeReceived", "terseLabel": "Collaborative Arrangement, Number of Shares To Be Received (in shares)" } } }, "localname": "CollaborativeArrangementNumberOfSharesToBeReceived", "nsuri": "http://www.dyadic.com/20210331", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual" ], "xbrltype": "sharesItemType" }, "dyai_CollaborativeArrangementOutstandingCommitment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents outstanding commitment for collaborative.", "label": "dyai_CollaborativeArrangementOutstandingCommitment", "terseLabel": "Collaborative Arrangement, Outstanding Commitment" } } }, "localname": "CollaborativeArrangementOutstandingCommitment", "nsuri": "http://www.dyadic.com/20210331", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual" ], "xbrltype": "monetaryItemType" }, "dyai_CollaborativeArrangementPaymentForAdditionalDevelopmentAndCommercialization": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents payments for additional development and commercialization for collaborative arrangement.", "label": "dyai_CollaborativeArrangementPaymentForAdditionalDevelopmentAndCommercialization", "terseLabel": "Collaborative Arrangement, Payment for Additional Development and Commercialization" } } }, "localname": "CollaborativeArrangementPaymentForAdditionalDevelopmentAndCommercialization", "nsuri": "http://www.dyadic.com/20210331", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual" ], "xbrltype": "monetaryItemType" }, "dyai_CollaborativeArrangementPaymentForResearchAndDevelopmentAgreement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents payment for research and development agreement for collaborate arrangement.", "label": "dyai_CollaborativeArrangementPaymentForResearchAndDevelopmentAgreement", "terseLabel": "Collaborative Arrangement, Payment for Research and Development Agreement" } } }, "localname": "CollaborativeArrangementPaymentForResearchAndDevelopmentAgreement", "nsuri": "http://www.dyadic.com/20210331", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual" ], "xbrltype": "monetaryItemType" }, "dyai_CollaborativeArrangementRevenueSharingPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents percentage of revenue sharing for collaborate arrangement.", "label": "dyai_CollaborativeArrangementRevenueSharingPercentage", "terseLabel": "Collaborative Arrangement, Revenue Sharing, Percentage" } } }, "localname": "CollaborativeArrangementRevenueSharingPercentage", "nsuri": "http://www.dyadic.com/20210331", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual" ], "xbrltype": "percentItemType" }, "dyai_CollaborativeArrangementVestingPercentages": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents vesting percentage for collaborative arrangement.", "label": "dyai_CollaborativeArrangementVestingPercentages", "terseLabel": "Collaborative Arrangement, Vesting Percentages" } } }, "localname": "CollaborativeArrangementVestingPercentages", "nsuri": "http://www.dyadic.com/20210331", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual" ], "xbrltype": "percentItemType" }, "dyai_ConcentrationRiskNumberOfCustomers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of major customers accounting for 10% or more of the specified concentration risk benchmark, which includes, but not limited to, sales revenue, accounts receivable, etc.", "label": "dyai_ConcentrationRiskNumberOfCustomers", "terseLabel": "Concentration Risk, Number of Customers" } } }, "localname": "ConcentrationRiskNumberOfCustomers", "nsuri": "http://www.dyadic.com/20210331", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "integerItemType" }, "dyai_ConcentrationRiskNumberOfSuppliers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of suppliers accounting for 10% or more of the specified concentration risk benchmark.", "label": "dyai_ConcentrationRiskNumberOfSuppliers", "terseLabel": "Concentration Risk, Number of Suppliers" } } }, "localname": "ConcentrationRiskNumberOfSuppliers", "nsuri": "http://www.dyadic.com/20210331", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "integerItemType" }, "dyai_ConsultantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information related to consultant.", "label": "Consultant [Member]" } } }, "localname": "ConsultantMember", "nsuri": "http://www.dyadic.com/20210331", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "dyai_ContractResearchOrganizationsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information related to contract research organizations, or to research services purchased from such organizations.", "label": "Contract Research Organizations [Member]" } } }, "localname": "ContractResearchOrganizationsMember", "nsuri": "http://www.dyadic.com/20210331", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies", "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "dyai_ContractorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information related to contractor.", "label": "Contractor [Member]" } } }, "localname": "ContractorMember", "nsuri": "http://www.dyadic.com/20210331", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "dyai_DebtSecuritiesHeldtomaturityPremiumPaidOnPurchase": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents premium paid on purchase for debt securities held-to-maturity.", "label": "dyai_DebtSecuritiesHeldtomaturityPremiumPaidOnPurchase", "terseLabel": "Debt Securities, Held-to-maturity, Premium Paid on Purchase" } } }, "localname": "DebtSecuritiesHeldtomaturityPremiumPaidOnPurchase", "nsuri": "http://www.dyadic.com/20210331", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-details-textual" ], "xbrltype": "monetaryItemType" }, "dyai_DeferredTaxAssetsValuationAllowanceCoveragePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percent after allocation of valuation allowance coverage of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "dyai_DeferredTaxAssetsValuationAllowanceCoveragePercent", "terseLabel": "Deferred Tax Assets, Valuation Allowance Coverage, Percent" } } }, "localname": "DeferredTaxAssetsValuationAllowanceCoveragePercent", "nsuri": "http://www.dyadic.com/20210331", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "percentItemType" }, "dyai_EmployeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information related to employees.", "label": "Employees [Member]" } } }, "localname": "EmployeesMember", "nsuri": "http://www.dyadic.com/20210331", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "dyai_ExecutivesAndKeyPersonnelMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents executives and key personnel.", "label": "Executives and Key Personnel [Member]" } } }, "localname": "ExecutivesAndKeyPersonnelMember", "nsuri": "http://www.dyadic.com/20210331", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "dyai_IDBiologicsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents ID Biologics Inc.", "label": "ID Biologics Inc [Member]" } } }, "localname": "IDBiologicsIncMember", "nsuri": "http://www.dyadic.com/20210331", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies", "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual" ], "xbrltype": "domainItemType" }, "dyai_ImpactOfCOVID19PolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for impact of COVID-19.", "label": "Impact of COVID-19, Policy [Policy Text Block]" } } }, "localname": "ImpactOfCOVID19PolicyPolicyTextBlock", "nsuri": "http://www.dyadic.com/20210331", "presentation": [ "http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "dyai_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents ownership percentage by noncontrolling owners for noncontrolling interest.", "label": "dyai_NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners", "terseLabel": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners" } } }, "localname": "NoncontrollingInterestOwnershipPercentageByNoncontrollingOwners", "nsuri": "http://www.dyadic.com/20210331", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual" ], "xbrltype": "percentItemType" }, "dyai_NoteToFinancialStatementDetailsTextual": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "localname": "NoteToFinancialStatementDetailsTextual", "nsuri": "http://www.dyadic.com/20210331", "xbrltype": "stringItemType" }, "dyai_NotesToFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "localname": "NotesToFinancialStatementsAbstract", "nsuri": "http://www.dyadic.com/20210331", "xbrltype": "stringItemType" }, "dyai_NovovetMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information related to Novovet.", "label": "Novovet [Member]" } } }, "localname": "NovovetMember", "nsuri": "http://www.dyadic.com/20210331", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies", "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual" ], "xbrltype": "domainItemType" }, "dyai_NumberOfResearchOrganizations": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of research organizations through which the entity operates.", "label": "dyai_NumberOfResearchOrganizations", "terseLabel": "Number of Research Organizations" } } }, "localname": "NumberOfResearchOrganizations", "nsuri": "http://www.dyadic.com/20210331", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "integerItemType" }, "dyai_OneCROMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information regarding one contract research organization.", "label": "One CRO [Member]" } } }, "localname": "OneCROMember", "nsuri": "http://www.dyadic.com/20210331", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies", "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "dyai_OpenMarketSaleAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information related to open market for sale agreement.", "label": "Open Market Sale Agreement [Member]" } } }, "localname": "OpenMarketSaleAgreementMember", "nsuri": "http://www.dyadic.com/20210331", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-", "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "dyai_OwnershipPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of ownership.", "label": "dyai_OwnershipPercentage", "terseLabel": "Ownership Percentage" } } }, "localname": "OwnershipPercentage", "nsuri": "http://www.dyadic.com/20210331", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual" ], "xbrltype": "percentItemType" }, "dyai_PrepaidExpensesAndOtherCurrentAssetsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for prepaid expenses and other current assets.", "label": "Prepaid Expenses and Other Current Assets, Policy [Policy Text Block]" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsPolicyPolicyTextBlock", "nsuri": "http://www.dyadic.com/20210331", "presentation": [ "http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "dyai_PrepaidResearchAndDevelopmentInProcessCurrent": { "auth_ref": [], "calculation": { "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the current amount of prepaid research and development in process as of the balance sheet date.", "label": "Investment in Alphazyme" } } }, "localname": "PrepaidResearchAndDevelopmentInProcessCurrent", "nsuri": "http://www.dyadic.com/20210331", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "monetaryItemType" }, "dyai_ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther": { "auth_ref": [], "calculation": { "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details": { "order": 2.0, "parentTag": "dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents facilities, overhead and other for research and development expense.", "label": "Facilities, overhead and other" } } }, "localname": "ResearchAndDevelopmentExpenseFacilitiesOverheadAndOther", "nsuri": "http://www.dyadic.com/20210331", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details" ], "xbrltype": "monetaryItemType" }, "dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty": { "auth_ref": [], "calculation": { "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents research and development expense including related party.", "label": "dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty", "totalLabel": "Research And Development Expense, Including Related Party" } } }, "localname": "ResearchAndDevelopmentExpenseIncludingRelatedParty", "nsuri": "http://www.dyadic.com/20210331", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details" ], "xbrltype": "monetaryItemType" }, "dyai_ResearchAndDevelopmentExpenseOutsideContractedServices": { "auth_ref": [], "calculation": { "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details": { "order": 1.0, "parentTag": "dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents outside contracted services for research and development expense.", "label": "Outside contracted services" } } }, "localname": "ResearchAndDevelopmentExpenseOutsideContractedServices", "nsuri": "http://www.dyadic.com/20210331", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details" ], "xbrltype": "monetaryItemType" }, "dyai_ResearchAndDevelopmentExpensePersonnelRelatedCosts": { "auth_ref": [], "calculation": { "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details": { "order": 0.0, "parentTag": "dyai_ResearchAndDevelopmentExpenseIncludingRelatedParty", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents personnel related costs for research and development expenses.", "label": "Personnel related costs" } } }, "localname": "ResearchAndDevelopmentExpensePersonnelRelatedCosts", "nsuri": "http://www.dyadic.com/20210331", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details" ], "xbrltype": "monetaryItemType" }, "dyai_ResearchAndDevelopmentInProcessCurrent": { "auth_ref": [], "calculation": { "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details": { "order": 2.0, "parentTag": "us-gaap_AccountsPayableCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents current research and development in process.", "label": "dyai_ResearchAndDevelopmentInProcessCurrent", "terseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentInProcessCurrent", "nsuri": "http://www.dyadic.com/20210331", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details" ], "xbrltype": "monetaryItemType" }, "dyai_ResearchServicesAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information related to research services agreement.", "label": "Research Services Agreement [Member]" } } }, "localname": "ResearchServicesAgreementMember", "nsuri": "http://www.dyadic.com/20210331", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies", "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual" ], "xbrltype": "domainItemType" }, "dyai_ResearchServicesPurchased": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the amount of research services purchased during the period.", "label": "dyai_ResearchServicesPurchased", "terseLabel": "Research Services Purchased" } } }, "localname": "ResearchServicesPurchased", "nsuri": "http://www.dyadic.com/20210331", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "dyai_SaleOfStockAuthorizedOfferingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents authorized offering amount of sale of stock.", "label": "dyai_SaleOfStockAuthorizedOfferingAmount", "terseLabel": "Sale of Stock, Authorized Offering Amount" } } }, "localname": "SaleOfStockAuthorizedOfferingAmount", "nsuri": "http://www.dyadic.com/20210331", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "dyai_SaleOfStockPercentageOfCommissionsPaidOfGrossProceedsFromSaleOfEachShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents percentage of commission paid on gross proceeds from sale of each share", "label": "dyai_SaleOfStockPercentageOfCommissionsPaidOfGrossProceedsFromSaleOfEachShare", "terseLabel": "Sale of Stock, Percentage of Commissions Paid of Gross Proceeds From Sale Of Each Share" } } }, "localname": "SaleOfStockPercentageOfCommissionsPaidOfGrossProceedsFromSaleOfEachShare", "nsuri": "http://www.dyadic.com/20210331", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-details-textual" ], "xbrltype": "percentItemType" }, "dyai_SaleOfStockReimbursableLegalExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents reimbursable legal expense for sale of stock.", "label": "dyai_SaleOfStockReimbursableLegalExpenses", "terseLabel": "Sale of Stock, Reimbursable Legal Expenses" } } }, "localname": "SaleOfStockReimbursableLegalExpenses", "nsuri": "http://www.dyadic.com/20210331", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "dyai_SaleOfStockTerminationAmountUnderAgreement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents termination amount under agreement for sale of stock.", "label": "dyai_SaleOfStockTerminationAmountUnderAgreement", "terseLabel": "Sale of Stock, Termination Amount Under Agreement" } } }, "localname": "SaleOfStockTerminationAmountUnderAgreement", "nsuri": "http://www.dyadic.com/20210331", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "dyai_ScheduleOfResearchAndDevelopmentCostsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of research and development costs.", "label": "Schedule of Research and Development Costs [Table Text Block]" } } }, "localname": "ScheduleOfResearchAndDevelopmentCostsTableTextBlock", "nsuri": "http://www.dyadic.com/20210331", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables" ], "xbrltype": "textBlockItemType" }, "dyai_ServiceAgreementToPerformResearchProjectMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information regarding a service agreement to perform a research project.", "label": "Service Agreement to Perform Research Project [Member]" } } }, "localname": "ServiceAgreementToPerformResearchProjectMember", "nsuri": "http://www.dyadic.com/20210331", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies", "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual" ], "xbrltype": "domainItemType" }, "dyai_ServiceFrameworkAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information related to service framework agreement.", "label": "Service Framework Agreement [Member]" } } }, "localname": "ServiceFrameworkAgreementMember", "nsuri": "http://www.dyadic.com/20210331", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies", "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual" ], "xbrltype": "domainItemType" }, "dyai_SharebasedCompensationAwardTrancheTwoThroughFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents shares-based compensation award tranche two through five.", "label": "Share-based Compensation Award Tranche Two through Five [Member]" } } }, "localname": "SharebasedCompensationAwardTrancheTwoThroughFiveMember", "nsuri": "http://www.dyadic.com/20210331", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "dyai_ShortTermCorporateBondsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents short-term corporate bonds.", "label": "Short-term Corporate Bonds [Member]" } } }, "localname": "ShortTermCorporateBondsMember", "nsuri": "http://www.dyadic.com/20210331", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details" ], "xbrltype": "domainItemType" }, "dyai_The2011PlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information regarding the 2011 plan.", "label": "The 2011 Plan [Member]" } } }, "localname": "The2011PlanMember", "nsuri": "http://www.dyadic.com/20210331", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "dyai_ThreeCROsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information regarding three contract research organizations.", "label": "Three CROs [Member]" } } }, "localname": "ThreeCROsMember", "nsuri": "http://www.dyadic.com/20210331", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies", "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "dyai_VLPbioMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information related to VL Pbio.", "label": "VL Pbio Member" } } }, "localname": "VLPbioMember", "nsuri": "http://www.dyadic.com/20210331", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies", "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual" ], "xbrltype": "domainItemType" }, "dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 1 - Organization and Summary of Significant Accounting Policies - Accounts Payable (Details)" } } }, "localname": "statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details", "nsuri": "http://www.dyadic.com/20210331", "xbrltype": "stringItemType" }, "dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 1 - Organization and Summary of Significant Accounting Policies - Accounts Receivable (Details)" } } }, "localname": "statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details", "nsuri": "http://www.dyadic.com/20210331", "xbrltype": "stringItemType" }, "dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 1 - Organization and Summary of Significant Accounting Policies - Accrued Expenses (Details)" } } }, "localname": "statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details", "nsuri": "http://www.dyadic.com/20210331", "xbrltype": "stringItemType" }, "dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 1 - Organization and Summary of Significant Accounting Policies - Prepaid Expenses and Other Current Assets (Details)" } } }, "localname": "statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details", "nsuri": "http://www.dyadic.com/20210331", "xbrltype": "stringItemType" }, "dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 1 - Organization and Summary of Significant Accounting Policies - Research and Development Costs (Details)" } } }, "localname": "statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details", "nsuri": "http://www.dyadic.com/20210331", "xbrltype": "stringItemType" }, "dyai_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 1 - Organization and Summary of Significant Accounting Policies" } } }, "localname": "statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-tables", "nsuri": "http://www.dyadic.com/20210331", "xbrltype": "stringItemType" }, "dyai_statement-statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 2 - Cash, Cash Equivalent, and Investments - Major Security Type (Details)" } } }, "localname": "statement-statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details", "nsuri": "http://www.dyadic.com/20210331", "xbrltype": "stringItemType" }, "dyai_statement-statement-note-2-cash-cash-equivalent-and-investments-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 2 - Cash, Cash Equivalent, and Investments" } } }, "localname": "statement-statement-note-2-cash-cash-equivalent-and-investments-tables", "nsuri": "http://www.dyadic.com/20210331", "xbrltype": "stringItemType" }, "dyai_statement-statement-note-5-sharebased-compensation-blackscholes-options-pricing-model-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 5 - Share-based Compensation - Black-Scholes Options Pricing Model (Details)" } } }, "localname": "statement-statement-note-5-sharebased-compensation-blackscholes-options-pricing-model-details", "nsuri": "http://www.dyadic.com/20210331", "xbrltype": "stringItemType" }, "dyai_statement-statement-note-5-sharebased-compensation-noncash-stock-option-compensation-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 5 - Share-based Compensation - Noncash Stock Option Compensation (Details)" } } }, "localname": "statement-statement-note-5-sharebased-compensation-noncash-stock-option-compensation-details", "nsuri": "http://www.dyadic.com/20210331", "xbrltype": "stringItemType" }, "dyai_statement-statement-note-5-sharebased-compensation-stock-option-activity-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 5 - Share-based Compensation - Stock Option Activity (Details)" } } }, "localname": "statement-statement-note-5-sharebased-compensation-stock-option-activity-details", "nsuri": "http://www.dyadic.com/20210331", "xbrltype": "stringItemType" }, "dyai_statement-statement-note-5-sharebased-compensation-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 5 - Share-based Compensation" } } }, "localname": "statement-statement-note-5-sharebased-compensation-tables", "nsuri": "http://www.dyadic.com/20210331", "xbrltype": "stringItemType" }, "dyai_statement-statement-note-6-shareholders-equity-schedule-of-stockholders-equity-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 6 - Shareholders' Equity - Schedule of Stockholders Equity (Details)" } } }, "localname": "statement-statement-note-6-shareholders-equity-schedule-of-stockholders-equity-details", "nsuri": "http://www.dyadic.com/20210331", "xbrltype": "stringItemType" }, "dyai_statement-statement-note-6-shareholders-equity-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 6 - Shareholders' Equity" } } }, "localname": "statement-statement-note-6-shareholders-equity-tables", "nsuri": "http://www.dyadic.com/20210331", "xbrltype": "stringItemType" }, "dyai_statement-statement-significant-accounting-policies-policies": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "localname": "statement-statement-significant-accounting-policies-policies", "nsuri": "http://www.dyadic.com/20210331", "xbrltype": "stringItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r108" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r36", "r60" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies", "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual" ], "xbrltype": "stringItemType" }, "srt_DirectorMember": { "auth_ref": [ "r108" ], "lang": { "en-us": { "role": { "label": "Director [Member]" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies", "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r187", "r188", "r273", "r274", "r275", "r276", "r277", "r278", "r297", "r319", "r321" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies", "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-blackscholes-options-pricing-model-details" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r187", "r188", "r273", "r274", "r275", "r276", "r277", "r278", "r297", "r319", "r321" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies", "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-blackscholes-options-pricing-model-details", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies", "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies", "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r178", "r187", "r188", "r273", "r274", "r275", "r276", "r277", "r278", "r297", "r319", "r321" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies", "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-blackscholes-options-pricing-model-details", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r178", "r187", "r188", "r273", "r274", "r275", "r276", "r277", "r278", "r297", "r319", "r321" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies", "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-blackscholes-options-pricing-model-details", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies", "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r132" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies", "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual" ], "xbrltype": "stringItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r105", "r106", "r174", "r176", "r320", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies", "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r105", "r106", "r174", "r176", "r320", "r346", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies", "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r108", "r263" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis": { "auth_ref": [ "r33" ], "lang": { "en-us": { "role": { "documentation": "Information by billing status of receivables.", "label": "Billing Status, Type [Axis]" } } }, "localname": "AccountsNotesLoansAndFinancingReceivablesByBillingStatusTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r26" ], "calculation": { "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable", "totalLabel": "Accounts Payable, Current, Total" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-", "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableCurrentAndNoncurrent": { "auth_ref": [ "r306", "r316" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "us-gaap_AccountsPayableCurrentAndNoncurrent", "terseLabel": "Accounts Payable, Total" } } }, "localname": "AccountsPayableCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableMember": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Obligations incurred and payable to vendors for goods and services received.", "label": "Accounts Payable [Member]" } } }, "localname": "AccountsPayableMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies", "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableOtherCurrent": { "auth_ref": [ "r10", "r26" ], "calculation": { "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details": { "order": 0.0, "parentTag": "us-gaap_AccountsPayableCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer.", "label": "us-gaap_AccountsPayableOtherCurrent", "terseLabel": "Other" } } }, "localname": "AccountsPayableOtherCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies", "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNet": { "auth_ref": [ "r16", "r310" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.", "label": "us-gaap_AccountsReceivableNet", "terseLabel": "Accounts Receivable, after Allowance for Credit Loss, Total" } } }, "localname": "AccountsReceivableNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r2", "r16", "r109", "r110" ], "calculation": { "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-", "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r27" ], "calculation": { "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses", "totalLabel": "Accrued Liabilities, Current, Total" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-", "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r9", "r10", "r27" ], "calculation": { "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details": { "order": 1.0, "parentTag": "us-gaap_AccountsPayableCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Legal expenses" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r17", "r217" ], "calculation": { "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r62", "r63", "r64", "r214", "r215", "r216" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-stockholders-equity-unaudited", "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-schedule-of-stockholders-equity-details" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r189", "r191", "r220", "r221" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-stockholders-equity-unaudited", "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-schedule-of-stockholders-equity-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r191", "r211", "r219" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "us-gaap_AllocatedShareBasedCompensationExpense", "verboseLabel": "Stock-based compensation" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-noncash-stock-option-compensation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "auth_ref": [ "r115", "r136", "r138", "r139" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable.", "label": "us-gaap_AllowanceForDoubtfulAccountsReceivable", "terseLabel": "Accounts Receivable, Allowance for Credit Loss, Ending Balance" } } }, "localname": "AllowanceForDoubtfulAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r76" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies", "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r59", "r94", "r97", "r102", "r134", "r239", "r241", "r249", "r303", "r311" ], "calculation": { "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r6", "r8", "r35", "r59", "r134", "r239", "r241", "r249" ], "calculation": { "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_AssetsCurrent", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-current assets:" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r192", "r212" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BilledRevenuesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Billed amounts due for services rendered or products shipped. This element is distinct from Billed contracts receivables because this is based on noncontract transactions.", "label": "Billed Revenues [Member]" } } }, "localname": "BilledRevenuesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r61", "r90" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and accounting policies concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Business Description and Accounting Policies [Text Block]" } } }, "localname": "BusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalizedContractCostAxis": { "auth_ref": [ "r151" ], "lang": { "en-us": { "role": { "documentation": "Information by cost capitalized in obtaining or fulfilling contract with customer.", "label": "Capitalized Contract Cost [Axis]" } } }, "localname": "CapitalizedContractCostAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies", "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_CapitalizedContractCostDomain": { "auth_ref": [ "r151" ], "lang": { "en-us": { "role": { "documentation": "Cost capitalized in obtaining and fulfilling contract with customer.", "label": "Capitalized Contract Cost [Domain]" } } }, "localname": "CapitalizedContractCostDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies", "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis": { "auth_ref": [ "r299", "r300", "r301" ], "lang": { "en-us": { "role": { "documentation": "Information by project.", "label": "Project [Axis]" } } }, "localname": "CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies", "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_Cash": { "auth_ref": [ "r24", "r329", "r330" ], "calculation": { "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details": { "order": 0.0, "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash, adjusted cost" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r1", "r24", "r53" ], "calculation": { "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details": { "order": 0.0, "parentTag": "us-gaap_InvestmentsAndCash", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents", "totalLabel": "Cash and cash equivalents, adjusted cost" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-", "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details": { "order": 1.0, "parentTag": "dyai_CashCashEquivalentsAndInvestmentsFairValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and cash equivalent, fair value" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r13", "r54", "r56" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": { "auth_ref": [ "r129" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).", "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]" } } }, "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r49", "r53", "r55" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r49", "r254" ], "calculation": { "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "Net decrease in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashMember": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.", "label": "Cash [Member]" } } }, "localname": "CashMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r235", "r236", "r238" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r29", "r156", "r307", "r314" ], "calculation": { "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and contingencies (Note 4)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r153", "r154", "r155", "r157" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-4-commitments-and-contingencies-" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r30" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance", "terseLabel": "Common Stock, Capital Shares Reserved for Future Issuance (in shares)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r62", "r63" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-stockholders-equity-unaudited", "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-", "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-details-textual", "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-schedule-of-stockholders-equity-details" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value (in dollars per share)", "terseLabel": "Common Stock, Par or Stated Value Per Share (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r15", "r158" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r15" ], "calculation": { "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $.001 par value: Authorized shares - 100,000,000; issued shares - 39,807,659 and 39,747,659, outstanding shares - 27,554,157 and 27,494,157 as of March 31, 2021 and December 31, 2020, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r85", "r86", "r107", "r247", "r248" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies", "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r85", "r86", "r107", "r247", "r248", "r328" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies", "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r85", "r86", "r107", "r247", "r248", "r328" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies", "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r81", "r309" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r85", "r86", "r107", "r247", "r248" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "us-gaap_ConcentrationRiskPercentage1", "terseLabel": "Concentration Risk, Percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r85", "r86", "r107", "r247", "r248" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies", "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r163", "r164", "r175" ], "calculation": { "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred research and development obligations" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateBondSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).", "label": "Corporate Bond Securities [Member]" } } }, "localname": "CorporateBondSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r179", "r186", "r327" ], "lang": { "en-us": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-", "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r43", "r298" ], "calculation": { "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Costs of research and development revenue", "terseLabel": "Cost of Goods and Services Sold, Total" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited", "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r42" ], "calculation": { "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "us-gaap_CostsAndExpenses", "totalLabel": "Total costs and expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs and expenses:" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r84", "r107" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies", "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "auth_ref": [ "r25" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.", "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r230" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "terseLabel": "Deferred Tax Assets, Net, Total" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r222" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "localname": "DisclosureTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies", "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-", "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies", "http://www.dyadic.com/20210331/role/statement-note-4-commitments-and-contingencies-", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-", "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-", "http://www.dyadic.com/20210331/role/statement-note-7-subsequent-events-" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r75" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Basic and diluted net loss per common share (in dollars per share)" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r56", "r76", "r77" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r254" ], "calculation": { "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of exchange rate changes on cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r27" ], "calculation": { "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee wages and benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r210" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r62", "r63", "r64", "r66", "r71", "r73", "r78", "r135", "r158", "r159", "r214", "r215", "r216", "r233", "r234", "r255", "r256", "r257", "r258", "r259", "r260", "r322", "r323", "r324" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-stockholders-equity-unaudited", "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-", "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-details-textual", "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-schedule-of-stockholders-equity-details" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r132" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "us-gaap_EquityMethodInvestmentOwnershipPercentage", "terseLabel": "Equity Method Investment, Ownership Percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "auth_ref": [ "r130" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security without readily determinable fair value.", "label": "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "terseLabel": "Equity Securities without Readily Determinable Fair Value, Amount" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock": { "auth_ref": [ "r131" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment in equity security without readily determinable fair value, which does not qualify for practical expedient to estimate fair value using net asset value per share. Includes, but is not limited to, information considered for determining upward and downward adjustment from observable price change.", "label": "Equity Securities without Readily Determinable Fair Value [Policy Text Block]" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValuePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r245" ], "lang": { "en-us": { "role": { "documentation": "Class of asset.", "label": "Asset Class [Domain]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r243", "r246" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r244", "r270", "r271", "r272" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r179", "r180", "r185", "r186", "r244", "r270" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r179", "r180", "r185", "r186", "r244", "r271" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r270", "r271", "r272" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r124", "r128", "r137", "r140", "r141", "r142", "r143", "r144", "r145", "r146", "r147", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-", "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-details-textual", "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details" ], "xbrltype": "stringItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r250", "r251", "r252", "r253" ], "calculation": { "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax", "negatedLabel": "Foreign currency exchange loss (gain), net" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossRealized": { "auth_ref": [ "r252", "r253" ], "calculation": { "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction realized gain (loss) recognized in the income statement.", "label": "us-gaap_ForeignCurrencyTransactionGainLossRealized", "negatedLabel": "Foreign currency exchange loss (gain), net" } } }, "localname": "ForeignCurrencyTransactionGainLossRealized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r56", "r262" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r44" ], "calculation": { "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited": { "order": 0.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r41" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-noncash-stock-option-compensation-details" ], "xbrltype": "domainItemType" }, "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain": { "auth_ref": [ "r122", "r126" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity).", "label": "Gross Unrealized Holding Gains" } } }, "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss": { "auth_ref": [ "r123", "r127" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity).", "label": "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss", "negatedLabel": "Gross Unrealized Holding Losses" } } }, "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_HeldToMaturitySecuritiesCurrent": { "auth_ref": [ "r120" ], "calculation": { "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details": { "order": 1.0, "parentTag": "us-gaap_InvestmentsAndCash", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at amortized cost (held-to-maturity), classified as current.", "label": "Short-term investment securities" } } }, "localname": "HeldToMaturitySecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-", "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_HeldToMaturitySecuritiesFairValue": { "auth_ref": [ "r121", "r125", "r305" ], "calculation": { "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details": { "order": 0.0, "parentTag": "dyai_CashCashEquivalentsAndInvestmentsFairValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity).", "label": "Corporate Bonds, fair value" } } }, "localname": "HeldToMaturitySecuritiesFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r152" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-noncash-stock-option-compensation-details" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-noncash-stock-option-compensation-details" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r39", "r56", "r225", "r226", "r228", "r229", "r231", "r232", "r347" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r51" ], "calculation": { "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "us-gaap_IncreaseDecreaseInAccountsPayable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r51" ], "calculation": { "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "us-gaap_IncreaseDecreaseInAccountsReceivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet": { "auth_ref": [ "r51" ], "calculation": { "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.", "label": "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet", "negatedLabel": "Interest receivable" } } }, "localname": "IncreaseDecreaseInAccruedInterestReceivableNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r51" ], "calculation": { "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "us-gaap_IncreaseDecreaseInAccruedLiabilities", "terseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r51" ], "calculation": { "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "us-gaap_IncreaseDecreaseInContractWithCustomerLiability", "terseLabel": "Deferred research and development obligation" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r51" ], "calculation": { "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "auth_ref": [], "calculation": { "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of nonoperating interest income (expense).", "label": "Interest income" } } }, "localname": "InterestIncomeExpenseNonoperatingNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestReceivableCurrent": { "auth_ref": [ "r34" ], "calculation": { "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.", "label": "Interest receivable" } } }, "localname": "InterestReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeAmortizationOfPremium": { "auth_ref": [ "r45" ], "calculation": { "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization of purchase premium on nonoperating securities.", "label": "Amortization of held-to-maturity securities, net" } } }, "localname": "InvestmentIncomeAmortizationOfPremium", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r133", "r318" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment, Policy [Policy Text Block]" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentTypeAxis": { "auth_ref": [ "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345" ], "lang": { "en-us": { "role": { "documentation": "Information by type of investments.", "label": "Investment Type [Axis]" } } }, "localname": "InvestmentTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentTypeCategorizationMember": { "auth_ref": [ "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345" ], "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value.", "label": "Investments [Domain]" } } }, "localname": "InvestmentTypeCategorizationMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details" ], "xbrltype": "domainItemType" }, "us-gaap_InvestmentsAndCash": { "auth_ref": [ "r315" ], "calculation": { "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of investments and unrestricted cash as of the balance sheet date.", "label": "us-gaap_InvestmentsAndCash", "totalLabel": "Total, adjusted" } } }, "localname": "InvestmentsAndCash", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r21", "r59", "r134", "r249", "r304", "r313" ], "calculation": { "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r28", "r59", "r134", "r240", "r241", "r242", "r249" ], "calculation": { "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "us-gaap_LiabilitiesCurrent", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "stringItemType" }, "us-gaap_MoneyMarketFundsAtCarryingValue": { "auth_ref": [], "calculation": { "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details": { "order": 1.0, "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.", "label": "Money Market Funds, adjusted cost" } } }, "localname": "MoneyMarketFundsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r179" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r49" ], "calculation": { "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r49" ], "calculation": { "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "totalLabel": "Net cash (used in) provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r49", "r50", "r52" ], "calculation": { "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r0", "r37", "r38", "r40", "r52", "r59", "r65", "r67", "r68", "r69", "r70", "r72", "r73", "r74", "r94", "r96", "r98", "r101", "r103", "r134", "r249", "r308", "r317" ], "calculation": { "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited", "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-stockholders-equity-unaudited", "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-schedule-of-stockholders-equity-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non-US [Member]" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies", "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r91" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "us-gaap_NumberOfOperatingSegments", "terseLabel": "Number of Operating Segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r94", "r96", "r98", "r101", "r103" ], "calculation": { "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "us-gaap_OperatingIncomeLoss", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r9", "r10", "r11", "r27" ], "calculation": { "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "us-gaap_OtherAccruedLiabilitiesCurrent", "verboseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r25" ], "calculation": { "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherPrepaidExpenseCurrent": { "auth_ref": [ "r3", "r7", "r150" ], "calculation": { "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details": { "order": 0.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid expenses - various" } } }, "localname": "OtherPrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireHeldToMaturitySecurities": { "auth_ref": [ "r47", "r119" ], "calculation": { "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow through purchase of long-term held-to-maturity securities.", "label": "us-gaap_PaymentsToAcquireHeldToMaturitySecurities", "negatedLabel": "Purchases of held-to-maturity investment securities" } } }, "localname": "PaymentsToAcquireHeldToMaturitySecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r192", "r212" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_PolicyTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_PolicyTextBlockAbstract", "terseLabel": "Accounting Policies" } } }, "localname": "PolicyTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r14" ], "calculation": { "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock, $.0001 par value: Authorized shares - 5,000,000; none issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r6", "r22", "r23" ], "calculation": { "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other current assets", "totalLabel": "Prepaid Expense and Other Assets, Current" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-", "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidInsurance": { "auth_ref": [ "r4", "r7", "r148", "r150" ], "calculation": { "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details": { "order": 1.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid insurance" } } }, "localname": "PrepaidInsurance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidTaxes": { "auth_ref": [ "r5", "r7", "r149", "r150" ], "calculation": { "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details": { "order": 2.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid taxes" } } }, "localname": "PrepaidTaxes", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities": { "auth_ref": [ "r46", "r119" ], "calculation": { "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from the sale or maturity of long-term held-to-maturity securities.", "label": "Proceeds from maturities of investment securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r48", "r213" ], "calculation": { "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from exercise of options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProjectMember": { "auth_ref": [ "r302" ], "lang": { "en-us": { "role": { "documentation": "Planned program of work.", "label": "Project [Domain]" } } }, "localname": "ProjectMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies", "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ReceivablesBillingStatusDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amounts due from customers (or dealers) within the next year (or operating cycle, if longer) for goods or services that have been delivered or used, but not yet paid.", "label": "Receivables Billing Status [Domain]" } } }, "localname": "ReceivablesBillingStatusDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r223", "r357" ], "calculation": { "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-noncash-stock-option-compensation-details" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r56", "r223" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r18", "r159", "r217", "r312", "r325", "r326" ], "calculation": { "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r62", "r63", "r64", "r66", "r71", "r73", "r135", "r214", "r215", "r216", "r233", "r234", "r322", "r324" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-stockholders-equity-unaudited", "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-schedule-of-stockholders-equity-details" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r92", "r93", "r95", "r99", "r100", "r104", "r105", "r107", "r173", "r174", "r298" ], "calculation": { "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Research and development revenue", "terseLabel": "Revenue from Contract with Customer, Excluding Assessed Tax, Total" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited", "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r57", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r177" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-", "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.", "label": "us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction", "terseLabel": "Sale of Stock, Percentage of Ownership after Transaction" } } }, "localname": "SaleOfStockPercentageOfOwnershipAfterTransaction", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r85", "r107" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies", "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "auth_ref": [ "r33" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]" } } }, "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.", "label": "Cash, Cash Equivalents and Investments [Table Text Block]" } } }, "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "auth_ref": [ "r204", "r205", "r206" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Activity [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r197", "r205", "r206" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r208" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": { "auth_ref": [ "r158" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.", "label": "Schedule of Stockholders Equity [Table Text Block]" } } }, "localname": "ScheduleOfStockholdersEquityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r51" ], "calculation": { "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "us-gaap_ShareBasedCompensation", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": { "auth_ref": [ "r193" ], "lang": { "en-us": { "role": { "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period (Year)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r193" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Expected stock price volatility, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-blackscholes-options-pricing-model-details" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Expected stock price volatility, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-blackscholes-options-pricing-model-details" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk-Free interest rate, maximum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-blackscholes-options-pricing-model-details" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk-Free interest rate, minimum" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-blackscholes-options-pricing-model-details" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r212" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r200" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Exercisable, shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-stock-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r200" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Exercisable, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-stock-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r203" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Expired, shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-stock-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r202" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Canceled, shares (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-stock-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Granted, shares (in shares)", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-stock-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r212" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Aggregate intrinsic value, outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-stock-option-activity-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r199", "r212" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "periodEndLabel": "Outstanding, shares (in shares)", "periodStartLabel": "Outstanding, shares (in shares)", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-stock-option-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r198" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "periodEndLabel": "Outstanding, weighted average exercise price (in dollars per share)", "periodStartLabel": "Outstanding, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-stock-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r190", "r195" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Exercised, weighted average exercise price (in dollars per share)", "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-stock-option-activity-details", "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-details-textual" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Expired, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-stock-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Canceled, weighted average exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-stock-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Granted, weighted average exercise price (in dollars per share)", "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-stock-option-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-based Payment Arrangement, Tranche One [Member]" } } }, "localname": "ShareBasedCompensationAwardTrancheOneMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies", "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-based Payment Arrangement, Tranche Three [Member]" } } }, "localname": "ShareBasedCompensationAwardTrancheThreeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies", "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share-based Payment Arrangement, Tranche Two [Member]" } } }, "localname": "ShareBasedCompensationAwardTrancheTwoMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies", "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r56", "r192", "r196" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-based Payment Arrangement [Policy Text Block]" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by supplier.", "label": "Supplier [Axis]" } } }, "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies", "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Specific identification or general nature of (for example, a construction contractor, a consulting firm) the party from whom the goods or services were or are to be received.", "label": "Supplier [Domain]" } } }, "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies", "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r194" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r209", "r218" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected life of options (Year)", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-blackscholes-options-pricing-model-details", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r212" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Aggregate intrinsic value, exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-stock-option-activity-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r212" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted-average remaining contractual term, exercisable (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-stock-option-activity-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r207" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted-average remaining contractual term, outstanding (Year)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-stock-option-activity-details" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "us-gaap_SharesOutstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-stockholders-equity-unaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r32", "r62", "r63", "r64", "r66", "r71", "r73", "r78", "r135", "r158", "r159", "r214", "r215", "r216", "r233", "r234", "r255", "r256", "r257", "r258", "r259", "r260", "r322", "r323", "r324" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-stockholders-equity-unaudited", "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-", "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-details-textual", "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-schedule-of-stockholders-equity-details" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-", "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited", "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-stockholders-equity-unaudited", "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies", "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details", "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details", "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details", "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual", "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details", "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details", "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables", "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-", "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-details-textual", "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details", "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-tables", "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies", "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual", "http://www.dyadic.com/20210331/role/statement-note-4-commitments-and-contingencies-", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-blackscholes-options-pricing-model-details", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-noncash-stock-option-compensation-details", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-stock-option-activity-details", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-tables", "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-", "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-details-textual", "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-schedule-of-stockholders-equity-details", "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-tables", "http://www.dyadic.com/20210331/role/statement-note-7-subsequent-events-", "http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r62", "r63", "r64", "r78", "r298" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-", "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-cash-flows-unaudited", "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited", "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-stockholders-equity-unaudited", "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies", "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-payable-details", "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details", "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accrued-expenses-details", "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual", "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-prepaid-expenses-and-other-current-assets-details", "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-research-and-development-costs-details", "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables", "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-", "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-details-textual", "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details", "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-tables", "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies", "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual", "http://www.dyadic.com/20210331/role/statement-note-4-commitments-and-contingencies-", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-blackscholes-options-pricing-model-details", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-noncash-stock-option-compensation-details", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-stock-option-activity-details", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-tables", "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-", "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-details-textual", "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-schedule-of-stockholders-equity-details", "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-tables", "http://www.dyadic.com/20210331/role/statement-note-7-subsequent-events-", "http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r14", "r15", "r158", "r159", "r201" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Exercise of stock options (in shares)", "negatedLabel": "Exercised, shares (in shares)", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-stockholders-equity-unaudited", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-stock-option-activity-details", "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Stock issued" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-schedule-of-stockholders-equity-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r32", "r158", "r159" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-stockholders-equity-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r15", "r19", "r20", "r59", "r117", "r134", "r249" ], "calculation": { "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "us-gaap_StockholdersEquity", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-", "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-stockholders-equity-unaudited", "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-schedule-of-stockholders-equity-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r58", "r159", "r162" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r261", "r265" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r261", "r265" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r261", "r265" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r264", "r266" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-7-subsequent-events-" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-", "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_SupplierConcentrationRiskMember": { "auth_ref": [ "r84" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services.", "label": "Supplier Concentration Risk [Member]" } } }, "localname": "SupplierConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies", "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_TableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "localname": "TableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables", "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-tables", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-tables", "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-tables" ], "xbrltype": "stringItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r111", "r112", "r113", "r114", "r116", "r118" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Accounts Receivable [Policy Text Block]" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r124", "r128", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-", "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-details-textual", "http://www.dyadic.com/20210331/role/statement-note-2-cash-cash-equivalent-and-investments-major-security-type-details" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockCommonShares": { "auth_ref": [ "r160" ], "lang": { "en-us": { "role": { "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.", "label": "Treasury stock (in shares)", "terseLabel": "Treasury Stock, Common, Shares (in shares)" } } }, "localname": "TreasuryStockCommonShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r31", "r160" ], "lang": { "en-us": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-stockholders-equity-unaudited", "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-schedule-of-stockholders-equity-details" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r31", "r160", "r161" ], "calculation": { "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "us-gaap_TreasuryStockValue", "negatedLabel": "Treasury stock, shares held at cost - 12,253,502", "terseLabel": "Treasury Stock, Value, Ending Balance" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-balance-sheets-current-period-unaudited-", "http://www.dyadic.com/20210331/role/statement-note-6-shareholders-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies", "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_UnbilledRevenuesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unbilled amounts due for services rendered or products shipped. This element is distinct from unbilled contracts receivables because this is based on noncontract transactions.", "label": "Unbilled Revenues [Member]" } } }, "localname": "UnbilledRevenuesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-accounts-receivable-details" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r224", "r227" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "us-gaap_UnrecognizedTaxBenefits", "terseLabel": "Unrecognized Tax Benefits, Ending Balance" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r79", "r80", "r82", "r83", "r87", "r88", "r89" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r212" ], "lang": { "en-us": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Axis]" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies", "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r212" ], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Domain]" } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies", "http://www.dyadic.com/20210331/role/statement-note-3-research-and-collaboration-agreements-sublicense-agreements-and-investments-in-privatelyheld-companies-details-textual", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-", "http://www.dyadic.com/20210331/role/statement-note-5-sharebased-compensation-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Basic and diluted weighted-average common shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.dyadic.com/20210331/role/statement-consolidated-statements-of-operations-unaudited" ], "xbrltype": "sharesItemType" } }, "unitCount": 7 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e4975-111524" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=SL6953423-111524" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5212-111524" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5033-111524" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5093-111524" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(19)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563" }, "r129": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117539-209714" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117539-209714" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68051541&loc=SL49131252-203054" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r155": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r157": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r162": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r177": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907" }, "r222": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r238": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "http://asc.fasb.org/topic&trid=5833765" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=121605123&loc=d3e30226-110892" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r262": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "http://asc.fasb.org/topic&trid=2175825" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r266": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-10(a)(32))", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=120398226&loc=d3e511914-122862" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-10(c)(3)(ii)(A))", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=120398226&loc=d3e511914-122862" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-10(c)(7)(ii))", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=120398226&loc=d3e511914-122862" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6806780-109447" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.1,2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(b))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column A))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "740", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r358": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r359": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r360": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" }, "r361": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r362": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r363": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r61": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6787-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765" }, "r90": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" } }, "version": "2.1" } ZIP 53 0001437749-21-012046-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-21-012046-xbrl.zip M4$L#!!0 ( +N K5*2E2WD\QP $S)!S4I)D)$@.@B,.44"0G)0P1,E94!A1!",* M(E'@ERBB*"!@(*B@2,X@0=<]]Y=]VU;K&ZY]M=U=U? M5?>P:XKRF3(!,)_4,]0#(% (T^A/QZ$F?>?Z*E/N\+ M='_>UCXV .0\/$"-+]@C?Y_U:^1A1N:?(PK[O3W8_S&BO-_+_#6RO^;/?1P( M^O4O!;9 5?_/Z_9]IOD]9OM^0X__:K_KV/^,V:\8TE,?44=^V0)Z5#.P]0. MK#,XS@YP Q#*/YZ6 ?@'4+X#C-IN :[N@-LEZES**! 'T-/0T*!IZ-%H>A8Z M6CH6#B9Z>B8.;C8V#C8V;A;Z??G]XU\+A(&.CH&1@9F1D9F=D9&1G=HQLO^: MPO*?+$!Y"[#0@ [HP2"' "@+!,8"H7P!G450FB 8D"4"LB^_'SX,= >.0*)H MT+1TD']60@ H[ \E,P"!0V!0.!2!0M(@8/2*H)(%!A=BE4=HGW9A.Q04JX!D M3WI8?D)8A,/\G:NB4O#E'BQ*--EB;7(=%Z+,F5=Q14SGGJ6;[OO\4!6N7JLI M]XW*N,:^L&F"GGA*P=47]YOZ9S8+JSX,S&Y9>X3'IQ95?QR<^Z&J;^,9D9!6 M7-,\-+_- D"A(%OX/B<4$J&\3T%(GA4.,@@ZQ(90B$UBIS)X9]ZSIBCB.AE\ M.1EKP8$+45H715()H,24W_>")/*YW'2M5$+=I_ZD\.\9B/]%@3("T,/V]V0! M,,!P\[*3DT91@(6G83A/^PUQ"@P]&6%UG1G>FCCV-,O_4'>[F>P M!>.+6\8VJH'2 B9;NS763Z)U*UX3ZLO37BHQ_D80B2U^\P&[=%2JN=7"?D%+Z<79S.]9I='^;9_X!-B6R(U9 S]&C$;KJOK( M+%U>,CNR7RB GT3T^9WA_AV.E^EU:BJC'?X-$J_>-.AT>?^XLJ/UE0($%Y+E M-/1D^'R>C P'O7TYA4/Y5%<8M>/[GXS5ER1E;64]F:TL&A^0[S!=K.*%"%U9 MJ&M:P?<:Z 19V5XC]7C4?GVV;#IH_$#@<=566;J]0%!A^U=5ANIH.=\JM_&M M.\O/L!ZJIY?#7&="WSSX./(M$/M98-/QN71G]>JZ=PQB0V[Q55COG!HVLW=E MJ^HM>;7N9M'.WKWC.W=;Z4;\:\U:TVED1?PBJDH"8T_$OF(N79X8B1AL6]AI M'I!?#>'K73OBD-KQ-"$9>X8T0XY9/=>Z5T<^XK_8O,S /JU:O(P[W G;97 ?5Z_8NI]E1 -W$,W<,EO<4F98\Y,RC;ROA MI/6N>/9M>+;Q[+D[MZZ.W5Y;\1TE= MA37A%,"&T&N/KPEL<"&/C7H.:\DY^8_W^E* FX:*BX/WMO"4;@$KC'FS5<>N MGLJ%,M7A9=^JIR[ATPT^G@O^#EIRRZL#]4GQ[=*,V=%*"@9>,B+W-G.VN;Z' M/'A]L_[1GD/]T!=_A&G%$%==$X]LT-A\\$,*H$ NI0"S84Y!Y,W>X&RU%YZH M5(&'APF1Q[*V^I;FC6LTOCD:/R?GN[S>F#_2V)F;/S3:&G-]:VAI'OLA1I:3 MW\X]56.9#Y<^S_5FD77EJ]$3"I"1:T4!-E[GOJ0 49/'GH:69:=M-8;DEQ'!/.P^Q$+RW5JI; M>>H1I;J$"V<_=M6,7>TCD/.=9X=2Q^A'5PH2K.7*G_DX'KM9[3^ZJ#+&,]E8C@RFLL&JQ(N?$)6\ MPLTI_/PR_4)MW$;B\,S84H'6I?GIO MX4J*GV %T8D0O.M8Z_3LC+!XX5S=2VO5 \C'C8M"=^=L)V^-?/XRBE<7K;09 M<"KM[POCF!@5X,QB]=WBR<:[#$KT=GK[=0@,>TZJ1N@J\S41$?]#VFG )\ MTL)2 +IA"F!N(T.6PL^,C?^#QJ6*R20<%2 S8 M.Z%/_$3DP.YUW-OMN5"0;&@P9&XHDIQ+Z=VR3&LM$2E>*GP7;;>0[<"UG'/6 M7T_FONOG@.&0?.^Q";MQ0MIUD0R-E^/A%S4=>&<>"]]SD:?I4G6>]D<97F^ M[OI X#K=WOQ2 ;BG^'.,E4B]E:$HAC*\_^[\];Y'[;_WP1<'98K>UA"+=3(S M-]4S--:E#@'T!L;>_@%0\%WLYQ\:;*Y_0M#6SEX0U0E 30X3QX 7' A@286 M>I;4I0QUL8(AH!'P#_)C\%>^TB=C8"8H"/S_"0LN,#@4I&<&8D4W]Q [G0ZE.80,"(X.]/;U"!25PDH+R MZNIJ@@;N$;[NH:$R9BXX'Y=@-T%L@%^@BW\D /SR>5]8J;$5!(.L(J^NHB*C M("O_MT#]E\K_4*AG^PL13N^?&82S_:^Q?V47D KOC9*D!_5/^GP;_@?QM M/UGJ^*_YB%M[N[A M'NSN#\ZP!F^9M[\G>-S^;MZAW@'^@M[^_^X0_YO3_DE^W6M0V K( +N3+,#< MQ0[ 5MH!.!L= '/, 360/\_-&&T-4+]Y-@+SO^[]OD#^[U6A=ZA=B+?G_CRL MN:4@+BPX_)>.^K4$$."O%B: '> !^ %A0 +\O:$ J )'@>. +G 2, 4L 3O@ M+( #O _(!B( "X"L4 \ 1^!-J ;& !& M@0E@%E@&UH ?P"Z8_*(@#! V" ]$ "(*.0Q1@*A!CD%T(<800=I 72 QF&3$(6(1N0'2@,2@]EA_)!Q:!R M4#6H-M0(:@D] _6$!D&CH''01&@Z- _Z!%H-?0=M@PY )Z#+T"T8 *.#<<*$ M8#(P-1@69@JSAWG @F$QL!NP5%@>K SV&M8,ZX--P+[!B' DG TN")>!'X4; MP*W@.'@0/ 9^"YX)?P2OAC?!^^"3\#4X&<& .(@XC-! &")L$9Z("$0\(A51 MA*A"?$ ,(&81/Y!()"=2'*F*-$#:(<\A+R!O(;.1SY!OD3W(:>06"H7B01U& M::%,42ZH4%0\*@/U!-6 ZD7-HG[2T-$(T"C0Z-'8T_C37*9)I7E,4T_32S-/ MLXMF1HNB-="F:#=T)/H.N@#]&MV%GD7OTK+0BM-JT5K2GJ.-I4VG+:/]0#M& M2Z"CHSM$ITYWFLZ;[A)=.MUSND]TDW1$>E9Z*7HLO2-]&'TB?3']6_IA>@(# M X,8PW$&>X90AD2&$H9&AJ\,/QG9&&49#1G=&/&,68S5C+V,WYG03*),VDQG MF:*84IDJF;J8OC&CF<68L8MUC86.193%G\6&ZQ/&9I85E@ M1;&*L>JRNK'&L>:S-K).L\'8A-FP;#BV*VP%;!_89MF1[.+LANSGV&^R/V7O M9%_C8.50XK#F.,^1Q5'',<$)XQ3C-.3TY;S#6<$YR+G#Q<>ES>7.=9VKC*N7 M:YO[ /=Q;G?N&]S/N >X=W@$>71Y?'B2>&IXOO#">:5X3_-&\.;P?N#]=H#] MP-$#N ,W#E0<&#D(/2AUT/S@A8/Y!]L/;O'Q\^GS!?)E\#7R?>/GY#_.?XX_ MA;^>?U& 3>"8@+= BD"#P)(@AZ"VH*]@NF"3X)K002$#H3"AAT*=0KN'Q ]9 M';I\Z-FA+\*TPFK"'L(IPN^%UT0$1$Q$+HJ4BHR(HD751+U$TT2;1;?%Q,5L MQ!+$:L06Q+G%#<6CQ$O%QR08)# 201)Y$OV22$DU21_);,EN*:B4LI275)94 MUV'H897#WH>S#_=((Z35I?VE\Z2'9.AEM&7"94IE)F4Y98UE+\O6R'Z7$Y&S METN2:Y8C'U$^XGNDX,BH/*O\2?G+\J_E-Q2D%' *60K]B@R*>HIXQ9>*ZTJ' ME=R5<_ZGJUS8G)R<:IT1CC;.#]V)KF8NN2Y;+D:NCYP7<-A<6FX9;?C;BENB^Y: M[LGN\QY:'LD>"YY:GO<\%[TP7JE>W[RQWIG>Z^<,SN6>V_8Q]2GVH?C:^#[S MH_%S]GOES^KOX]\4P!]P/J G\'!@?.!$D$;0_:"U8*/@HA!(R)F0EZ'L8#+5 M'B81=C5L,OQ8>%;XSPCKB,KS+.?]S[='2D5>CYR/THLJO "_@+OP_J+0Q=B+ MD]':T0]C(#&N,>_QPO@X_.PE_4N/8FEC?6([+A^YG'QY\XK-E==Q?'&7XJ:O MZE\MC6>,#XX?2CB:D'L-?LW[6N=UQ>L9U\DWW&ZTWCQR,_4FZ1;N5NMM^=OI MMRF)'HF==U3NY-Q%WO6_.YB$27J4S)(=8I@RHV4S?M.]UM2E5)S MTVC3PM(FTHW37V:(9-S-(&5Z90YDG4Y?+EWLS= M^8C\\/SYPJL"YH+U0I+BGB+;A;M%?L73SPR?]14HEI2 M\OC@XSNET-*PTL4GCD^ZG^H\?5DF4_;P&>>SF\^!YV'/E\J=RP5ZI5 MEKT0??&@BJWJ1C6D.K)ZK<:K9N*EW5R=?O7]]]'75&]DWQ;5"M5EU''5W MZFGKX^HI#5$-6V\#WWY[Y_EN^KW3^]%&V\;^IM--G1^,/GSZJ/>QL5F[N>&3 MUJ?:%HV65ZUJK35M*FW5[2P M-+L7!=XGO+U:/K[:OV:[-K@>O4S9N$7@(Q9M*F^^WS+:^_O#[ ML;M]XR?/ST=$-6+SCLW._&X$"45*WY/<>TTV(H]1_"B4OU7;C@-_5-N@?PJ, MVN P:H> 4P6!1.P+$HE"T:!02#2:EA:-_N=J&PP&0\ 1:"02S4"+IF5@HE;; MF)CV=;]_T#/]A]4VEK]7V]"4)@B8U@*HO]?3 #@"!D5"@-^K;2#7?U]M@X+4 MH' H$@4#.V@(! IC@0,((59Y[=-(-I=#0;'L"DD/41R_JEV3BIRN:R+!E]=% ML4H6R7D5N)#WRCKB]_(K5;@LW4(;>Z=HQ*Z@:;EYXE)T]0I>6/=92?!N3!.H M]2[WL*OW?]6\_DW13S14JF(JNKSB;J%6JAOYE8T2 MDGW3A+B4@A?_2%GO;W6Z?\OYOZ#\CP6]S:)88@\%4/]"K)P/Z**3:UEN:!LF M-1 MYOGTVWH^^UC?08R5P"NBS[ T5KR2?X1(+R-6JRE]GF8\^HINN#'1N$(\ MOEKB30.Q7:ZK01'?J19YCZ#:>LRA3PG3(? )KQ1SG?1C0[DC_XRN5HI@%&%D MT&PM:.G]TR:4LB"]0/*'@^\51#ZZ3EE,?WK_-D^][@#!DQP\W7$6=X<R<2K-936_HB0+'%DVOQ761V'&32O70S5#Z!JO_@R77=I17>>=VA6@ M=/\H)DW4[<7GSN.)'>K/5OV^Y9EVU)W03YZRO'U",KV2M!&]ES5RZ-1]N8[GK;&2T2E-?=N&F#WUI<&N4PNN3 M"'VS8/OE.'G]) BWEI[^0^D#Y.A9HNYL@%Q,*+[3>*EZ;NI[0&O#D8Z9 !'] M4/*CBC[15*.$"?L">=KK-<[X]-GL_%3S9@AITO-KL\DMM%'+U#%?4N\0:1W< M%F2C+C-_6*[%5"DFG'AV6KN!5+A!JG>XK'_EU"U$8N29)O,23^>.)C.2W<4@ M&I-'"A [KG(FHWY=I,@@0R\N.9N460,P?2- M7N+<2*]1[ME!]=/UHA+&2=V;D\;/C^O;BJ@;.+ ="KP;=6P2#, V0>PJBC0I MEC$[W^]7-*39P97Z))1/2IWENWBVCL*11&71.QP6YLCQ4\[A%]']3MKA,^=, MOR]N8.;D4L.FB;$@>]QL:,W]JCT,.:BRM272][<,=>_UQH8Z?8/ M\HV)9]2Z%KT?&*8D;#H5-*3@RMM",QESU7Z8=(N9LVTT?F=[.SU MNMWF9#M:6)LJ>4"#O%=X5@B-BMH<5W[U@I#ZVUN&EF"7N_3.1*U*LDWN/?RL M ;Z5O%-63D;MP[.S/TH:1@I5GZJV:J+/Y_ /A0Y_5#N? M2^F1( VDD0-?8SHP[1\(XLD40$4V;(APZBE95"/\%9S3ABO7X=XR4JVQA*5R MZ-K1V+L40*?RP\+D3OB,AI88DZN"9_/!O*"#SOQU3H8Q-OC.2 K0J19C3#QJ MNB$^.S0SE%';,-NAGF.PDFQD*)+JS>"6Z7TV>,-@OE2>I(B2\Z.OF+HK\NKN M#V%-!/W=7;P%#ZD:C$$7V,)()0,8I:I<"2*, )71)T38WCM#,-Y6#;>(BD@^ M+'?8S(T__>!UV,6-DAB%#1[2HE1H:][7 F<3Q%;3VO7,YNEWO;!7>.@M;' JG&.DW=ALJ;R M\6USX6_\MEGKPC_(Q;6V8%3=P:9B2PZ,;"2\C+&/G%ONY(_L?KBQFB[]W5_: MO:^@_))4G -.%.)\2?G4[ISZ2K>SD%YL==R7(3QR_=K 12\'PQ\H M(]D3";>+.P\7&DAV7%YG?I,(=/ MF^DK#V^[27[0TOZDC.*+=\6^R!>2[-D<&CF=->SXN6*ZR?- BW/(:-S954KO MSG@IN*0PV%271ZJ+RWP$4J+XR$^??#&)?NS4FDS(G(I0,!(VUWXC+S*G].*\ MFV_34.$$XD-\VA8%6.J-,:4&-,:*?(;81@XY0&#; M('3P6U0,UMXOZ)C3[=-\$\@]^E[Z^VF9GY?>DE<,81?[O.7UHJZPJGSY?A3G MD,OD@6M#)RDV>I9-1RQ$S >0IB+ ^Y:*D< H:C8^C#%?R/2ORH_T.5W;N\6= M;&J.GHS]JLZ<0?/X^:..U'S#>+49'=V^EA\!?LO!2^7O[=RT[Z+FB"AR]#A1 M@&A"?#,3T,Y@1!#_]#H@:W4S^]S@Z*DW]39R[*;G^)+.5WQSN-CX;8Q[0R># M[LOXKMV(QFU9+WWZ=NWKLZLQ"12@.P/?*8>?3>_&3(A2@,<9E:1$@;F$%++3 M$ 4H-1S?%',BW!PG>B@Q_43CEXHPU)@UM.U0@"UO\1%/TE07:?K[[7QB6MN. MTZS';<_\R(\''/"*WNM/,*EJP0 M(Y\QC_&=H-%, FF" KS5MZ8 CSP[ZDMW2R[DB%=@FN7QMM&K M<9AY< 6B+$8)OR94 5H(99);=MQ7F4Q6:K9_@E[&;"_5^_.+?BXMMZ'T_^]N M/_#']O? [3U)*:3A#?"_D=.<7*YFQPR?A>Z&?XEJAL,I M_[CS)%7!$&:QQ2 MLPWG\_)]^[R/N"6&')+PW]8J'[&_^"7C#KL8?3-#XAN&\3P*D&.O4CHGUS+> MOH+"EJ=9#"K?D5ZRSO3(9= RG$]%VDZ?O"O5U&TYUW6:33H8EJV9ZS&3*&.M M_JF;%4X:Y\=WO:( AS'R>"G2;>+5(K(K\1@%:-D>*:KQ#BH>&;_6:,)J#_=T M,ADS4QF^.ISNF2AB8/U]=Z3#G\_:RX@][A+U:MWRZ)CE SW#4X;_#U!+ P04 M " "[@*U2VW@6)7@. #PI $0 &1Y86DM,C R,3 S,S$N>'-D[5U; M<]LV%G[?F?T/7+UL=J:T)#M)&T^ M[*SS]=X\O[\<##H&]Y%G(X=Z^*SCT!YX M-F97U,7&'Q=WGPW3Z+T_[9^,;HVOXTOCN'?<-WOOS/Z):7[Z^,3M4V[-L8L, M0.#Q4R@XZ\Q]?W':[3X^/AX]GAQ1-NL>]WK][A^WG^]EW4Y4V:*!Y[-E(O T M8MPS>WWSI)^(!8R!=GERT5.%H(V)6@8>0/7^ATSU)2)K MRD"!3:PCB[JB\7[O9%47/UES==OBB0*+0[SO:XU+H((XCJM[B%A< MW8%\).#WUWOPJ.<%KKH/VV==?[G 7:AD0BW,B)7(E0NM"W!BJ9'! X7FG/E) M]2GB$]DV%*JKFJ)'KA0('ZG$_ 7+001/A*E^61<(N#E#:+'92_1 T0<\R4$6 M/U$("2RVOPXM-@@5#;W^AP\?NO)IQT"^S\@D M\/$-9>X5GJ+ 32!]U> '#(EV(:PX6 7>_Y:A=1C'[$9]K\@%_,%LG#I\( ( M8Q@R3!!W09EO>!NBA90)@\MG:B%?AC8AP_.$Q =S)7T$W7:ZVR+8&*^5("12 M\E-C$)MC6H4B7RK\:*X:J RCB&DY %Q#(G3DW"L) TU'BS"OEU&'; XGHD,O)J?',;6I.KX*3?UJFF0?%,@SZ.^ M;$R6Q:6+!?&F-"J"0I&BG,9Y[QV>&C)I.47,$JH6IS;=!:,+S'P"SDVESK*! M.#G1T<:?WB MZEC(V58=$+$"1WJEI4K9>+JM4B!"/-)BG18,;ZL3B'!(R&MY2C0PA@H&@54Y M9&.^S.U-FUJ!_( \VX3_$W]IBK'(7-E+QQ!R7^\&9=E]"+!ZNPFZ&-_*7^$J MILJ"^%.OUS-,XRKJ*_WQW+.-:]FM,5AU^[&;Z6L#1L"Q/?0^R<^9<1$)1S6* M!->Y5UTNZU^U9%0:.[2:GRWJ<>H06TX1$^3(;)S/,?:Y&XE&N/-90C'&$DXQM<8SG\.7-G* M>PLDRN?8)V *_K+,R?2MBT?'6GADO!FMP3L0*W1N4LQ-.C7%U"F[Y"N_ZB%1 MA7YT$>:DB##) V[0J3%,- #>$R MC_K8[)M@5N21OV4/(]8.Z'L:$9?:IVHHLH/RN)(E)@$5A^"L/+=0+D)TF9 MP0K)*^?$B2DZ0,R:2Q=9U''0A+)H[,\8CB8,'DQ@#&&/XW1IUJO$,Q<,+.UC M9SG'CFC/72?(*C%FJP59\AK M$,\8Q:J80A=H,M+EE1/[K?"J2_P5!2 7$K,!]L14T##*E;:NBT@?E$1Z*U.J M!$#$I12 5^[\=R:?(X:%$;GG#9U^;BO]/'[V,>9%?,K]^_/8E;GX )1@A\TI*C*%G7Y M]ECI6Y&EWB>=&MA>U:#%Q($#1"D"'\PM;UN5X]:YHW@KCX'0=B8"-?40<".GXR0^0L\N< M) M%%ZW4VYJ-DY.K$*XQ#N$>:-C$]U$9-QFV,,SS,+!C/NR2DD6P=-%3O5G: ME)YF7,J-NP1[0MH#69NP M M$+%-_"0R$!QNI5-_CEGRUASB7+Q$UP(*;P]6 M$[&/U9O"S8D]"C4RKB.-9 M#H9$1OQ=X+C4ZT%UO$%R@9>L"5N]6YTD4U] %1\\G?@1D6G31QD?>?6 M'(2Y21>B3.P.0M(,2P"7VMC1,R5K0:"+4>JSGT)&F<:%P&G>AT"-80A4A"H -/'K9/O7Z64="7.=9\JY\K5S3?TRB];OBC_H@(9<_4!P!S-Z7D&78C\RL MC]WL;7I1R?JM>_+.O>AR7TD^<3'9G_$Q8'0**#>OE^&_8E!>.CKP\\*Q3 ML2X1*W!QK9G/ G%G;##A/O$# >0W1H/%64=>;7Q*@'\=([R^++RJ^M2/FQG M,Z%BQPCKAI?_C&5=.PA7]^D;!E5ZB:.C^.2H3*\J==ND5[SG<>[9J7.%@3=B MU,*<1Z\?9!2L+%1'T[#$I1X,.+;,ZAG=Z736L1BVB:]2/[PMV%=ICZ!_!DET M#&AE#6]:"5 M\#=@[QYN D_L<8O_5MO<'%B?VN>[081]0XZ %^+?2N(9!XB-)UN/CY7:J]W/ M!WS.&/)FLL959+/A--GZ3/3>2J2^XK';FKLV!W XXP\\'\-9C>H'#EW3+!TZA9'TSR%4(+QH]3=0=!K[\!1R87%<7 M0)1IFB>T;[Z&M%W\#^A[;MMRC8*<%'N!RT(]"%\$.=$K+V6FJ=?D_AI./>XK MSZG;-+0+(S6:F.[$70 !%O$ 1LHHG ;1#)<9I4"NK7/P-T@5UK#R,B65$L^H M7C6Z>Z*9T YWA'^/0_IEP'T*HS:E586:]0E+(/N:8:;!73DP[X/%PB%5%$K7 MW)E"N8LN<0]DX C'KJ^]%.7M6S&*&Y;$@SCTI5^MY!OZ5*C:7A4I4^N3*M_] M$OD*3_SH#2^"^>_8L6$H(U^^\35BV"6!.T+$'GJC %P@?]8@U*:.8&MGLRL\ MQ0Q6?&/T%/ZMCECB2[%SQZ&/HHM+^H 9A.PH>*_,4$-R1S-:+F/C7TZ /.1: M_F["(/TK$)&BQ74:Y/J^F/&UZW3M+ARZQ#@35#:+VQ= KI]@7(G40>P]_1YCY,!=@"Z0YPR_#:[Z'PI/ M$2K6;<4I@CBB%W,29*MB!$:[7\-'#X@T)XM5FGJQ7*\:5HE5;M[,;E+@7)** MX\8QO2$>1&]8LB97;4>GB./X1#Y6OV+MUH5(@9RKH/.T;KDU]DB?\TBD7*]4 MS1;J]P"I1";KSQ;N/ES&JRAEWI[ +JG4OF77T,.7=\-UXV?*VC??#A?8NT7L M._;OD8.3G:6,%B65=D\IQ622@%<^VO&F2G0G0/PN >1G\D* Z&P]7"@4IA%- M&FA%;A$IL-T;"ML*M74+6:U Y,P;9!%'+IJ'L"Z<8V3'WHW-4%^\M0OL0I4@ MVW<"<;!RAQWQXR8CQ/QE)6/D2>ZG'<01$[%QO$^$[7O,'HBUVE>N+;V?]D@6 MM)%WY=]+5[)%GN2>V2$O3K8A0.I]A2O6*.9L3J927FWWN4H68[S_:>4+<1;*OB">C;/ZEM?XN-?OCR ,KJNB>M!&^#"$+N^&/ L^ M6]P^Z-\^CR:$KN/.E+4/=.J'3E[F>LK0+B_?;>O.,9[;!*I+FU_&^,J>7Y'] M6%I M+3(P,C$P,S,Q7V-A;"YX;6SM75]3XS@2?[^J^P[9[+-( C=[-U/#;C$!YJB" M"07,WKY=";E#=&-+.,,(CRNX.^]^OT='U^.RLWY,I9A&..8/#/N/]WW[]ZU\^ M_X305V @< I1[W;9NYEE+ )QS!/H_?'EZKR'>L-?/HT.+B]ZWV_&O?WA_@@- M/Z#1 4*_?HXI^_%)_[K%$GI*"";S?P_[LS2=?QH,[N_O]QYN1;S'Q=U@?S@\ M&*RH^R6Y?C=*UPR;Q!\&Q9MKTA=#WQ_DM*./'S\.\G?7I))N(U2#C@9_7)Q? MDQDD&%&F9X1H623])/,7SSG!:3Z-M1!ZE13Z/[0B0_HE--I'!Z.]!QGUU:SW M>L74"1[#%4Q[^N_WJ[,GGQDM<43)'N')0$_Z\.!@--!T R5S"@FP%!'.)(]I MI-<.K5^6B$\1G^LE53@DRAC.(JI(%,S\4V<"IH=]-3Y%JY&U8#^W'CA=SI5F M29K,8^@/-G 2'),LSMG.U?\EN4;3$>1",GA(02EWN00KX6).GDS,IB9.L;S- MES63Z [CN99K.( XE:M7]!0.T7!4KN[/YV#JPPO!M-I4(-A*T[VH MD]6$U0ILH.Q>["N0@ 69*:4^A@7$?*Z]@7D?6/'X@+( EL&IX,F8,[4W2?HO MFL[&F4S5-(N3!Q)G.IX[DLK 2HAN\$,E0.>13+ W?/B1(#TN5)1XV%>1YKTR MF+.T##N+<=3\OG#N3R.DDF(@LR3)QT3*72*043@"4<0_%7_5_8"64P M9IC=P96"?S*= JE*:/P(T7VT6WS^9+HITX2U0K_&>4SEG$L;Y C0GBF-Q!>XMNX*G&T MY@L)TA404(KH@NHE:R# A-HOJYCE44A3E[]DO!%U0%I5^6WZ6V(:>4849T M-J@\W<*T2YL/$ S(8FE:@#0,$ S(=:;H"M(PP/OQ@T%4%4#E6>$-/R(JB7>9-H4;INQ/$-/ M.?DQF>>9SLD#"$)EY5FL-5_WD*YG6, 7Y8ZC,4^T_\U]5 4.,W&K,Y?=E7X= M+!Q_G9#;H;@8ZC0XY\-!'>.\MBHT#V =#GO>SG34Y=NVX/_63;%]%U:A,DNU MQ?XA>.R&2,L6Y"_!@VQ8(K,%_O);VS1?@P>;:LR5%"G M^PZ9.F^=NO)4>!K>7@IW%VNJJ M0Z[U_S>+M97-H/KQO,]B:&T$W;4X,9X"&B&U;IB5 3#"+$+YNHFE[ON1]([1 M*258D>,B/U"PT)S'E"B]0O.B/H"@;"?,^;FN#2"25U(46UXD0!&DF,9KK/5] M4CZEZZ#9RC^\+CNV\G)164PJBTA%I:VJ$:">P4=Q?%.U0V#GPEQ.N7ZFXJ*1/?#@!6>'/'#B[=P_/ZMAF MSVPF]BY\;D :(=C&X06&/BQ2*C%5*J%V (Y/ 6JB)#NF,-UXC1YQA_4*R74W M@F>]B"'Y[GJ$SL;OK7EQO7Z/2:4G+VX4XLUX<0L4K;QXN=OL;Y@9PW%FL_#HRCR]*;ATM@Q!>OE:\3F[?=58'Z_ M'K"CI@;F_>UQ-M%@3Q>6;W&L2R5(SD#7?U?EX'E^8/)XA1?9>_56PW=]>=E- MOE:>N"SBN'MBIP&\)ZAO,[M^TM)L!\'$\AX/N4"(U![,\\/+O+H[QG.:XK@* M@)G:@_BFFX"^;_;9G$D%:>8<3$JR'P(;&CR-&^*)JS= ZOJ5#1C MLN3R]S3)1]=J!E)+WSV$#8>J'Q6FE7_&8Y6V2&V0*N_'V[)Y!61>C)!"B8UC MUF^<$8OR0P6MEUZ&XFI5K7TU4+ZWPKS:DSU33!E$)U@PY7FE"INS),NK&<

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